

US009518252B2

(12) **United States Patent**  
**Grallert et al.**

(10) **Patent No.:** **US 9,518,252 B2**  
(45) **Date of Patent:** **Dec. 13, 2016**

(54) **LISTERIA BACTERIOPHAGE P825 AND USES THEREOF**

(75) Inventors: **Holger Grallert**, Weilheim (DE); **Julia Lorenz**, Regensburg (DE); **Anna Scherzinger**, Bernried (DE)

(73) Assignee: **DSM IP ASSETS B.V.**, Heerlen (NL)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 97 days.

(21) Appl. No.: **14/119,811**

(22) PCT Filed: **May 29, 2012**

(86) PCT No.: **PCT/EP2012/002270**

§ 371 (c)(1),  
(2), (4) Date: **Sep. 30, 2014**

(87) PCT Pub. No.: **WO2012/159774**

PCT Pub. Date: **Nov. 29, 2012**

(65) **Prior Publication Data**

US 2015/0037284 A1 Feb. 5, 2015

(30) **Foreign Application Priority Data**

May 26, 2011 (EP) ..... 11004348

(51) **Int. Cl.**

**C12N 7/00** (2006.01)  
**A01N 63/00** (2006.01)  
**A61K 35/76** (2015.01)  
**C07K 14/005** (2006.01)  
**C07K 16/40** (2006.01)  
**C12N 9/36** (2006.01)  
**C12Q 1/18** (2006.01)  
**G01N 33/569** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C12N 7/00** (2013.01); **A01N 63/00** (2013.01); **A61K 35/76** (2013.01); **C07K 14/005** (2013.01); **C07K 16/40** (2013.01); **C12N 9/2462** (2013.01); **C12Q 1/18** (2013.01); **G01N 33/56911** (2013.01); **C12N 2795/00021** (2013.01); **C12N 2795/00022** (2013.01); **C12N 2795/00031** (2013.01); **C12N 2795/00032** (2013.01); **C12N 2795/00051** (2013.01); **G01N 2333/32** (2013.01)

(58) **Field of Classification Search**

None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,322,783 B1 \* 11/2001 Takahashi ..... A23L 3/3571  
424/543  
2004/0029250 A1 \* 2/2004 Sulakvelidze ..... A01N 63/00  
435/235.1  
2004/0223954 A1 \* 11/2004 Bruessow ..... A23K 1/17  
424/93.6  
2009/0246336 A1 \* 10/2009 Burnett ..... A23L 3/3571  
426/326

FOREIGN PATENT DOCUMENTS

WO 2010/020657 2/2010

OTHER PUBLICATIONS

Loessner et al., Applied and Environmental Microbiology, Jun. 1990, 56(6):1912-1918.\*  
International Search Report for PCT/EP2012/002270 Mailed September 26, 2012.  
Van Der Mee-Marquet et al., "Evaluation of Seven Experimental Phages for Inclusion in the International Phage Set for the Epidemiological Typing of Listeria Monocytogenes," Applied and Environmental Microbiology, vol. 63, No. 9, pp. 3374-3377, (1997).  
Carlton et al., "Bacteriophage P100 for Control of Listeria Monocytogenes in Foods: Genome Sequence, Bioinformatic Analyses, Oral Toxicity Study, and Application," Regulatory Toxicology and Pharmacology, vol. 43, No. 3, pp. 301-312, (Dec. 1, 2005).  
Klumpp et al., "The Terminally Redundant, Nonpermuted Genome of Listeria Bacteriophage A511: A Model for the SPO1-Like Myoviruses of Gram-Positive Bacteria," Journal of Bacteriology, vol. 190, No. 17, pp. 5753-5765, (Sep. 2008).  
Gaeng et al., "Gene Cloning and Expression and Secretion of Listeria Monocytogenes Bacteriophage-Lytic Enzymes in Lactococcus Lactis," Applied and Environmental Microbiology, vol. 66, No. 7, pp. 2951-2958, (Jul. 1, 2000).  
Borysowski et al., "Bacteriophage Endolysins As a Novel Class of Antibacterial Agents," Experimental Biology and Medicine, vol. 231, No. 4, pp. 366-377, (Apr. 1, 2006).  
Guenther et al., "Virulent Bacteriophage for Efficient Biocontrol of Listeria Monocytogenes in Ready-To-Eat Foods," Applied and Environmental Microbiology, vol. 75, No. 1, pp. 93-100, (Jan. 1, 2009).  
Hagens et al., "Application of Bacteriophages for Detection and Control of Foodborne Pathogens," Applied Microbiology and Biotechnology, vol. 76, No. 3, pp. 513-519 (Jun. 7, 2007).

\* cited by examiner

Primary Examiner — Nicole Kinsey White  
(74) Attorney, Agent, or Firm — McBee Moore  
Woodward & Vanik IP, LLC

(57) **ABSTRACT**

The present invention relates to a novel *Listeria* bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling *Listeria* contamination and infection.

**14 Claims, 8 Drawing Sheets**

Figure 1




Figure 2




Figure 3






Figure 4




Figure 5




Figure 6




Figure 7







Figure 8



**LISTERIA BACTERIOPHAGE P825 AND  
USES THEREOF**

CROSS REFERENCE TO RELATED  
APPLICATIONS

This application is a §371 National Stage Application of PCT/EP2012/002270, filed May 29, 2012, which claims priority to European Application No. 11004348.6, filed May 26, 2011.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a novel *Listeria* bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling *Listeria* contamination and infection.

Description of Related Art

The gram-positive bacterium *Listeria monocytogenes* is a bacterial pathogen which is known as the causative organism in several outbreaks of food-borne disease. Listeriosis is a life-threatening infection of humans worldwide which is caused by *Listeria monocytogenes* and which is characterized by a variety of symptoms and conditions, including diarrhea, abortion and encephalitis. In industrialized countries, high mortality is associated with listeriosis following *Listeria monocytogenes* food contamination. In humans, the prevalence of listeriosis has risen significantly since the 1980s, resulting in intensified surveillance of *Listeria monocytogenes* in food industry. This contributed to a decrease of human listeriosis cases in the last two decades (McLauchlin 1987, Oevermann et al. 2008). However, its prevalence has again increased in the last few years (Gillespie et al. 2006, Goulet et al. 2008, Gillespie et al. 2009).

The species *Listeria monocytogenes* encompasses numerous strains and the genetic diversity amongst them is high (Doumith et al. 2004). Various strains have been implicated in both human and animal disease, and current surveillance schemes for foods are based on the assumption that all *Listeria monocytogenes* isolates are potentially pathogenic, resulting in costly recalls in food industry (Oevermann et al. 2010).

While listeriosis is greatly aided by early administration of antibiotics with rapid bactericidal activity against *Listeria monocytogenes*, research to improve food safety is directed to exploring novel technologies such as the use of bacteriophage for specific killing of bacteria.

Bacteriophages are viruses that infect bacteria. They are obligate intracellular parasites and lack their own metabolism. Phages are the natural enemies of bacteria. They are host-specific in that they infect specific bacterial species or even specific strains (Hagens and Loessner 2007). There are a few exceptions like *Listeria* bacteriophage A511, which can infect and kill bacteria within an entire genus. The extreme specificity of phages renders them ideal candidates for applications designed to increase food safety. Phages can be used for biocontrol of bacteria without interfering with the natural microflora.

Endolysins from *Listeria* bacteriophages are promising tools for detection and control of *Listeria* contamination and infection. These proteins have a modular organization, which is characterized by an N-terminal localized enzymatically active domain (EAD), which contributes lytic activity,

and a C-terminal localized cell wall binding domain (CBD), which targets the lysin to its substrate.

It is an object of the present invention to provide a novel *Listeria* bacteriophage and novel endolysins against *Listeria*, which exhibit improved properties over known *Listeria* bacteriophages and known endolysins against *Listeria*.

SUMMARY

The present invention provides a novel *Listeria* bacteriophage designated ProCC P825, which has been deposited at DSMZ, Braunschweig, Germany, under international deposit number DSM 23783 in accordance with the Budapest treaty for deposit of cell cultures. In the present invention, the novel bacteriophage "ProCC P825" is simply named "P825". Therefore, whenever reference is made herein to "P825", the novel bacteriophage "ProCC P825" as deposited at DSMZ, Braunschweig, Germany, under deposit number DSM 23783 is meant.

The present invention provides the novel *Listeria* bacteriophage designated ProCC P825 and a novel endolysin designated PlyP825, which is encoded by the novel *Listeria* bacteriophage P825. The novel endolysin designated PlyP825 is encoded by the nucleic acid sequence shown in SEQ ID NO: 1, which comprises 945 nucleotides. The corresponding amino acid sequence of PlyP825 is set forth in SEQ ID NO: 2 and comprises 315 amino acid residues accordingly. The novel endolysin PlyP825 is particularly useful in the control of *Listeria* contamination and infection.

Aspects of the invention are:

1. A bacteriophage capable of lysing *Listeria* serovars 1/2, 3, 4, 5, and 6.
2. The bacteriophage of item 1, wherein the bacteriophage has a genome (i) comprising the DNA sequence of SEQ ID NO: 7; (ii) having at least 90% or 95% sequence identity with the DNA sequence of SEQ ID NO: 7; or (iii) having at least 90% or 95% sequence identity with the DNA sequence of the genome of bacteriophage ProCC P825 deposited under accession No. DSM 23783.
3. A nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
  - (a) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2;
  - (b) a polynucleotide encoding a fragment, analog or functional derivative of a polypeptide encoded by the polynucleotide of (a), wherein said fragment, analog or functional derivative has endolysin activity;
  - (c) a polynucleotide which is at least 75% identical to the polynucleotide of (a), and which encodes a polypeptide having endolysin activity;
  - (d) a polynucleotide encoding a polypeptide having an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 2 and having endolysin activity;
  - (e) a polynucleotide which hybridizes under stringent conditions to the polynucleotide of any one of (a) to (d);
  - (f) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1;
  - (g) a polynucleotide which is at least 75% identical to the nucleotide sequence of SEQ ID NO: 1 and which encodes a polypeptide having endolysin activity;
  - (h) a polynucleotide comprising part of the nucleotide sequence of (f) and which encodes a fragment, analog or functional derivative of the polypeptide having the amino acid sequence of SEQ ID NO: 2, wherein said fragment, analog or functional derivative has endolysin activity; and



(i) a polynucleotide that is the complement of the full length of a polynucleotide of any of (a) to (h).

4. A vector comprising the nucleic acid molecule of item 3.

5. A host cell transformed or transfected with the nucleic acid molecule of item 3, or the vector of item 4.

6. The host cell of item 5, containing a polypeptide expressed from the nucleic acid molecule of item 3, or from the vector of item 4.

7. A method of making a polypeptide encoded by the nucleic acid molecule of item 3, comprising culturing the host cell of item 5 under conditions such that the polypeptide encoded by the nucleic acid molecule of item 3 is expressed, and recovering the polypeptide encoded by said nucleic acid molecule.

8. A polypeptide encoded by the nucleic acid molecule of item 3, or obtainable by the method of item 7.

9. An endolysin protein obtainable from (i) the bacteriophage of item 1 or 2, or (ii) bacteriophage ProCC P825 deposited under accession No. DSM 23783, or a fragment, analog or functional derivative thereof having endolysin activity.

10. A chimeric lysin protein comprising:

(i) the polypeptide of item 8 or the endolysin protein of item 9 and a heterologous protein, wherein the chimeric lysin protein has lysin activity; or

(ii) the polypeptide of item 8 or the endolysin protein of item 9, wherein the enzymatically active domain (EAD) of the polypeptide of item 8 or the endolysin protein of item 9 is substituted with an EAD of a heterologous lysin protein, wherein the chimeric lysin has lysin activity.

11. A composition, preferably a pharmaceutical composition or a disinfecting composition, comprising (i) the bacteriophage of item 1 or 2, (ii) the nucleic acid molecule of item 3, (iii) the vector of item 4, (iv) the host cell of item 5 or 6, (v) the polypeptide of item 8, (vi) the endolysin protein of item 9, or (vii) the chimeric lysin of item 10.

12. A solution, preferably a disinfecting solution, comprising (i) the bacteriophage of item 1 or 2, (ii) the nucleic acid molecule of item 3, (iii) the vector of item 4, (iv) the host cell of item 5 or 6, (v) the polypeptide of item 8, (vi) the endolysin protein of item 9, or (vii) the chimeric lysin of item 10.

13. A method for controlling *Listeria* contamination, preferably for sanitizing and/or disinfecting *Listeria* contamination, comprising applying the composition according to item 11 or the solution of item 12 to the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method.

14. Use of (i) the bacteriophage of item 1 or 2, (ii) the nucleic acid molecule of item 3, (iii) the vector of item 4, (iv) the host cell of item 5 or 6, (v) the polypeptide of item 8, (vi) the endolysin protein of item 9, or (vii) the chimeric lysin of item 10 in a method for controlling *Listeria* contamination, preferably for sanitizing and/or disinfecting *Listeria* contamination, with the proviso that the method is not a therapeutic method.

15. The bacteriophage of item 1 or 2, the nucleic acid molecule of item 3, the vector of item 4, the host cell of item 5 or 6, the polypeptide of item 8, the endolysin protein of item 9, or the chimeric lysin of item 10 for use in the treatment and/or prevention of a *Listeria* infection.

16. A kit comprising (i) the bacteriophage of item 1 or 2, (ii) the nucleic acid molecule of item 3, (iii) the vector of item 4, (iv) the host cell of item 5 or 6, (v) the polypeptide of item 8, (vi) the endolysin protein of item 9, or (vii) the chimeric lysin of item 10.

17. An antibody or fragment thereof that binds specifically to the polypeptide of item 8, the endolysin protein of item 9, or the chimeric lysin protein of item 10.

18. A nucleic acid molecule comprising the DNA sequence of the genome of the bacteriophage of item 1 or 2.

19. A product comprising (i) the bacteriophage of item 1 or 2, (ii) the polypeptide of item 8, (iii) the endolysin protein of item 9, or (iv) the chimeric lysin of item 10.

20. The product of item 19, which is a food product, preferably a dairy product.

21. A bacteriophage having lytic activity against *Listeria* serovar 3 obtainable by (a) plating a sample containing bacteriophage and *Listeria* bacteria serovar 3 to obtain plaques, and (b) purifying the phage contained within the one or more plaques.

22. A bacteriophage, which has lytic activity against *Listeria* serovar 3.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows trypsin digestion of endolysins PlyP825, Ply511 and PlyP40. Aliquots were analyzed at 0 and 3 min. The marker is shown in kDa. Analysis was performed on a 4-12% SDS-Gel (NuPage Novex, Invitrogen).

FIG. 2 shows MBC (minimum bactericidal concentration) testing of endolysins PlyP825, Ply511 and PlyP40 in buffer pH 6 against *Listeria monocytogenes* EGDe sv 1/2a and *Listeria innocua* WSLC2011 sv 6a. Buffer: 20 mM sodium phosphate, 50 mM sodium chloride, 0.05% Tween pH 6.

FIG. 3 shows MBC testing of endolysins PlyP825, Ply511 and PlyP40 in milk 1.5% fat against *Listeria monocytogenes* EGDe sv 1/2a and *Listeria innocua* WSLC2011 sv 6a. Testing was performed with 20 µg/ml endolysin.

FIG. 4 shows MBC testing of endolysins PlyP825, Ply511 and PlyP40 in milk 3.5% fat against *Listeria monocytogenes* EGDe sv 1/2a. Testing was performed with 20 µg/ml endolysin.

FIG. 5 shows a comparison of the relative lytic activity of endolysins Ply511, PlyP40, and PlyP825 as a function of the pH.

FIG. 6 shows a comparison of the relative lytic activity of endolysins Ply511, PlyP40, and PlyP825 as a function of the salt concentration.

FIG. 7 shows a comparison of the relative lytic activity of endolysins Ply511, PlyP40, and PlyP825 as a function of the EDTA concentration.

FIG. 8 shows a comparison of the MIC of endolysins Ply511, PlyP40, and PlyP825 against *Listeria monocytogenes* ProCC S1095 sv 1/2a, *Listeria monocytogenes* ProCC S1135 sv 3a, *Listeria monocytogenes* ProCC S776 sv 4b, and *Listeria innocua* ProCC S1147 sv 6a.

#### DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

Bacteriophage-encoded endolysins are highly active enzymes, which hydrolyze bacterial cell walls. These phage-encoded cell wall lytic enzymes are synthesized late during virus replication and mediate the release of progeny virions. Endolysins can be used to lyse *Listeria* cells in various applications including *Listeria* contamination and infection. Endolysins can also be used to lyse *Listeria* cells simply to recover nucleic acids or cellular protein for detection or differentiation.

The novel *Listeria*-specific bacteriophage ProCC P825 ("P825") provided by the present invention has been deposited internationally on Jul. 14, 2010 at the DSMZ—



Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany, under international deposit accession No. DSM No. 23783 in accordance with the Budapest treaty concerning deposit of cell cultures. The address of DSMZ is Inhoffenstr. 7B, 38124 Braunschweig, Germany.

The name and address of the depositor of the novel bacteriophage P825 is as follows: Hyglos Invest GmbH, Am Neuland 1, 82347 Bernried, Germany. Evidence is provided by a separate document enclosed with this application that the depositor Hyglos Invest GmbH, Bernried, Germany, has authorized the applicant to refer to the deposited biological material in the present application, and has given his unre- served and irrevocable consent to the deposited material being made available to the public (in accordance with, for example, Rule 33 EPC). In addition, said separate document provides evidence that the depositor Hyglos Invest GmbH, Bernried, Germany, has given his consent that the applicant makes use of the so-called "expert solution" (in accordance with, for example, Rule 32 EPC).

The novel *Listeria*-specific bacteriophages provided by the present invention are capable of lysing *Listeria* serovars 1/2, 3, 4, 5 and 6. Thus, bacteriophages according to the present invention are broad host range bacteriophages. Importantly, these novel phages are capable of lysing *Listeria* serovar 3, which is one of the clinically relevant *Listeria* serovars. Therefore, bacteriophages of the present invention are in particular those which are capable of lysing *Listeria* serovar 3. This activity is unique to the novel bacteriophages provided by the present invention. *Listeria*-specific bacteriophages described in the art do not exhibit this specific property. The novel bacteriophages provided by the present invention are strictly lytic and therefore invariably lethal to a *Listeria* bacterial cell after infection. The lytic activity comes from the endolysin encoded by the novel phages capable of lysing *Listeria* serovars 1/2, 3, 4, 5 and 6. Therefore, the endolysin encoded by the novel bacteriophages of the present invention can be used for controlling *Listeria* contamination and infection. The endolysins encoded by the novel bacteriophages comprise an EAD (enzymatically active domain), which contributes for the lytic activity of the endolysin, and a CBD (cell wall binding domain), which targets the lysin to its substrate.

In various embodiments, a novel *Listeria*-specific bacteriophage provided by the present invention is a non-modified bacteriophage capable of lysing *Listeria* serovars 1/2, 3, 4, 5 and 6, in particular a non-modified bacteriophage capable of lysing *Listeria* serovar 3. As used herein, a non-modified bacteriophage is a wild-type bacteriophage.

The novel *Listeria* bacteriophage P825 is capable of lysing *Listeria* serovars 1/2, 3, 4, 5 and 6. Importantly, phage P825 is capable of lysing *Listeria* serovar 3, which is one of the clinically relevant *Listeria* serovars. This activity is unique to the novel bacteriophage P825. Bacteriophages described in the art do not exhibit this specific property. The novel *Listeria* bacteriophage P825 is strictly lytic and therefore invariably lethal to a *Listeria* bacterial cell after infection. The lytic activity comes from the endolysin PlyP825 encoded by the phage P825. Therefore, PlyP825 can be used for controlling *Listeria* contamination and infection. PlyP825 comprises an EAD (enzymatically active domain), which contributes for the lytic activity of the endolysin, and a CBD (cell wall binding domain), which targets the lysin to its substrate. The nucleotide and amino acid sequence of the PlyP825 EAD are shown in SEQ ID NOs: 3 and 4, respectively. The nucleic acid sequence encoding the PlyP825 EAD comprises nucleotides 1 to 426 of SEQ ID NO: 1. The

amino acid sequence of the PlyP825 EAD comprises amino acid residues 1 (M1) to 142 (E142) of SEQ ID NO: 2. In the present invention, the EAD of SEQ ID NO: 4 may also be called "the lytic domain" of the PlyP825 endolysin of SEQ ID NO: 2.

The nucleotide and amino acid sequence of the PlyP825 CBD are shown in SEQ ID NOs: 5 and 6, respectively. The nucleic acid sequence encoding the PlyP825 CBD comprises nucleotides 487 to 945 of SEQ ID NO: 1. The amino acid sequence of the PlyP825 CBD comprises amino acid residues 163 (G163) to 315 (N315) of SEQ ID NO: 2. In the present invention, the CBD of SEQ ID NO: 4 may also be called "the cell wall binding domain" of the PlyP825 endolysin of SEQ ID NO: 2.

The nucleotide sequence of the genome of phage P825 is depicted in SEQ ID NO: 7, and contains 66,849 nucleotides, including the stop codon.

#### Lytic Activity of Phages of the Present Invention

The phages provided by the present invention exhibit lytic activity against *Listeria* bacteria. As demonstrated by the inventors, phage P825 completely inhibited growth of *Listeria monocytogenes* strains. Phage P825 not only inhibited growth but actually reduced *Listeria* titers. As confirmed by enrichment studies, applying phage P825 completely eradicated *Listeria* bacteria. The lysis spectrum of phage P825 has been shown to be consistent with the host specificity provided by the tail spike protein of phage P825 responsible for receptor binding on the *Listeria* cell surface.

The present invention provides bacteriophages capable of lysing *Listeria* serovars 1/2, 3, 4, 5, and 6. A preferred phage is phage P825. The present invention also provides phages that are capable of lysing *Listeria* serovars 1/2, 3, 4, 5, 6 and 7. A preferred phage is phage P825. In various embodiments, a phage according to the present invention is capable of specifically lysing *Listeria* serovar 3. A preferred phage is phage P825.

As described above, the phages provided by the present invention exhibit lytic activity against *Listeria* bacteria, i.e., they have the activity of lysing *Listeria* bacteria, in particular *Listeria* serovars 1/2, 3, 4, 5, 6 and 7, in particular *Listeria* serovar 3. In the context of the present invention, the terms "exhibiting lytic activity against *Listeria* bacteria", "having lytic activity against *Listeria* bacteria", "having the activity of lysing *Listeria* bacteria" and "being capable of lysing *Listeria* bacteria" may be used interchangeably. The present invention provides a bacteriophage capable of lysing *Listeria* bacteria, preferably *Listeria monocytogenes*, wherein the bacteriophage has a genome (i) comprising the DNA sequence of SEQ ID NO: 7; (ii) having at least 90% or 95% sequence identity with the DNA sequence of SEQ ID NO: 7; or (iii) having at least 90% or 95% sequence identity with the DNA sequence of the genome of bacteriophage ProCC P825 deposited under accession No. DSM 23783. In various embodiments, the phage provided by the present invention is capable of lysing any one of the *Listeria* species described herein. In various embodiments, the phage according to the present invention has a genome having at least 96%, 97%, 98%, or 99% sequence identity with the DNA sequence of the genome of bacteriophage ProCC P825 deposited under accession No. DSM 23783. In various embodiments, the phage according to the present invention has a genome having at least 96%, 97%, 98%, or 99% sequence identity with the DNA sequence of SEQ ID NO: 7. Preferably, the phage according to the present invention is bacteriophage ProCC P825 deposited under accession No. DSM 23783.



The present invention provides a nucleic acid molecule comprising the DNA sequence of the genome of a bacteriophage according to the present invention. In various embodiments, the nucleic acid molecule comprises the DNA sequence of SEQ ID NO: 7. In various embodiments, the nucleic acid molecule has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the DNA sequence of SEQ ID NO: 7. In various embodiments, the nucleic acid molecule has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the DNA sequence of the genome of bacteriophage ProCC P825 deposited under accession No. DSM 23783. The present invention provides any polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 7 or variants thereof as described herein above.

#### Lytic Activity of Proteins of the Invention

A major problem of phage endolysins is the proteolytic instability. Until now, two *Listeria* endolysins are known that are not restricted to lyse distinct *Listeria* serovars like Ply500 and Ply118 (Loessner et al., 2002), but are able to lyse several *Listeria* serovars: Ply511 of *Listeria* phage A511 and PlyP40 of *Listeria* phage P40. However, a bacteriophage according to the present invention is capable of lysing all of serovars 1/2, 3, 4, 5, and 6. This property is unique to bacteriophages of the present invention. Thus, bacteriophages according to the present invention are broad host range bacteriophages. Importantly, bacteriophages of the present invention are capable of lysing *Listeria* serovar 3, which is one of the clinically relevant serovars. This activity is not shared by any known *Listeria*-specific bacteriophages.

In order to compare the proteolytic sensitivity of the three endolysins of phages A511, P40, and P825, they were Trypsin-digested in equimolar amounts. Aliquots were retained and analyzed after 0 and 3 min incubation at room temperature (FIG. 1). As shown in FIG. 1, PlyP825 shows less proteolytic degradation sites than Ply511 and PlyP40.

PlyP825 was analyzed for its activity against different *Listeria* strains with serovars 1/2, 3, 4, 5 and 6. Exponential *Listeria* cells were poured in LB-Top Agar in plates. Onto the solidified agar 2 µg of PlyP825 was spotted. After incubation over night at 30° C. all 22 strains tested were lysed by the endolysin PlyP825 (Table 2). Thus, PlyP825 is a broad range *Listeria* endolysin.

The minimum bactericidal concentrations (MBC) of endolysins PlyP825, Ply511 and PlyP40 in buffer and in milk were determined and compared. For determining the MBC in buffer pH 6 the endolysin enzymes were incubated with 10<sup>5</sup> cells/ml of strains *Listeria monocytogenes* EGDe sv 1/2a and *Listeria innocua* WSLC2011 sv 6a in buffer (20 mM Sodium-phosphate, 50 mM sodium chloride, 0.05% Tween 20 pH 6) at 30° C. After 1 h the samples were plated and cell numbers counted. FIG. 2 shows the results: PlyP825 reduces effectively pathogenic and non-pathogenic *Listeria* cells in buffer: 0.032 µg/ml endolysin were sufficient to reduce 4.5 (WSLC2011) or 3.1 (EGDe) orders of magnitude of *Listeria* cells. This is about 0.5 to 1.5 log more than Ply511 and 0.9-1.3 log more than PlyP40 were able to reduce with the same protein concentration.

For determining the MBC in milk the enzymes were incubated with 10<sup>5</sup> cells/ml of strains *Listeria monocytogenes* EGDe sv 1/2a and *Listeria innocua* WSLC2011 sv 6a in milk with 1.5% fat at 30° C. After 3 h the samples were plated and cell numbers counted. FIG. 3 shows the results: PlyP825 shows the highest *Listeria* cell reduction in milk. Independent from the test strain PlyP825 reduces 1.4-1.7 orders of magnitude more cells than the other two broad *Listeria* endolysins Ply511 and PlyP40 in milk with 1.5% fat.

Besides the enzymes were incubated with 10<sup>5</sup> cells/ml of strains *Listeria monocytogenes* EGDe sv 1/2a in milk with 3.5% fat at 30° C. After 3 h the samples were plated and cell numbers counted. FIG. 4 shows the results: Also in milk with 3.5% fat PlyP825 reduces the highest cell number.

#### PlyP825 Nucleic Acid and Amino Acid Sequences and Variants Thereof

The present invention provides a nucleic acid molecule comprising a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2. The present invention also provides a nucleic acid molecule, which comprises a polynucleotide that is at least 75% or at least 80% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. The present invention further provides a nucleic acid molecule, which comprises a polynucleotide that is at least 85% or at least 90% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. In various embodiments, the said nucleic acid molecule comprises a polynucleotide that is at least 91% or at least 92% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. Preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 93% or at least 94% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. More preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 95% or at least 96% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. Still more preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 97%, at least 98%, or even at least 99% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2.

Furthermore, the present invention provides a nucleic acid molecule comprising a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 75% or at least 80% identical to the amino acid sequence of SEQ ID NO: 2, and which has endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. The present invention also provides a nucleic acid molecule comprising a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 85% or at least 90% identical to the amino acid sequence of SEQ ID NO: 2, and which has endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. In various embodiments, the said nucleic acid molecule comprises a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 91% or at least 92% identical to the amino acid sequence of SEQ ID NO: 2, and which has endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. Preferably, the said nucleic acid molecule comprises a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 93% or at least 94% identical to the amino acid sequence of SEQ ID NO: 2, and which has endolysin activity, preferably the activity of the



endolysin of SEQ ID NO: 2. More preferably, the said nucleic acid molecule comprises a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 95% or at least 96% identical to the amino acid sequence of SEQ ID NO: 2, and which has endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. Still more preferably, the said nucleic acid molecule comprises a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 97%, at least 98%, or even 99% identical to the amino acid sequence of SEQ ID NO: 2, and which has endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2.

Furthermore, the present invention provides a nucleic acid molecule comprising a polynucleotide, which encodes a fragment, analog or functional derivative of a polypeptide encoded by a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2, wherein said fragment, analog or functional derivative has endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. Preferably, the said nucleic acid molecule comprises a polynucleotide, which encodes a fragment, analog or functional derivative of a polypeptide encoded by the polynucleotide of SEQ ID NO: 1, wherein said fragment, analog or functional derivative has endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2.

The present invention provides a nucleic acid molecule comprising a polynucleotide, which hybridizes under stringent conditions to any one of the polynucleotides described in the three preceding paragraphs. The present invention also provides a nucleic acid molecule comprising a polynucleotide that is the complement of the full-length of any one of the polynucleotides described in the three preceding paragraphs.

The present invention provides a nucleic acid molecule comprising a polynucleotide having the nucleotide sequence of SEQ ID NO: 1. The present invention also provides a nucleic acid molecule, which comprises a polynucleotide that is at least 75% or at least 80% identical to the nucleotide sequence of SEQ ID NO: 1, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. The present invention further provides a nucleic acid molecule, which comprises a polynucleotide that is at least 85% or at least 90% identical to the nucleotide sequence of SEQ ID NO: 1, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. In various embodiments, the said nucleic acid molecule comprises a polynucleotide that is at least 91% or at least 92% identical to the nucleotide sequence of SEQ ID NO: 1, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. Preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 93% or at least 94% identical to the nucleotide sequence of SEQ ID NO: 1, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. More preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 95% or at least 96% identical to the nucleotide sequence of SEQ ID NO: 1, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2. Still more preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 97%, at least 98%, or even at least 99% identical to the nucleotide sequence of SEQ ID NO: 1, and that encodes a polypeptide having endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2.

Furthermore, the present invention provides a nucleic acid molecule comprising a polynucleotide that is a part of the nucleotide sequence of SEQ ID NO: 1, and that encodes a fragment, analog or functional derivative of the polypeptide having the amino acid sequence of SEQ ID NO: 2, wherein said fragment, analog or functional derivative has endolysin activity, preferably the activity of the endolysin of SEQ ID NO: 2.

The present invention provides a nucleic acid molecule comprising a polynucleotide, which hybridizes under stringent conditions to any one of the polynucleotides described in the two preceding paragraphs. Preferably, the present invention provides a nucleic acid molecule comprising a polynucleotide, which hybridizes under stringent conditions to the polynucleotide of SEQ ID NO: 1. The present invention also provides a nucleic acid molecule comprising a polynucleotide that is the complement of the full-length of any one of the polynucleotides described in the two preceding paragraphs. Preferably the present invention provides a nucleic acid molecule comprising a polynucleotide that is the complement of the full-length of the polynucleotide of SEQ ID NO: 1.

PlyP825 EAD Nucleic Acid and Amino Acid Sequences and Variants Thereof

The present invention provides a nucleic acid molecule comprising a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 4. The present invention also provides a nucleic acid molecule, which comprises a polynucleotide that is at least 75% or at least 80% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 4, and that encodes a polypeptide having the lytic activity of the EAD of SEQ ID NO: 4. The present invention further provides a nucleic acid molecule, which comprises a polynucleotide that is at least 85% or at least 90% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 4, and that encodes a polypeptide having the lytic activity of the EAD of SEQ ID NO: 4. In various embodiments, the said nucleic acid molecule comprises a polynucleotide that is at least 91% or at least 92% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 4, and that encodes a polypeptide having the lytic activity of the EAD of SEQ ID NO: 4. Preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 93% or at least 94% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 4, and that encodes a polypeptide having the lytic activity of the EAD of SEQ ID NO: 4. More preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 95% or at least 96% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 4, and that encodes a polypeptide having the lytic activity of the EAD of SEQ ID NO: 4. Still more preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 97%, at least 98%, or even at least 99% identical to a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 4, and that encodes a polypeptide having the lytic activity of the EAD of SEQ ID NO: 4.

Furthermore, the present invention provides a nucleic acid molecule comprising a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 75% or at least 80% identical to the amino acid sequence of SEQ ID NO: 4, and which has the lytic activity of the EAD of SEQ ID NO: 4. The present invention also provides a nucleic acid molecule comprising a polynucleotide, which encodes a polypeptide having an amino acid sequence that







Furthermore, the present invention provides a nucleic acid molecule comprising a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 75% or at least 80% identical to the amino acid sequence of SEQ ID NO: 6, and which has the cell wall binding activity of the CBD of SEQ ID NO: 6. The present invention also provides a nucleic acid molecule comprising a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 85% or at least 90% identical to the amino acid sequence of SEQ ID NO: 6, and which has the cell wall binding activity of the CBD of SEQ ID NO: 6. In various embodiments, the said nucleic acid molecule comprises a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 91% or at least 92% identical to the amino acid sequence of SEQ ID NO: 6, and which has the cell wall binding activity of the CBD of SEQ ID NO: 6. Preferably, the said nucleic acid molecule comprises a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 93% or at least 94% identical to the amino acid sequence of SEQ ID NO: 6, and which has the cell wall binding activity of the CBD of SEQ ID NO: 6. More preferably, the said nucleic acid molecule comprises a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 95% or at least 96% identical to the amino acid sequence of SEQ ID NO: 6, and which has the cell wall binding activity of the CBD of SEQ ID NO: 6. Still more preferably, the said nucleic acid molecule comprises a polynucleotide, which encodes a polypeptide having an amino acid sequence that is at least 97%, at least 98%, or even 99% identical to the amino acid sequence of SEQ ID NO: 6, and which has the cell wall binding activity of the CBD of SEQ ID NO: 6.

Furthermore, the present invention provides a nucleic acid molecule comprising a polynucleotide, which encodes a fragment, analog or functional derivative of a polypeptide encoded by a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 6, wherein said fragment, analog or functional derivative has the cell wall binding activity of the CBD of SEQ ID NO: 6. Preferably, the said nucleic acid molecule comprises a polynucleotide, which encodes a fragment, analog or functional derivative of a polypeptide encoded by the polynucleotide of SEQ ID NO: 5, wherein said fragment, analog or functional derivative has the cell wall binding activity of the CBD of SEQ ID NO: 6.

The present invention provides a nucleic acid molecule comprising a polynucleotide, which hybridizes under stringent conditions to any one of the polynucleotides described in the three preceding paragraphs. The present invention also provides a nucleic acid molecule comprising a polynucleotide that is the complement of the full-length of any one of the polynucleotides described in the three preceding paragraphs.

The present invention provides a nucleic acid molecule comprising a polynucleotide having the nucleotide sequence of SEQ ID NO: 5. The present invention also provides a nucleic acid molecule, which comprises a polynucleotide that is at least 75% or at least 80% identical to the nucleotide sequence of SEQ ID NO: 5, and that encodes a polypeptide having the cell wall binding activity of the CBD of SEQ ID NO: 6. The present invention further provides a nucleic acid molecule, which comprises a polynucleotide that is at least 85% or at least 90% identical to the nucleotide sequence of SEQ ID NO: 5, and that encodes a polypeptide having the cell wall binding activity of the CBD of SEQ ID NO: 6. In various embodiments, the said nucleic acid molecule comprises a polynucleotide that is at least 91% or at least 92% identical to the nucleotide sequence of SEQ ID NO: 5, and

that encodes a polypeptide having the cell wall binding activity of the CBD of SEQ ID NO: 6. Preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 93% or at least 94% identical to the nucleotide sequence of SEQ ID NO: 5, and that encodes a polypeptide having the cell wall binding activity of the CBD of SEQ ID NO: 6. More preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 95% or at least 96% identical to the nucleotide sequence of SEQ ID NO: 5, and that encodes a polypeptide having the cell wall binding activity of the CBD of SEQ ID NO: 6. Still more preferably, the said nucleic acid molecule comprises a polynucleotide that is at least 97%, at least 98%, or even at least 99% identical to the nucleotide sequence of SEQ ID NO: 5, and that encodes a polypeptide having the cell wall binding activity of the CBD of SEQ ID NO: 6.

Furthermore, the present invention provides a nucleic acid molecule comprising a polynucleotide that is a part of the nucleotide sequence of SEQ ID NO: 5, and that encodes a fragment, analog or functional derivative of the polypeptide having the amino acid sequence of SEQ ID NO: 6, wherein said fragment, analog or functional derivative has the cell wall binding activity of the CBD of SEQ ID NO: 6.

The present invention provides a nucleic acid molecule comprising a polynucleotide, which hybridizes under stringent conditions to any one of the polynucleotides described in the two preceding paragraphs. Preferably, the present invention provides a nucleic acid molecule comprising a polynucleotide, which hybridizes under stringent conditions to the polynucleotide of SEQ ID NO: 5. The present invention also provides a nucleic acid molecule comprising a polynucleotide that is the complement of the full-length of any one of the polynucleotides described in the two preceding paragraphs. Preferably the present invention provides a nucleic acid molecule comprising a polynucleotide that is the complement of the full-length of the polynucleotide of SEQ ID NO: 5.

For a variant polypeptide of the present invention having an amino acid sequence at least, for example, 95% "identical" to the reference amino acid sequence of a reference polypeptide defined by a certain SEQ ID NO, is intended that the amino acid sequence of the variant polypeptide is identical to the reference amino acid sequence, except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the reference polypeptide shown in the respective SEQ ID NO. In other words, to obtain a variant polypeptide having an amino acid sequence at least 95% identical to the reference amino acid sequence of a certain reference SEQ ID NO, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the N-terminal or C-terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of a reference SEQ ID NO can be determined conventionally using appropriate computer programs (i.e., sequence alignment programs) known in the art.

As used herein, a nucleic acid molecule of the present invention is DNA or RNA.



## Vectors and Host Cells

The present invention provides recombinant vectors containing nucleic acid molecules of the present invention. In various embodiments, provided is a single recombinant vector containing a single nucleic acid molecule of the present invention. In various other embodiments, provided is a single recombinant vector containing several nucleic acid molecules of the present invention. In still other embodiments, provided are several recombinant vectors each containing a single nucleic acid molecule of the present invention. In still further embodiments, provided are several recombinant vectors each containing several nucleic acid molecules of the present invention.

In various embodiments, the nucleic acid molecule or nucleic acid molecules contained in a single or several vectors according to the present invention are operatively linked to an expression control sequence allowing expression of the polynucleotide or polynucleotides in prokaryotic or eukaryotic host cells. Preferably, the expression control sequence is a promoter or a promoter sequence. Suitable promoters are known to the skilled artisan. In various embodiments, the vector is a plasmid. Other suitable vectors will be readily apparent to the skilled artisan. A recombinant vector according to the present invention may also be called expression vector or expression construct.

The expression constructs according to the present invention may further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the EAD and/or CBD of the transcripts expressed by the constructs according to the present invention will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

In various embodiments, the expression vectors according to the present invention will include at least one selectable marker. Suitable selection markers are known to the skilled artisan.

The present invention provides a method of making a recombinant vector comprising inserting a nucleic acid molecule of the present invention into a vector.

The present invention also provides a method of making a recombinant host cell comprising introducing a nucleic acid molecule or a recombinant vector according to the present invention into a host cell.

The present invention also provides a host cell genetically engineered with a nucleic acid molecule or a recombinant vector according to the present invention. In various embodiments, "genetically engineered" means that the host cell is transformed or transfected with a nucleic acid molecule or a recombinant vector according to the present invention. In various embodiments, the genetically engineered host cell according to the present invention contains a polypeptide expressed from a nucleic acid molecule or from a recombinant vector in accordance with the present invention. Representative examples of appropriate host cells include, but are not limited to, bacterial cells such as *E. coli* cells, fungal cells such as yeast cells, insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells, animal cells such as CHO, COS, and HEK293 cells, and plant cells. Appropriate culture mediums and conditions for host cells of the present invention are known in the art.

## Proteins/Polypeptides

Recombinant proteins of the present invention can be isolated and purified from a host cell of the present invention containing or expressing the proteins/polypeptides by techniques known in the art including, but not limited to, lysis,

chromatography, filtration, and centrifugation. In various embodiments, the isolated and/or purified protein according to the present invention is labeled. Preferably, the label is selected from the group consisting of an enzyme label, a radioisotope, a fluorescent label, and biotin.

A protein of the present invention having lytic activity, preferably the PlyP825 endolysin, can be isolated from the host cell prior to administration in methods of controlling *Listeria* contamination and infection according to the present invention, or the host cell containing the recombinant protein can be directly applied or administered without prior isolation of the protein having lytic activity. For example, a host bacterium, which produces the PlyP825 endolysin of the present invention can be applied in methods of controlling *Listeria* contamination and infection according to the present invention where the endolysin would be secreted, for example, into food or foodstuff, onto a surface or in the gut of a subject. The PlyP825 endolysin of the present invention can then attack *Listeria* cells present in such an environment.

The present invention also provides a method of making a polypeptide of the present invention encoded by a nucleic acid molecule of the present invention, wherein the method comprises (i) culturing a genetically engineered host cell of the present invention under conditions such that the polypeptide encoded by a nucleic acid molecule of the present invention is expressed, and (ii) recovering the polypeptide encoded by the nucleic acid molecule. The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For example, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage of the polypeptide. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides of the present invention for, inter alia, inducing secretion, improving stability and/or facilitating purification are familiar to the ones of ordinary skill and belong to routine techniques in the art. A preferred fusion protein comprises a heterologous region from an immunoglobulin that is useful to stabilize and purify proteins.

As one of skill in the art will appreciate, polypeptides of the present invention can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins may facilitate purification and may show an increased half-life in vivo.

For many proteins it is known in the art that one or more amino acids may be deleted from the N-terminus or C-terminus without substantial loss of biological function or activity. Here, biological function/activity includes any function and activity of the proteins of the present invention described herein including, but not limited to, any lytic function/activity and cell wall binding function/activity described herein.

In the present invention, since the protein of SEQ ID NO: 2 is a member of the endolysin polypeptide family, deletions of C-terminal amino acids up to the Arg (R) residue at position 143 in SEQ ID NO: 2 retains the lytic activity of the endolysin protein, i.e. the lytic activity to *Listeria* bacterial cells. Accordingly, the present invention provides endolysin polypeptides having one or more residues deleted from the C-terminus of the amino acid sequence of the endolysin protein of SEQ ID NO: 2, up to the Arg residue at position



143 (R143) in the amino acid sequence of SEQ ID NO: 2, and polynucleotides encoding such polypeptides.

The present invention provides polypeptides encoded by the nucleic acid molecules of the present invention. The present invention also provides polypeptides obtainable by methods of making the polypeptides according to the present invention. Therefore, the present invention encompasses and provides each polypeptide that is encoded by any nucleic acid molecule of the present invention. Furthermore, the present invention encompasses and provides each polypeptide that is obtainable by any method of making the polypeptide according to the present invention.

#### Antibodies

The present invention also provides an antibody or fragment thereof that binds specifically to a polypeptide of the present invention. Preferably, the antibody specifically binds to the full-length polypeptide having the amino acid sequence of SEQ ID NO: 2, 4 or 6. In various embodiments, the antibody specifically binds to the lytic domain of the endolysin polypeptide having the amino acid sequence of SEQ ID NO: 2, wherein the lytic domain comprises the amino acid sequence of residues 1 (M1) to 142 (E142) of SEQ ID NO: 2. In various embodiments, the antibody specifically binds to the cell wall binding domain of the endolysin polypeptide having the amino acid sequence of SEQ ID NO: 2, wherein the cell wall binding domain comprises the amino acid sequence of residues 163 (G163) to 315 (N315) of SEQ ID NO: 2.

In various embodiments, the antibody of the present invention is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a Fab fragment, a F(ab')<sub>2</sub> fragment, and a scFv fragment. In various embodiments, the antibody according to the present invention is labeled. Preferably, the label is selected from the group consisting of an enzyme label, a radioisotope, a fluorescent label, and biotin. The polypeptides of the present invention can be used to raise polyclonal and monoclonal antibodies provided by the present invention. The antibodies of the present invention may be prepared by any of a variety of methods available in the art and known to the skilled artisan.

The antibody fragments provided by the present invention, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acid residues, provided the activity of the antibody fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding. In any case, antibody fragments according to the present invention must possess a bioactive property, such as specific binding to its cognate antigen.

Functional or active regions of the antibodies or antibody fragments of the present invention may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody or antibody fragment.

#### Combinations of Proteins of the Invention with Known *Listeria*-Specific Phages

The present invention provides the combination of a protein of the present invention, preferably an endolysin protein, with one or more other *Listeria*-specific bacteriophages described in the art. Such combinations can be used for controlling *Listeria* contamination and/or infection

according to the present invention. In various embodiments concerning the combination of a protein of the present invention with one or more *Listeria* bacteriophages known in the art the protein of the present invention is the lytic domain of an endolysin protein according to the present invention. Preferably, the lytic domain of an endolysin protein according to the present invention is an EAD according to the present invention. In various other embodiments concerning the combination of a protein of the present invention with one or more *Listeria* bacteriophages known in the art the protein of the present invention is the cell wall binding domain of an endolysin protein according to the present invention. Preferably, the cell wall binding domain of an endolysin protein according to the present invention is a CBD to the present invention.

#### Combinations of Proteins of the Invention with Known Endolysins

Also provided by the present invention is the combination of a protein of the present invention, preferably an endolysin protein, with one or more endolysins from other *Listeria*-specific bacteriophages described in the art. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention. In various embodiments concerning the combination of a protein of the present invention with one or more endolysins from *Listeria* bacteriophages known in the art the protein of the present invention is the lytic domain of an endolysin protein according to the present invention. Preferably, the lytic domain of an endolysin protein according to the present invention is an EAD according to the present invention. In various other embodiments concerning the combination of a protein of the present invention with one or more endolysins from *Listeria* bacteriophages known in the art the protein of the present invention is the cell wall binding domain of an endolysin protein according to the present invention. Preferably, the cell wall binding domain of an endolysin protein according to the present invention is a CBD to the present invention.

#### Combinations of Proteins of the Invention with Known Lytic Domains

The present invention provides the combination of a protein of the present invention, preferably an endolysin protein, with one or more lytic domains of endolysins from other *Listeria*-specific bacteriophages described in the art. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention. Furthermore, based on sequence homology the skilled person is also able to determine the lytic domain of the endolysins encoded by known phages. In various embodiments concerning the combination of a protein of the present invention with one or more lytic domains of endolysins from *Listeria* bacteriophages known in the art the protein of the present invention is the lytic domain of an endolysin protein according to the present invention. Preferably, the lytic domain of an endolysin protein according to the present invention is an EAD according to the present invention. In various other embodiments concerning the combination of a protein of the present invention with one or more lytic domains of endolysins from *Listeria* bacteriophages known in the art the protein of the present invention is the cell wall binding domain of an endolysin protein according to the present invention. Preferably, the cell wall binding domain of an endolysin protein according to the present invention is a CBD to the present invention.

Also provided by the present invention is the combination of a protein of the present invention, preferably an endolysin protein, with one or more lytic domains of autolysins



described in the art. Autolysins are bacteriolytic enzymes that digest the cell-wall peptidoglycan of the bacteria that produce them. Autolysins are involved in cell wall reconstruction during bacterial cell division. Thus, the present invention provides a protein of the present invention, preferably an endolysin protein, in combination with one or more lytic domains of autolysins. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention.

Also provided by the present invention is the combination of a protein of the present invention, preferably an endolysin protein, with one or more lytic domains of bacteriocins described in the art. Bacteriocins are molecules also produced and secreted by microorganisms. They are antibacterial substances of a proteinaceous nature that are produced by different bacterial species. A subclass of bacteriocins consists of enzymes (proteinaceous toxins) which are produced by bacteria to inhibit the growth of similar or closely related concurrence bacterial strain(s) in their habitat. Many bacteria produce antimicrobial bacteriocin peptides. Thus, the present invention provides a protein of the present invention, preferably an endolysin protein, in combination with one or more lytic domains of bacteriocins. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention. Based on sequence homology the skilled person is able to determine the lytic domain of bacteriocins known in the art.

Also provided by the present invention is the combination of a protein of the present invention, preferably an endolysin protein, with one or more antimicrobial peptides. Antimicrobial peptides are ubiquitous, gene-encoded natural antibiotics that have gained recent attention in the search for new antimicrobials to combat infectious disease. Antimicrobial peptides generally have a length between 12 and 50 amino acids. The amphipathicity of the antimicrobial peptides allows to partition into the membrane lipid bilayer. The ability to associate with membranes is a definitive feature of antimicrobial peptides. Thus, the present invention provides a protein of the present invention, preferably an endolysin protein, in combination with one or more antimicrobial peptides. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention.

#### Combinations of Proteins of the Invention with Known Cell Wall Binding Domains

The present invention provides the combination of a protein of the present invention, preferably an endolysin protein, with one or more cell wall binding domains of endolysins from other *Listeria* bacteriophages described in the art. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention. As for the lytic domain encoded by the endolysins from known phages, based on sequence homology the skilled person is also able to determine the cell wall binding domain of the endolysins encoded by known phages. In various embodiments concerning the combination of a protein of the present invention with one or more cell wall binding domains of endolysins from *Listeria* bacteriophages known in the art the protein of the present invention is the lytic domain of an endolysin protein according to the present invention. Preferably, the lytic domain of an endolysin protein according to the present invention is an EAD according to the present invention. In various other embodiments concerning the combination of a protein of the present invention with one or more cell wall binding domains of endolysins from *Listeria* bacteriophages known in the art the protein of the present invention is the cell wall

binding domain of an endolysin protein according to the present invention. Preferably, the cell wall binding domain of an endolysin protein according to the present invention is a CBD to the present invention.

Also provided by the present invention is the combination of a protein of the present invention, preferably an endolysin protein, with one or more cell wall binding domains of autolysins known in the art. Thus, the present invention provides a protein of the present invention, preferably an endolysin protein, in combination with one or more cell wall binding domains of autolysins. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention. Based on sequence homology the skilled person is able to determine the cell wall binding domain of autolysins known in the art.

Also provided by the present invention is the combination of a protein of the present invention, preferably an endolysin protein, with one or more cell wall binding domains of bacteriocins described in the art. Thus, the present invention provides a protein of the present invention, preferably an endolysin protein, in combination with one or more cell wall binding domains of bacteriocins. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention. Based on sequence homology the skilled

#### Chimeric Proteins

The present invention further provides a chimeric protein comprising a protein according to the present invention, preferably an endolysin protein of the present invention, and one or more heterologous proteins. Preferably, the chimeric protein of the present invention has endolysin activity. More preferably, the chimeric protein has the endolysin activity of the polypeptide of SEQ ID NO: 2. In various embodiments, the heterologous protein is a heterologous endolysin protein. In various embodiments, the chimeric protein according to the present invention comprises the lytic domain of an endolysin of the present invention and one or more heterologous proteins, wherein the lytic domain has the lytic activity of the EAD of SEQ ID NO: 4. Preferably, the lytic domain is the lytic domain of the endolysin of SEQ ID NO: 2 or the EAD of SEQ ID NO: 4. In various other embodiments, the chimeric protein according to the present invention comprises the cell wall binding domain of an endolysin of the present invention and one or more heterologous proteins, wherein the cell wall binding domain has the cell wall binding activity of the EAD of SEQ ID NO: 6. Preferably, the cell wall binding domain is the cell wall binding domain of the endolysin of SEQ ID NO: 2 or the CBD of SEQ ID NO: 6.

The present invention also provides a chimeric protein comprising an endolysin protein according to the present invention, wherein a catalytic domain of the endolysin protein is substituted with a catalytic domain of a heterologous endolysin protein, wherein the chimeric protein has endolysin activity. Preferably, such a chimeric protein has the endolysin activity of the polypeptide of SEQ ID NO: 2. In various embodiments, the catalytic domain of the endolysin protein of the present invention is the lytic domain, i.e., the EAD, and the catalytic domain of the heterologous endolysin protein is also its lytic domain. Accordingly, in various embodiments, the present invention provides a chimeric protein comprising an endolysin protein according to the present invention, wherein the lytic domain (i.e., the EAD) is substituted with the lytic domain of a heterologous endolysin protein, wherein the chimeric protein has endolysin activity. Preferably, the chimeric protein has the endolysin activity of the polypeptide of SEQ ID NO: 2. In various



embodiments, the present invention provides a chimeric protein comprising an endolysin protein according to the present invention, wherein the cell wall binding domain (i.e., the CBD) is substituted with the cell wall binding domain of a heterologous endolysin protein, wherein the chimeric protein has endolysin activity. Preferably, such a chimeric protein has the endolysin activity of the polypeptide of SEQ ID NO: 2.

The present invention further provides a chimeric protein comprising an endolysin protein of the present invention and one or more lytic domains (i.e., EADs) and/or one or more cell wall binding domains (i.e., CBDs) of other known endolysins from *Listeria* bacteriophages known in the art.

The present invention also provides a chimeric protein comprising a lytic domain of the present invention and one or more lytic domains (i.e., EADs) and/or one or more cell wall binding domains (i.e., CBDs) of other known endolysins from *Listeria* bacteriophages known in the art.

The present invention also provides a chimeric protein comprising a cell wall binding domain of the present invention and one or more lytic domains (i.e., EADs) and/or one or more cell wall binding domains (i.e., CBDs) of other known endolysins from *Listeria* bacteriophages known in the art.

In various embodiments, the chimeric proteins according to the present invention comprise more than one endolysin protein of the present invention. That is, the chimeric proteins according to the present invention may comprise tandem repeats of an endolysin protein of the present invention. Furthermore, in various embodiments the chimeric proteins according to the present invention comprise more than one lytic domain of the present invention. That is, the chimeric proteins according to the present invention may comprise one or more tandem repeats of a lytic domain of the present invention. Still further, in various embodiments the chimeric proteins according to the present invention comprise more than one cell wall binding domain of the present invention. That is, the chimeric proteins according to the present invention may comprise one or more tandem repeats of a cell wall binding domain of the present invention.

The present invention also provides chimeric proteins comprising the combination of a protein of the present invention with one or more endolysins from known *Listeria*-specific bacteriophages as described above.

The present invention also provides chimeric proteins comprising the combination of a protein of the present invention with one or more lytic domains from known endolysins as described above.

The present invention also provides chimeric proteins comprising the combination of a protein of the present invention with one or more lytic domains from known autolysins as described above.

The present invention also provides chimeric proteins comprising the combination of a protein of the present invention with one or more lytic domains from known bacteriocins as described above.

The present invention also provides chimeric proteins comprising the combination of a protein of the present invention with one or more antimicrobial peptides as described above.

The present invention also provides chimeric proteins comprising the combination of a protein of the present invention with one or more cell wall binding domains from known endolysins as described above.

The present invention also provides chimeric proteins comprising the combination of a protein of the present

invention with one or more cell wall binding domains from known autolysins as described above.

The present invention also provides chimeric proteins comprising the combination of a protein of the present invention with one or more cell wall binding domains from known bacteriocins as described above.

Combinations of Phages of the Invention with Known Phages

The present invention provides the combination of a phage of the present invention with one or more bacteriophages, preferably known *Listeria*-specific phages, described in the art. Such combinations can be used for controlling *Listeria* contamination and/or infection according to the present invention. A preferred phage used in phage combinations according to the present invention is phage P825.

Compositions and Solutions

The present invention provides compositions comprising phage combinations and/or protein combinations of the invention as described herein above. Specifically, such a combination is the combination of a protein of the present invention with one or more known *Listeria* bacteriophages. Furthermore, such a combination is particularly the combination of a protein of the present invention with one or more endolysins from known *Listeria* bacteriophages. Such a combination is also particularly the combination of a protein of the present invention with one or more lytic or cell wall binding domains of endolysins from known *Listeria* bacteriophages. Still further, such a combination is the combination of a phage of the present invention, preferably phage P825, with one or more known *Listeria* bacteriophages.

The present invention also provides compositions comprising chimeric proteins according to the present invention. In general, the present invention provides a composition comprising a protein or polypeptide according to the present invention. The present invention also provides a composition comprising a nucleic acid molecule or a vector according to the present invention. The present invention further provides a composition comprising a host cell according to the present invention. The present invention further provides a composition comprising a protein or polypeptide according to the present invention. The present invention further provides a composition comprising a chimeric lysin according to the present invention. Still further, the present invention provides a composition comprising a phage of the present invention, preferably phage P825.

In various embodiments, a composition of the present invention further comprises listeriolysin, a surface disinfectant, an antibiotic, a surfactant, a lytic enzyme, or a bacteriophage specific for bacterial contaminants other than *Listeria* bacteria.

In various embodiments, a composition according to the present invention is a pharmaceutical composition.

In various embodiments, a composition according to the present invention is a disinfecting composition.

In various embodiments, a composition according to the present invention is a diagnostic composition. A phage of the present invention, preferably phage P825, is suitable for detecting the presence of *Listeria* bacteria according to the present invention. Therefore, a diagnostic composition according to the present invention preferably comprises a phage of the present invention, more preferably phage P825.

In various embodiments, a composition of the present invention is an antibiotic for use in therapeutic and non-therapeutic applications according to the present invention.

The present invention provides solutions, preferably disinfecting solutions, comprising phage combinations and



protein combinations of the invention as described herein above. Specifically, such a combination is the combination of a protein of the present invention with one or more known *Listeria* bacteriophages. Furthermore, such a combination is particularly the combination of a protein of the present invention with one or more endolysins from known *Listeria* bacteriophages. Such a combination is also particularly the combination of a protein of the present invention with one or more lytic or cell wall binding domains of endolysins from known *Listeria* bacteriophages. Still further, such a combination is the combination of a phage of the present invention, preferably phage P825, with one or more known *Listeria* bacteriophages.

The present invention also provides solutions, preferably disinfecting solutions, comprising chimeric proteins according to the present invention. In general, the present invention provides a solution, preferably a disinfecting solution, comprising a phage or protein or polypeptide according to the present invention. The present invention also provides a solution, preferably a disinfecting solution, comprising a nucleic acid molecule or a vector according to the present invention. The present invention further provides a solution, preferably a disinfecting solution, comprising a host cell according to the present invention.

#### Products

The present invention provides products comprising chimeric proteins according to the present invention. In general, the present invention provides a product comprising a protein or polypeptide according to the present invention, including any fragments, analogs or functional derivatives thereof having endolysin activity. The present invention further provides a product comprising a chimeric lysin according to the present invention. Still further, the present invention provides a product comprising a phage of the present invention, preferably phage P825.

The present invention also provides products comprising phage combinations and/or protein combinations of the invention as described herein above. Specifically, such a combination is the combination of a protein of the present invention with one or more known *Listeria* bacteriophages. Furthermore, such a combination is particularly the combination of a protein of the present invention with one or more endolysins from known *Listeria* bacteriophages. Such a combination is also particularly the combination of a protein of the present invention with one or more lytic or cell wall binding domains of endolysins from known *Listeria* bacteriophages. Still further, such a combination is the combination of a phage of the present invention, preferably phage P825, with one or more known *Listeria* bacteriophages.

In various embodiments, a product of the present invention further comprises listeriolysin, a surface disinfectant, an antibiotic, a surfactant, a lytic enzyme, or a bacteriophage specific for bacterial contaminants other than *Listeria* bacteria.

In various embodiments, a product according to the present invention is a food product. Preferably, the food product is any of a dairy product, a fruit product and a vegetable product.

#### Methods for Controlling *Listeria* Contamination

The present invention provides a method for controlling *Listeria* contamination, preferably for sanitizing and/or disinfecting *Listeria* contamination, comprising applying a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention to the present invention to the

site of *Listeria* contamination, with the proviso that the method is not a therapeutic method.

The present invention provides a method for controlling *Listeria* contamination, preferably for sanitizing and/or disinfecting *Listeria* contamination, comprising applying a phage or a composition or solution according to the present invention to the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method.

The present invention provides a composition or solution according to the present invention for use in therapy and/or prophylaxis.

The present invention provides a phage according to the present invention for use in diagnosis. Preferably, the bacteriophage for use in diagnosis is phage P825.

In various embodiments, controlling *Listeria* contamination according to the present invention is sanitizing and/or disinfecting *Listeria* contamination.

In various embodiments, controlling *Listeria* contamination according to the present invention is non-therapeutically treating *Listeria* contamination. Preferably, treating *Listeria* contamination is eradicating or removing undesired colonization of *Listeria* bacteria.

In the present invention, "*Listeria* contamination" means "undesired *Listeria* contamination". In the present invention, undesired *Listeria* contamination includes, but is not limited to, contamination of pathogenic *Listeria* bacteria. Here, pathogenic means exhibiting pathogenicity to human beings and/or animals. *Listeria monocytogenes* is pathogenic to both human and animals. Therefore, in the present invention controlling *Listeria* contamination preferably is controlling *Listeria monocytogenes* contamination.

In various embodiments, controlling *Listeria* contamination is cleaning from *Listeria* contamination.

In various embodiments, controlling *Listeria* contamination according to the present invention is *Listeria* decontamination. As used herein, *Listeria* decontamination means that after applying a phage or a composition or solution according to the present invention to the site of *Listeria* contamination the number of *Listeria* bacteria is reduced compared to the number of *Listeria* bacteria prior to applying a phage or a composition or solution according to the present invention to the site of *Listeria* contamination. The same holds for applying a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention in *Listeria* decontamination.

The present invention provides a combined treatment for controlling *Listeria* contamination, which comprises applying a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention and a further/additional anti-*Listeria* agent to the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method. The present invention also provides a combined treatment for controlling *Listeria* contamination, which comprises applying a phage or composition or solution according to the present invention and a further/additional anti-*Listeria* agent to the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method. Here, the further/additional anti-*Listeria* agent preferably is a disinfectant, an antimicrobial agent effective against *Listeria* bacteria, an enzyme, or a surfactant. The group of such antimicrobial agents effective against *Listeria* bacteria includes, but is not limited to, vancomycin, danofloxacin, and neomycin. Furthermore, in case of an enzyme as further/



additional anti-*Listeria* agent to be used in the present invention, the group of suitable enzymes includes enzymes aiding in breaking up biofilms. Such enzymes are known in the art and include, but are not limited to, polysaccharide depolymerases and proteases. The surfactant is particularly useful to solubilize and remove dirt so that the *Listeria* bacteria are accessible to the lytic proteins of the present invention.

The further/additional anti-*Listeria* agent may be applied to the site of *Listeria* contamination before or after applying a phage or a composition or solution according to the present invention to the site of *Listeria* contamination. This applies in analogy to the use of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention in a combined treatment comprising a further/additional anti-*Listeria* agent as used herein.

The present invention further provides a combined treatment for controlling *Listeria* contamination, which comprises a thermal treatment of the site of *Listeria* contamination, and subsequently applying a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention to the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method. The present invention further provides a combined treatment for controlling *Listeria* contamination, which comprises a thermal treatment of the site of *Listeria* contamination, and subsequently applying a phage or a composition or solution according to the present invention to the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method. Specifically, thermal treatment of the site of *Listeria* contamination is heat treatment of the site of *Listeria* contamination, more preferably heat treatment at a temperature of at least 70° C., or 71° C. Still more preferably, thermal treatment is heat treatment at a temperature of at least 72° C., or 73° C. Even more preferably, thermal treatment is heat treatment at a temperature of at least 74° C., or 75° C.

The present invention provides a combined treatment for controlling *Listeria* contamination, which comprises applying a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention and an irradiation treatment of the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method. The present invention also provides a combined treatment for controlling *Listeria* contamination, which comprises applying a phage or a composition or solution according to the present invention and an irradiation treatment of the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method. As used herein, irradiation treatment means subjecting the site of *Listeria* contamination to ionizing radiation, also called ionizing energy. The radiation used to treat the site of *Listeria* contamination may be applied before or after a phage or a composition or solution according to the present invention is applied to the site of *Listeria* contamination. This applies in analogy to the use of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention in a combined treatment comprising irradiation treatment as used herein.

The present invention provides a combined treatment for controlling *Listeria* contamination, which comprises applying a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention and high intensity light emission treatment to the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method. The present invention also provides a combined treatment for controlling *Listeria* contamination, which comprises applying a phage or a composition or solution according to the present invention and high intensity light emission treatment to the site of *Listeria* contamination, with the proviso that the method is not a therapeutic method. Specifically, high intensity light emission treatment may be performed by a pulsed power source, as described in MacGregor et al. 1998 ("Light inactivation of food-related pathogenic bacteria using a pulsed power source", *Letters in Applied Microbiology* 27(2):67-70). The high intensity light emission treatment may be applied to the site of *Listeria* contamination before or after a phage or a composition or solution according to the present invention is applied to the site of *Listeria* contamination. This applies in analogy to the use of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention in a combined treatment comprising high intensity light emission treatment as used herein.

A nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention can be applied on or into food or food products. Similarly, phages, compositions and solutions of the present invention can be applied on or into food or food products. Therefore, in various embodiments controlling *Listeria* contamination, preferably sanitizing and/or disinfecting *Listeria* contamination, is controlling *Listeria* contamination of food or a food product.

In various embodiments, controlling *Listeria* contamination, preferably sanitizing and/or disinfecting *Listeria* contamination, is controlling *Listeria* contamination of a solid surface. In various embodiments, such a solid surface is the surface of a food package, a food storage container or food processing equipment. The surface of food processing equipment includes the various physical sites within the food processing facilities/equipment.

The present invention provides food or a food product comprising a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention. The present invention also provides food or a food product comprising a phage or a composition or solution according to the present invention.

The present invention further provides a food package or food storage container comprising a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention. The present invention still further provides a food package or food storage container comprising a phage or a composition or solution according to the present invention. In various embodiments, the nucleic acid molecule, vector, host cell, protein or polypeptide, or chimeric lysin of the present invention is introduced into the food package or food storage container prior to sealing the food package or food



storage container. In various embodiments, a phage or composition or solution according to the present invention is introduced into the food package or food storage container prior to sealing the food package or food storage container. In various embodiments, the food, food product, food package or food storage container further comprises a further/additional anti-microbial agent. Here, the further/additional antimicrobial agent preferably is an antimicrobial agent effective against *Listeria* bacteria or other pathogenic bacteria. In various embodiments, the food, food product, food package or food storage container of the present invention has undergone thermal treatment prior to introducing the nucleic acid molecule, vector, host cell, protein or polypeptide, or chimeric lysin of the present invention to the food, food product, food package or food storage container. In various embodiments, the food, food product, food package or food storage container of the present invention has undergone thermal treatment prior to introducing a phage or the composition or solution of the present invention to the food, food product, food package or food storage container. Specifically, thermal treatment of the food, food product, food package or food storage container of the present invention is heat treatment of the food, food product, food package or food storage container of the present invention, more preferably heat treatment at a temperature of at least 70° C., or 71° C. Still more preferably, thermal treatment is heat treatment at a temperature of at least 72° C., or 73° C. Even more preferably, thermal treatment is heat treatment at a temperature of at least 74° C., or 75° C.

In the present invention, applying a phage or a composition or solution according to the present invention to the site of *Listeria* contamination includes incubating the site of *Listeria* contamination with a phage or a composition or solution according to the present invention. This applies in analogy to the use of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention as used herein. In the present invention, applying a phage or a composition or solution according to the present invention to the site of *Listeria* contamination also includes administering a phage or a composition or solution according to the present invention to the site of *Listeria* contamination. This applies in analogy to the use of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention as used herein.

The nucleic acid molecule, vector, host cell, protein or polypeptide, chimeric lysin, phage, composition or solution according to the present invention may be applied to the food, food product, food package or food storage container of the present invention by a number of means, including, but not limited to, admixing the nucleic acid molecule, vector, host cell, protein or polypeptide, chimeric lysin, phage, composition or solution into the food or food product, or spraying the nucleic acid molecule, vector, host cell, protein or polypeptide, chimeric lysin, phage, composition or solution according to the present invention into the food package or food storage container. Likewise, in the present invention the nucleic acid molecule, vector, host cell, protein or polypeptide, endolysin protein, chimeric lysin, phage, composition or solution according to the present invention may be applied to food processing facilities/equipment by a number of means including, but not limited to, spraying the nucleic acid molecule, vector, host cell, protein or polypeptide, endolysin protein, chimeric lysin, phage, composition

or solution onto the food processing facilities/equipment and/or directly applying the nucleic acid molecule, vector, host cell, protein or polypeptide, chimeric lysin, phage, composition or solution to the food processing facilities/equipment. Said applications significantly reduce the numbers of *Listeria* bacteria.

The concentration of a protein according to the present invention, preferably an endolysin protein, for administration on or into food, food products, foodstuff and/or into various physical sites within food processing plants can be determined by one of skill in the art. That is, a suitable concentration is, for example, a concentration that provides for effectively controlling *Listeria* contamination according to the present invention. In various embodiments, the concentration is contemplated to be in the range of about 0.1-100 µg/ml, including the range of about 1-10 µg/ml and 0.5-5 µg/ml. In various embodiments, the concentration is contemplated to be in the range of about 1-5 µg/ml, 5-10 µg/ml, or 10-20 µg/ml. In various other embodiments, the concentration is contemplated to be in the range of about 20-40 µg/ml, 40-60 µg/ml, 60-80 µg/ml, or 80-100 µg/ml. The endolysin provided by the present invention can be applied in a liquid or a powdered form to food, food products, foodstuff, and/or food processing equipment. The nucleic acid molecule, vector, host cell, protein or polypeptide, chimeric lysin, phage, composition or solution of the present invention is administered until a successful reduction of the *Listeria* contamination is achieved or until the amount of *Listeria* bacteria is substantially reduced.

The present invention also provides the use of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, or a protein or polypeptide of the present invention in a non-therapeutic method for controlling *Listeria* contamination according to the present invention as described herein above.

#### Methods for Controlling *Listeria* Infection

The present invention provides a method for treating and/or preventing *Listeria* infection of a subject comprising administering a phage or a composition or solution of the present invention to the subject.

The present invention also provides a method for treating and/or preventing *Listeria* infection of a subject comprising administering a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention to the subject.

The methods for treating and/or preventing *Listeria* infection according to the present invention include treating and/or preventing a disease or condition caused by a *Listeria* infection. In various embodiments, the disease or condition caused by a *Listeria* infection is listeriosis. Listeriosis is an infection resulting from the ingestion of food or foodstuff contaminated by *Listeria* bacteria. In various embodiments listeriosis is caused by a *Listeria* infection resulting from the ingestion of food or foodstuff contaminated by *Listeria*. Preferably, listeriosis according to the present invention is caused by a *L. monocytogenes* infection resulting from the ingestion of food or foodstuff contaminated by *L. monocytogenes*. In various other embodiments the disease or condition caused by a *Listeria* infection is brain abscess, hepatitis, peritonitis, arthritis, gastroenteritis, encephalitis, sepsis, local wound infection, and inflammation of conjunctiva and cornea. Preferably, the disease or condition caused by a *Listeria* infection is listeriosis.



In various embodiments of the therapeutic methods of treatment according to the present invention the subject is a subject suffering from a *Listeria* infection or a subject supposed to suffer from a *Listeria* infection. In various 5  
embodiments of the therapeutic methods of treatment according to the present invention the subject is a subject at risk for a *Listeria* infection.

In various embodiments of the therapeutic methods of treatment according to the present invention the *Listeria* infection is a *Listeria monocytogenes* infection. 10

In various embodiments of the therapeutic methods of treating and/or preventing a disease or condition caused by a *Listeria* infection according to the present invention the disease or condition caused by a *Listeria* infection is a disease or condition caused by a *Listeria monocytogenes* 15  
infection.

In the present invention, the subject is a mammal including animals and human beings. In various embodiments, the subject preferably is a human being, more preferably a patient in need of a method for treating and/or preventing 20  
*Listeria* infection according to the present invention.

In various embodiments, the subject is a pregnant woman. In various other embodiments, the subject is a newborn baby. In various other embodiments, the subject is an elderly person, preferably a person of at least 60 years of age, more preferably a person of at least 65 years of age, still more preferably a person of at least 70 years of age. Even more preferably, the elderly person is a person of at least 75 years of age. In still more preferred embodiments, the elderly person is a person of at least 80 years of age.

The present invention provides a kit comprising a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention. The present invention also provides a kit comprising a phage or a composition or solution of the present invention. In various embodiments, the kit according to the present invention is a kit for use in a therapeutic or non-therapeutic method according to the present invention, or a kit for carrying out a therapeutic or non-therapeutic method according to the present invention. In various other embodiments, the kit according to the present invention is a kit for controlling *Listeria* contamination according to the present invention. In various 40  
embodiments, the kit is a diagnostic kit.

In various embodiments, the pharmaceutical composition according to the present invention comprises optionally a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" includes, but is not limited to, a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the medicament/pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art. Pharmaceutical carriers are known to those skilled in the art. Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19<sup>th</sup> ed.) ed. A. R. Gennaro, Mack Publishing Company, Easton, Pa. 1995. Typically, an appropriate amount of a pharmaceutically acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-

acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include 5  
sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.

In the therapeutic methods of treatment according to the present invention, the dosage or dosages to be administered to a subject will vary with the age, condition, sex and extent of the *Listeria* infection and/or disease or condition caused by a *Listeria* infection in the subject, route of administration, or whether other drugs are included in the regimen. The dosage or dosages to be administered to a subject can be determined by one of skill in the art. Furthermore, the dosage to be administered to a subject can be adjusted by the individual physician in the event of any counter indications. 20

Pharmaceutical compositions of the present invention may be administered by any suitable route of administration including, but not limited to, oral administration, rectal administration, parenteral administration, intravaginal administration, intraperitoneal administration, topical administration (as by powders, ointments, drops or transdermal patch), buccal administration, administration by inhalant or by nasal administration. As used herein, nasal administration, including topical intranasal administration, means delivery of a phage or a composition or solution of the present invention into the nose and nasal passages through one or both of the nares, and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of a phage or the composition or solution. This applies in analogy to the use of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention as used herein. Administration of a phage or the composition or solution by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. 35  
Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. This applies in analogy to the use of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention as used herein. 40

The term "parenteral" as used herein refers to modes of administration, which include, but are not limited to, intravenous, intramuscular, intraperitoneal, subcutaneous and intra-articular injection and infusion. 45

In various embodiments, the dosage of administration for the phage P825 is contemplated to be in the range of about  $10^3$  to about  $10^{13}$  pfu/per kg bodyweight/per day, preferably in the range of about  $10^{12}$  pfu/per kg bodyweight/per day.

In various embodiments, the dosage of administration for the PlyP825 endolysin is contemplated to be in the range of about 2-2000 ng/per g bodyweight/per day, preferably in the range of about 20-200 ng/per g bodyweight/per day. 60

Pharmaceutical compositions according to the present invention may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the active ingredient of choice. 65



Formulations for topical administration of a phage or a composition or solution according to the present invention may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Also, formulations for topical administration of a nucleic acid molecule of the present invention, a vector of the present invention, a host cell of the present invention, a protein or polypeptide of the present invention, or a chimeric lysin of the present invention may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.

The addition of conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable in formulations for topical administration of compositions according to the present invention.

In the present invention, food, foodstuff, and food products include, but are not limited to, dairy products, meat products, fish products, unpasteurized food products, fruits, vegetables and salads. As used herein, the term "dairy product" is intended to include any food product made using milk or milk products, including, but not limited to, milk, yoghurt, ice cream, cheese, butter, and cream. In various embodiments, the milk is raw milk or milk that has been pasteurized. As used herein, the term "meat product" is intended to include any food product, which contains animal tissue, including, but not limited to, beef, pork, and poultry. The term "ready to eat meat product" is intended to include any meat product, which does not require cooking prior to consumption, including, but not limited to, pates, hot dogs, bologna, salami, and cold cuts. As used herein, the term "fish product" is intended to include any food product, which contains tissue from an aquatic animal, including, but not limited to, lobster, crab, fresh water and saltwater fish and other seafoods. As used herein, the term "unpasteurized food product" is intended to include any food product, which is prepared using unpasteurized primary ingredients and which does not undergo a final (listeriocidal) heat treatment. As used herein, the term "salad" is intended to include any food product, which contains mixtures of vegetables or fruits, and particularly such mixtures as are presented for consumers to choose from in a display commonly referred to as a "salad bar".

#### Method for Detecting *Listeria* Bacteria

The present invention provides a method for detecting the presence of *Listeria* bacteria according to the present invention, preferably *Listeria monocytogenes*, comprising (i) providing a sample suspected to contain *Listeria* bacteria, preferably *L. monocytogenes*; (ii) incubating the sample of (i) with a phage or a composition according to the present invention, preferably a diagnostic composition; and (iii) detecting in the sample of (ii) the presence of lysis of *Listeria* bacteria, preferably *L. monocytogenes*, or lysis activity of phage P825 against the *Listeria* bacteria, preferably *L. monocytogenes*, contained in the sample, wherein the presence of lysis of *Listeria* bacteria, preferably *L. monocytogenes*, or lysis activity of a phage of the invention, preferably P825, against *Listeria* bacteria, preferably *L. monocytogenes*, is indicative of the presence of *Listeria* bacteria, preferably *L. monocytogenes*. In various embodiments, the sample of (i) is obtained from a food product, a food processing equipment, a food storage container, or a patient suspected of suffering from a bacterial contamination comprising *Listeria* bacteria, preferably *L. monocytogenes*. Further Characteristics of PlyP825

The pH optimum for the lytic activity of endolysin PlyP825 was determined (Example 5 and FIG. 5). PlyP825 exhibit highest lytic activity at neutral to slightly alkaline (basic) pH. Thus, endolysin PlyP825 has a pH optimum at

neutral to slightly alkaline (basic) pH. In various embodiments, the endolysin provided by the present invention is characterized as having a pH optimum at about pH 8.5 with respect to its lytic activity. In various other embodiments, the endolysin provided by the present invention is characterized as exhibiting improved lytic activity at a pH of about 5.5, about 6.5 or about 7.5.

The salt optimum (NaCl) for the lytic activity of endolysin PlyP825 was determined (Example 6 and FIG. 6). PlyP825 exhibits highest lytic activities in the concentration range of about 150-250 mM NaCl. Thus, endolysin PlyP825 has a salt (NaCl) optimum of about 150-250 mM NaCl. In various embodiments, the endolysin provided by the present invention is characterized as having a salt (NaCl) optimum at a concentration in the range of about 150-250 mM NaCl. In various other embodiments, the endolysin provided by the present invention is characterized as having a salt (NaCl) optimum at a concentration of any one of about 150 mM, about 200 mM or 250 mM NaCl.

The lytic activity of endolysin PlyP825 in the presence of different concentrations of EDTA was determined (Example 7 and FIG. 7). While Ply511 was inactivated already at a concentration of 1 mM EDTA, the relative lytic activity of PlyP825 remained at a level of about 70% up to a concentration of about 25 mM EDTA.

The minimum inhibitory concentration (MIC) of endolysin PlyP825 against *Listeria monocytogenes* ProCC S1095 sv 1/2a, *Listeria monocytogenes* ProCC S1135 sv 3a, *Listeria monocytogenes* ProCC S776 sv 4b, and *Listeria innocua* ProCC S1147 sv 6a was determined (Example 8 and FIG. 8). The minimum inhibitory concentration (MIC) is defined as the lowest concentration of an antimicrobial agent at which the visible growth of a microorganism is suppressed (Andrews et al. 2001). The MIC values varied depending on the *Listeria* strain tested. For inhibiting *Listeria monocytogenes* ProCC S1095 sv 1/2a and *Listeria monocytogenes* ProCC S1135 sv 3a less PlyP825 protein was required than for inhibiting *Listeria monocytogenes* ProCC S776 sv 4b. The MIC values for PlyP825 are, depending on the *Listeria* strain tested, about 2.3-times lower, or up to 17.75-times higher than the MIC values for PlyP40.

#### *Listeria* Serovar 3 Specific Bacteriophage

The present invention provides bacteriophage capable of lysing *Listeria* serovar 3 obtainable by (a) plating a sample containing bacteriophage and *Listeria* bacteria serovar 3 using agar plates to obtain plaques, and (b) purifying the phage contained within the one or more plaques obtained.

In various embodiments, the step of plating a phage-containing sample and *Listeria* bacteria serovar 3 comprises mixing a phage-containing sample and *Listeria* serovar 3 host cells in molten, "soft" agar. The resulting suspension is then poured on to an appropriate "nutrient" basal agar medium to form a thin "top layer" which hardens and immobilises the bacteria. In various embodiments, the step of plating a phage-containing sample and *Listeria* bacteria serovar 3 follows the double agar layer method as described by Adams (1959).

During incubation the uninfected *Listeria* bacteria multiply to form a confluent lawn of bacterial growth over the surface of the plate. Each infected bacterium bursts after a short time and liberates progeny phages that infect adjacent bacteria, which in turn are lysed. This "chain" reaction spreads in a circular motion until brought to a halt by a decline in bacterial metabolism. Plaques are zones of bacterial lysis caused by bacteriophage action and appear as circular zones of lysis on lawns of bacterial cells.



Phages may be purified by removing, picking off, a well isolated plaque using either a Pasteur pipette or more crudely, but just as effectively, a wire loop. Using a sterile Pasteur pipette, the area around the plaque is stabbed and pieces of soft area are “sucked” into the pipette. The agar should be gently broken into smaller pieces with the wire-loop, mixed briefly with a vortex-mixer and left for 5-10 minutes at ambient temperature. The phage suspension may then be filter-sterilised through a 0.45 µm syringe-mounted, filtration unit to remove any bacteria including phage-resistant host bacteria.

In various embodiments, the sample is an environmental sample, preferably a sample from environmental water, more preferably a water sample from a rivulet. In various embodiments, the sample is a phage suspension.

In case of the phage-containing sample being a phage suspension, the step of plating a phage-containing sample and *Listeria* bacteria serovar 3 comprises mixing a small volume of a dilution of a phage suspension and *Listeria* serovar 3 host cells in molten, “soft” agar.

#### FURTHER DEFINITIONS

In the present invention, “Percentage (%) of sequence identity” is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The terms “identical” or percent “identity”, in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or sub-sequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be “substantially identical”. This definition also refers to the complement of a test sequence. Optionally, the identity exists over a region that is at least about 50 amino acids or nucleotides in length, or more preferably over a region that is 75-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, sub-sequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

The terms nucleic acid molecule and nucleic acid sequence may be used herein interchangeably.

As discussed herein there are numerous variants of the proteins and polypeptides of the present invention. Protein variants and derivatives are well understood to those of skill

in the art and in can involve amino acid sequence modifications. For example, amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within protein molecules according to the present invention. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known to the ones skilled in the art. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional variants are those in which at least one amino acid residue has been removed and a different amino acid residue inserted in its place such that a conservative substitution is obtained. The meaning of a conservative substitution is well known to the person skilled in the art.

Certain post-translational modifications are the result of the action of recombinant host cells on the expressed polypeptide. Glutamyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains, acetylation of the N-terminal amine and, in some instances, amidation of the C-terminal carboxyl. Such post-translational modifications are also contemplated by the present invention.

The term “*Listeria*” as used herein means the bacterial genus *Listeria*. In the present invention, the genus *Listeria* encompasses all known *Listeria* species. In particular, in the present invention the genus *Listeria* includes, but is not limited to, the following *Listeria* species: *L. monocytogenes*, *L. seeligeri*, *L. ivanovii*, *L. innocua*, *L. welshimeri*, *L. grayi* ssp. *grayi*, and *L. grayi* ssp. *murrayi*.

In the present invention, the preferred *Listeria* species is a *Listeria* species that is pathogenic to human beings and/or animals.

In various embodiments of the present invention, the preferred *Listeria* species is *Listeria monocytogenes*, which is pathogen to both human and animals. This applies in particular to the therapeutic and non-therapeutic methods of the present invention.

In the present invention, *Listeria* serovars 1/2, 3, and 4 include, but are not limited to, *Listeria monocytogenes* serovars 1/2, 3, and 4, respectively.

In various embodiments, the preferred *Listeria monocytogenes* serovar is serovar 1/2. In various other embodiments, the preferred *Listeria monocytogenes* serovar is sero-



var 3. In various further embodiments, the preferred *Listeria monocytogenes* serovar is serovar 4.

In the present invention *Listeria monocytogenes* includes serotypes 1/2a, 1/2b, 1/2c, 3a, 3b, 3c, 4a, 4ab, 4b, 4c, 4d, 4e, and 7. In various embodiments, the *Listeria* species is selected from the group consisting of *L. monocytogenes* serotype 1/2a, *L. monocytogenes* serotype 1/2b, *L. monocytogenes* serotype 1/2c, *L. monocytogenes* serotype 3a, *L. monocytogenes* serotype 3b, *L. monocytogenes* serotype 3c, *L. monocytogenes* serotype 4a, *L. monocytogenes* serotype 4ab, *L. monocytogenes* serotype 4b, *L. monocytogenes* serotype 4c, *L. monocytogenes* serotype 4d, *L. monocytogenes* serotype 4e, and *L. monocytogenes* serotype 7.

In more preferred embodiments of the present invention the *Listeria* species is selected from the group consisting of *L. monocytogenes* 1142 serovar 1/2a, *L. monocytogenes* 1042 serovar 4b, *L. monocytogenes* 1019 serovar 4c, *L. monocytogenes* 1001 serovar 1/2c, *L. monocytogenes* EGDe serovar 1/2a, *L. monocytogenes* SLCC 7150 serovar 1/2a, *L. monocytogenes* SLCC 7154 serovar 1/2c, *L. monocytogenes* SLCC 7290 serovar 1/2c, *L. monocytogenes* 0756062 serovar 1/2c, *L. monocytogenes* WSLC1485 serovar 1/3a, *L. monocytogenes* WSLC 11082 serovar 1/3c, *L. monocytogenes* WSLC 11083 serovar 1/3c, *L. monocytogenes* ScottA serovar 4b, *L. monocytogenes* WSLC 1048 serovar 4d, *L. monocytogenes* 8309032 serovar 4d, and *L. monocytogenes* 8309033 serovar 4e.

In various embodiments, the preferred *Listeria* species is *Listeria ivanovii*, which is pathogenic to animals. In preferred embodiments, the *Listeria* species is *Listeria ivanovii* serotype 5.

The literature discloses reports about diseases in human beings resulting from infection with *Listeria seeligeri* (Rocourt et al. 1987) and *L. ivanovii* (Cummins et al. 1994). In the present invention *Listeria seeligeri* includes serotypes 1/2a, 1/2b, 1/2c, 4b, 4c, 4d, and 6b. In various embodiments, the *Listeria* species is selected from the group consisting of *L. seeligeri* serotype 1/2a, serotype 1/2b, serotype 1/2c, serotype 4b, serotype 4c, serotype 4d, and serotype 6b.

In the present invention *Listeria innocua* includes serotypes 3, 6a, 6b, 4ab, and U/S. In various embodiments, the *Listeria* species is selected from the group consisting of *L. innocua* serotype 3, *L. innocua* serotype 6a, *L. innocua* serotype 6b, *L. innocua* serotype 4ab, and *L. innocua* serotype U/S. Preferably, *L. innocua* is *L. innocua* 2011 serotype 6a.

In the present invention *Listeria welshimeri* includes serotypes 1/2a, 4c, 6a, 6b, and U/S. In various embodiments, the *Listeria* species is selected from the group consisting of *L. welshimeri* serotype 1/2a, *L. welshimeri* serotype 4c, *L. welshimeri* serotype 6a, *L. welshimeri* serotype 6b, and *L. welshimeri* serotype U/S.

In the present invention *Listeria grayi* includes serotype *Grayi*. In various embodiments, the *Listeria* species is *L. grayi* serotype *Grayi*.

In the present invention, the terms “serotype” and “serovar” may be used interchangeably.

In the present invention, the terms “controlling *Listeria* contamination” and “controlling undesired *Listeria* colonization” may be used interchangeably.

The term “endolysin”, as used herein, denotes enzymes that are naturally encoded by bacteriophages and are produced by them at the end of their life cycle in the host to lyse the host cell and thereby release the progeny phages. As described in the background section, endolysins are comprised of at least one enzymatically active domain (EAD) and a non-enzymatically active cell binding domain (CBD).

The EADs can exhibit different enzymatic activities as described herein, such as, e.g., N-acetyl-muramoyl-L-alanine amidase, (endo)-peptidase, transglycosylase, glycosyl hydrolase, (N-acetyl)-muramidase, or N-acetyl-glucosaminidase. The terms “endolysin(s)” and “lysin(s)” may be used herein interchangeably.

The term “domain” or “protein domain”, as used herein, denotes a portion of an amino acid sequence that either has a specific functional and/or structural property. On the basis of amino acid sequence homologies, domains can frequently be predicted by employing appropriate computer programs that compare the amino acid sequences in freely available databases with known domains, e.g., Conserved Domain Database (CDD) at the NCBI (Marchler-Bauer et al., 2005, Nucleic Acids Res. 33, D192-6), Pfam (Finn et al., 2006, Nucleic Acids Research 34, D247-D251), or SMART (Schultz et al., 1998, Proc. Natl. Acad. Sci. USA 95, 5857-5864, Letunic et al., 2006, Nucleic Acids Res 34, D257-D260).

Whenever reference is made to the activity of the polypeptide of SEQ ID NO: 2 (PlyP825), the endolysin activity of PlyP825 is meant. Specifically, the endolysin activity of the polypeptide of SEQ ID NO: 2 (PlyP825) is the lytic activity of the polypeptide of SEQ ID NO: 2 (PlyP825) against *Listeria* bacterial cells described herein, preferably against pathogenic *Listeria* bacterial cells, more preferably *Listeria monocytogenes*. In general, the enzymatic activity of the endolysin of SEQ ID NO: 2 is analogous to the enzymatic activity of known endolysins exhibiting lytic activity against *Listeria* bacterial cells. More specifically, the lytic activity of the endolysin PlyP825 is hydrolytic activity, still more specifically hydrolytic activity against peptidoglycan in the cell wall of *Listeria* bacterial cells. Therefore, the lytic activity of the endolysin PlyP825 may also be described as peptidoglycan hydrolase activity.

As described herein, the EAD of SEQ ID NO: 4 has lytic activity against *Listeria* bacterial cells. In particular, the lytic activity of the EAD of SEQ ID NO: 4 is defined as lytic activity against *Listeria* bacterial cells. More specifically, the enzymatic activity of the EAD of SEQ ID NO: 4 is analogous to the enzymatic activity of known EADs exhibiting lytic activity against *Listeria* bacterial cells. Given the fact that the polypeptide of SEQ ID NO: 4 represents the EAD of the endolysin of SEQ ID NO: 2, and given that EADs from *Listeria* bacteriophages are known and described in the art, the nature of the lytic activity of the EAD of SEQ ID NO: 4 of the present invention is clear to the skilled person. In various embodiments of the present invention, the lytic activity of the EAD of SEQ ID NO: 4 against *Listeria* bacterial cells is peptidoglycan hydrolase activity, i.e. hydrolytic activity against peptidoglycan in the cell wall of *Listeria* bacterial cells. The peptidoglycan hydrolase activity of the EAD of SEQ ID NO: 4 may also be called peptidoglycan-digesting activity or muralytic activity. In various embodiments, the lytic activity of the EAD of SEQ ID NO: 4 is muramidase activity or N-Acetyl-glucosaminidase activity. In various embodiments, the lytic activity of the EAD of SEQ ID NO: 4 is amidase activity or endopeptidase activity. Preferably, the lytic activity of the EAD of SEQ ID NO: 4 is peptidoglycan amidase activity. More preferably, the lytic activity of the EAD of SEQ ID NO: 4 is L-muramoyl-L-alanine amidase activity, D-alanyl-glycyl endopeptidase activity, or D-6-meso-DAP-peptidase or meso-DAP-D-Ala peptidase activity. In various embodiments, the lytic activity of the EAD of SEQ ID NO: 4 is peptidoglycan transglycosylase activity. More preferably, the lytic activity of the EAD of SEQ ID NO: 4 is murein transglycosylase



activity. In various embodiments, the lytic activity of the EAD of SEQ ID NO: 4 is peptidase activity, preferably carboxypeptidase activity. In various embodiments, the lytic activity of the EAD of SEQ ID NO: 4 is glycosyl hydrolase activity. In various embodiments, the lytic activity of the EAD of SEQ ID NO: 4 is N-acetylmuramoyl-L-alanine amidase activity. In various embodiments, the lytic activity of the EAD of SEQ ID NO: 4 is cysteine histidine-dependent amidohydrolase/peptidase activity.

As described herein, the CBD of SEQ ID NO: 6 has cell wall binding activity. This cell wall binding activity provides for targeting the lysin to its substrate, namely the peptidoglycan of *Listeria* bacterial cells. Therefore, in particular the cell wall binding activity of the CBD of SEQ ID NO: 6 is *Listeria* cell wall binding activity. In general, the enzymatic activity of the CBD of SEQ ID NO: 6 is analogous to the enzymatic activity of known CBDs that likewise provide for targeting lysin to its substrate in the cell wall of *Listeria* bacterial cells. Given the fact that the polypeptide of SEQ ID NO: 6 represents the CBD of the endolysin of SEQ ID NO: 2, and given that CBDs from *Listeria* bacteriophages are known and described in the art, the nature of the cell wall binding activity of the EAD of SEQ ID NO: 6 of the present invention is clear to the skilled person. Accordingly, it is also clear to the skilled person that CBDs according to the present invention have no or no significant hydrolytic activity like the EADs, i.e. CBDs according to the present invention have no or no significant hydrolytic activity against *Listeria* bacterial cell walls. Here, no or no significant hydrolytic activity is intended to describe the situation whereby the hydrolytic activity of a CBD of the present invention is not sufficient to prevent the application of such a CBD to bind to the cell wall of a *Listeria* bacterial cell. A CBD according to the present invention is supposed to be a protein, which has no or no significant hydrolytic activity itself.

In various embodiments, the cell wall binding activity of the CBD of SEQ ID NO: 6 is binding to peptidoglycan of the cell wall of *Listeria* bacterial cells. Preferably, the cell wall binding activity of the CBD of SEQ ID NO: 6 is binding to a carbohydrate or cholin moiety in the cell wall of *Listeria* bacterial cells. More preferably, the cell wall binding activity of the CBD of SEQ ID NO: 6 is binding to a carbohydrate of the peptidoglycan or teichoic acid or lipoteichoic acid in the cell wall of *Listeria* bacterial cells.

The terms “protein” and “polypeptide” are used in the present invention interchangeably. As used herein, the term endolysin denotes an enzyme. Accordingly, whenever reference is made herein to a protein or polypeptide of the present invention, this also includes endolysins of the present invention. The terms “endolysin(s)” and “endolysin protein(s)” or “endolysin polypeptide(s)” may be used herein interchangeably.

Furthermore, basically the terms “protein” and “polypeptide” as used herein also encompass any “chimeric lysin” provided by the present invention. However, for clarity reasons concerning the scope of the present invention sometimes reference is made herein to “proteins and polypeptides of the present invention” on the one hand, and “chimeric lysins of the present invention” on the other hand. The terms “chimeric lysin(s)” and “chimeric endolysin” may be used herein interchangeably. Furthermore, the terms “chimeric (endo)lysin(s)” and “chimeric (endo)lysin protein(s)” or “chimeric (endo)lysin polypeptide(s)” may be used herein interchangeably.

Furthermore, the term “sv” represent the well known abbreviation of the term “serovar”.

When particular embodiments of the invention are described herein, the corresponding paragraphs/text passages of the description invariably make reference to means and/or methods described elsewhere in the description. In this context, terms like “according to the present invention”, “of the present invention” and “provided by the present invention” are used. That is, when a particular embodiment of the invention is described in a certain paragraph or text passage, reference is made to means and/or methods “according to the present invention” or “of the present invention”, which are described elsewhere in the description. For a particular embodiment described, such references are intended to incorporate for the particular embodiment all means and/or methods, which are described elsewhere in the description and which are provided by the present invention and therefore form part of the scope of the invention. For example, if the description of a particular embodiment refers to “the endolysin according to the present invention” or “the endolysin of the present invention”, or “the endolysin provided by the present invention”, it is intended that all endolysins, which are described elsewhere in the description, and which are provided by the present invention and therefore form part of the scope of the invention, are applicable to the particular embodiment. This particularly applies, for example, to fragments and variants of polypeptides according to the present invention, which are defined in the present invention and which are applicable to the various embodiments described throughout the application text.

The above principle applies to all embodiments making use of terms like “according to the present invention”, “of the present invention” and “provided by the present invention”. It goes without saying that not each embodiment described herein can specifically mention the means and/or methods of the invention, which are already defined elsewhere in the description, and which are applicable to the various embodiments described throughout the application text. Otherwise, each patent application would comprise several hundreds of description pages.

Furthermore, terms like “in various embodiments” and “in various other/further embodiments” mean “in various embodiments of the present invention” and “in various other/further embodiments of the present invention”

The invention is exemplified by the examples, which are not considered to limit the scope of the present invention.

#### Example 1

##### Lytic Activity of Phage ProCC P825

The phage P825 provided by the present invention exhibits its lytic activity against *Listeria* serovars 1/2, 3, 4, 5 and 6. As demonstrated by the inventors, phage P825 completely inhibited growth of *Listeria monocytogenes* strains.

250 µl overnight culture of different *Listeria* strains were added to 3 ml TB-top-agar (TB-medium, 0.75% (v/v) agar, 2 mM CaCl<sub>2</sub>, 10 mM MgSO<sub>4</sub>), and poured into TB-agar plates. 5 µl of phage P825 (10<sup>9</sup> pfu/ml) were spotted onto the top-agar plates and dried for about 30 minutes. The plates were incubated overnight at room temperature. Evaluation of lysis spots demonstrated that phage P825 was lytic for all *Listeria* strains tested. Evaluation of lysis spots was performed as follows:

More than 75% of strains tested from one serovar show a lysis spot: “+”

Less than 25% of strains tested from one serovar show a lysis spot: “-”

Not determined: nn.



TABLE 1

Comparison of lytic activity of <i>Listeria</i> phages on <i>Listeria</i> serovars ("+", "-", and "nn" in accordance with the above definition)					
<i>Listeria</i> phage	Serovar 1/2	Serovar 3	Serovar 4	Serovar 5	Serovar 6
P825	+	+	+	+	+
A511	+	-	+	+	+
P100	+	-	+	+	+
A118	+	-	-	nn	nn
A500	-	-	+	nn	+
P40	-	-	+	+	+
PhiLM4	-	-	+	nn	+

Phage P825 has been shown to be lytic against *Listeria* serovars 1/2, 3, 4, 5 and 6. The host range is broader than that of known phages A511, P100, A118, A500, P40, and PhiLM4, as shown in the above Table 1. Importantly, novel phage P825 is capable of lysing *Listeria* serovar 3, which is one of the clinically relevant *Listeria* serovars. This activity is unique to novel phage P825. Known *Listeria*-specific bacteriophages A511, P100, A118, A500, P40, and PhiLM4 do not share this property.

Furthermore, phage P825 not only inhibited growth but actually reduced *Listeria* titers. As confirmed by enrichment studies, applying phage P825 completely eradicated *Listeria* bacteria. The lysis spectrum of phage P825 has been shown to be consistent with the binding specificity provided by the tailspike protein of phage P825.

#### Example 2

##### Proteolytic Stability of PlyP825 Compared to Ply511 and PlyP40

In order to compare the proteolytic sensitivity of the three endolysins they were Trypsin-digested in equimolar amounts. Aliquots were retained and analyzed after 0 and 3 min incubation at room temperature (FIG. 1). As shown in FIG. 1, PlyP825 possesses less proteolytic degradation sites compared to Ply511 and PlyP40.

#### Example 3

##### Lytic Activity of PlyP825 Against a Broad Range of *Listeria* Serovars

PlyP825 was analyzed for its activity against different *Listeria* strains with serovars 1/2, 3, 4, 5 and 6. Overnight cultures of *Listeria* cells were poured 1:6 in LB-Top Agar in plates. Onto the solidified agar 2 µg of PlyP825 was spotted. After incubation over night at 30° C. all 22 strains tested were lysed by the endolysin PlyP825 (Table 2). Thus, PlyP825 is a broad range *Listeria* endolysin.

TABLE 2

22 <i>Listeria</i> strains tested for lysis by PlyP825. ProCC S: Culture Collection Number of Hyglos Invest GmbH, Bernried, Germany. "+" indicates lysis of this strain by PlyP825.			
ProCC S	Strain	Serovar	PlyP825
1095	<i>Listeria monocytogenes</i> EGDe	1/2a	+
995	<i>Listeria monocytogenes</i> SLCC 7150	1/2a	+
1153	<i>Listeria seeligeri</i> WSLC 40140	1/2b	+

TABLE 2-continued

22 <i>Listeria</i> strains tested for lysis by PlyP825. ProCC S: Culture Collection Number of Hyglos Invest GmbH, Bernried, Germany. "+" indicates lysis of this strain by PlyP825.			
ProCC S	Strain	Serovar	PlyP825
1002	<i>Listeria monocytogenes</i> SLCC 7154	1/2c	+
1003	<i>Listeria monocytogenes</i> SLCC 7290	1/2c	+
2867	<i>Listeria monocytogenes</i> 0756062	1/2c	+
1135	<i>Listeria monocytogenes</i> WSLC1485	3a	+
1154	<i>Listeria seeligeri</i> WSLC 40127	3b	+
2991	<i>Listeria seeligeri</i> WSLC 41113	3b	+
2974	<i>Listeria monocytogenes</i> WSLC 11082	3c	+
2975	<i>Listeria monocytogenes</i> WSLC 11083	3c	+
776	<i>Listeria monocytogenes</i> ScottA	4b	+
1144	<i>Listeria monocytogenes</i> WSLC 1048	4d	+
2919	<i>Listeria monocytogenes</i> 8309032	4d	+
2920	<i>Listeria monocytogenes</i> 8309033	4e	+
857	<i>Listeria ivanovii</i> WSLC 3009	5	+
1014	<i>Listeria ivanovii</i> SLCC 4706	5	+
1164	<i>Listeria ivanovii</i> ssp. <i>londoniensis</i> WSLC 30167	5	+
1150	<i>Listeria ivanovii</i> ssp. <i>ivanovii</i> WSLC 30165	5"	+
1147	<i>Listeria innocua</i> WSLC2011	6a	+
773	<i>Listeria innocua</i> WSLC 2012	6b	+
1754	<i>Listeria seeligeri</i> WSLC 41116	6b	+

#### Example 4

##### Minimum Bactericidal Concentration of PlyP825 in Buffer and Milk

The minimum bactericidal concentrations (MBCs) of the endolysins PlyP825, Ply511 and PlyP40 in buffer and in milk were determined and compared.

For determining the MBC in buffer pH 6 the endolysin enzymes were incubated with 10<sup>5</sup> cells/ml of strains *Listeria monocytogenes* EGDe sv 1/2a and *Listeria innocua* WSLC2011 sv 6a in buffer (20 mM sodium phosphate, 50 mM sodium chloride, 0.05% Tween pH 6) at 30° C. After 1 h the samples were plated and cell numbers counted. FIG. 2 shows the results: PlyP825 reduces effectively pathogenic and non-pathogenic *Listeria* cells in buffer: 0.032 µg/ml endolysin were sufficient to reduce 4.5 (WSLC2011) or 3.1 (EGDe) orders of magnitude of *Listeria* cells. This is about 0.5 to 1.5 log more than Ply511 and 0.9-1.3 log more than PlyP40 were able to reduce with the same protein concentration.

For determining the MBC in milk the enzymes were incubated with 10<sup>5</sup> cells/ml of strains *Listeria monocytogenes* EGDe sv 1/2a and *Listeria innocua* WSLC2011 sv 6a in milk with 1.5% fat at 30° C. After 3 h the samples were plated and cell numbers counted. FIG. 3 shows the results: PlyP825 shows the highest *Listeria* cell reduction in milk. Independent from the test strain PlyP825 reduces 1.4-1.7 orders of magnitude more cells than the other two broad *Listeria* endolysins Ply511 and PlyP40 in milk with 1.5% fat. Besides the enzymes were incubated with 10<sup>5</sup> cells/ml of strains *Listeria monocytogenes* EGDe sv 1/2a in milk with 3.5% fat at 30° C. After 3 h the samples were plated and cell numbers counted. FIG. 4 shows the results. Also in milk with 3.5% fat PlyP825 reduces the highest cell number.

#### Example 5

##### pH Optimum of PlyP825

The pH optimum for the lytic activity of endolysin PlyP825 was determined and compared with that of endo-



lysins Ply511 and PlyP40. The results are shown in FIG. 5. The lytic activity as a function of the pH was determined applying photometric lysis tests. In particular, heat-inactivated cells of *Listeria monocytogenes* ProCC S1095 sv 1/2a were suspended in buffer (50 mM sodium citrate, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 50 mM borate and 100 mM NaCl), which was adjusted to pH values of 4.5, 5.5, 6.5, 7.5, 8.5 and 9.5, respectively. As shown in FIG. 5, PlyP825 and Ply511 exhibit highest lytic activity at neutral to slightly alkaline (basic) pH. Thus, endolysins PlyP825 and Ply511 have a pH optimum at neutral to slightly alkaline (basic) pH. The result shown for Ply511 confirms the pH optimum described in the literature (Pieper et al. 2005). PlyP40 exhibits highest lytic activity at acidic pH. Thus, endolysin PlyP40 has a pH optimum at acidic pH.

#### Example 6

##### Salt (NaCl) Optimum of PlyP825

The salt optimum (NaCl) for the lytic activity of endolysin PlyP825 was determined and compared with that of endolysins Ply511 and PlyP40. The results are shown in FIG. 6. The lytic activity of endolysins Ply511, PlyP40 and PlyP825 against *Listeria monocytogenes* ProCC S1095 sv 1/2a was determined at pH6 for concentrations of 0 mM, 10 mM, 50 mM, 100 mM, 150 mM, 250 mM, and 500 mM NaCl. As shown in FIG. 6, endolysins Ply511 and PlyP825 exhibit highest lytic activities in the concentration range of about 150-250 mM NaCl. Thus, endolysins Ply511 and PlyP825 have a salt (NaCl) optimum of about 150-250 mM NaCl. Furthermore, as shown in FIG. 6 endolysin PlyP40 exhibits highest lytic activity at a concentration of about 150 mM NaCl. Thus, endolysin PlyP40 has a salt (NaCl) optimum of about 150 mM NaCl.

#### Example 7

##### Relative Lytic Activity of PlyP825 in the Presence of EDTA

The lytic activity of endolysin PlyP825 in the presence of different concentrations of EDTA was determined and compared with that of endolysins Ply511 and PlyP40. The results are shown in FIG. 7. The lytic activity as a function of the EDTA concentration was determined applying photometric lysis tests using *Listeria monocytogenes* ProCC S1095 sv 1/2a as reference strain. The incubation period was one hour at pH 6 and different concentrations of EDTA. As shown in FIG. 7, Ply511 was inactivated already at a concentration of 1 mM EDTA, and at a concentration of 250 mM EDTA the residual activity was about 1%. Furthermore, as shown in FIG. 7, the relative lytic activity of PlyP40 remained almost unchanged up to a concentration of 100 mM EDTA, and the relative lytic activity of PlyP825 remained at a level of about 70% up to a concentration of about 25 mM EDTA. At a concentration of 250 mM EDTA the residual lytic activity of PlyP825 was about 2.5%.

#### Example 8

##### MIC of PlyP825 Against *Listeria*

The minimum inhibitory concentration (MIC) of endolysin PlyP825 against *Listeria monocytogenes* ProCC S1095 sv 1/2a, *Listeria monocytogenes* ProCC S1135 sv 3a, *Listeria monocytogenes* ProCC S776 sv 4b, and *Listeria*

*innocua* ProCC S1147 sv 6a was determined and compared with that of endolysins Ply511 and PlyP40. The results are shown in FIG. 8. The minimum inhibitory concentration (MIC) is defined as the lowest concentration of an antimicrobial agent at which the visible growth of a microorganism is suppressed (Andrews et al. 2001). For determining the MIC cells of *Listeria monocytogenes* ProCC S1095 sv 1/2a, *Listeria monocytogenes* ProCC S1135 sv 3a, *Listeria monocytogenes* ProCC S776 sv 4b, and *Listeria innocua* ProCC S1147 sv 6a, respectively, were incubated in TB medium at pH 6. The growth of the *Listeria* strains tested was observed by determining optical density (OD). As shown in FIG. 8, the MIC values varied depending on the *Listeria* strain tested. For inhibiting *Listeria monocytogenes* ProCC S1095 sv 1/2a and *Listeria monocytogenes* ProCC S1135 sv 3a in general less protein was required than for inhibiting *Listeria monocytogenes* ProCC S776 sv 4b and *Listeria innocua* ProCC S1147 sv 6a. Ply511 shows the lowest MIC values 0.10 to 3.34 pmol/ml. The concentrations for PlyP40 were higher than the concentrations for Ply511, namely by a factor of about 1.75 to about 3.5. The MIC values for PlyP825 are, depending on the *Listeria* strain tested, about 2.3-times lower, or up to 17.75-times higher than the MIC values for PlyP40.

#### REFERENCES

- McLauchlin J. (1987). *Listeria monocytogenes*, recent advances in the taxonomy and epidemiology of listeriosis in humans. *Journal of Applied Bacteriology* 63(1):1-11.
- Oevermann A., Botteron C., Seuberlich T. et al. (2008). Neuropathological survey of fallen stock: active surveillance reveals high prevalence of encephalitic listeriosis in small ruminants. *Veterinary Microbiology* 130 (3-4):320-329.
- Gillespie I. A., McLauchlin J., Grant K. A. et al. (2006). Changing pattern of human listeriosis, England and Wales, 2001-2004, *Emerging Infectious Diseases* 12(9): 1361-1366.
- Goulet V., Hedberg C., Le Monnier A., and de Valk H. (2008). Increasing incidence of listeriosis in France and other European countries, *Emerging Infectious Diseases* 14(5):734-740.
- Gillespie I. A., McLauchlin J., Little C. L. et al. (2009). Disease presentation in relation to infection foci for non-pregnancy associated human listeriosis in England and Wales, 2001 to 2007. *J. Clin. Microbiology* 47(10): 3301-3307.
- Doumith M., Cazalet C., Simoes N., et al. (2004). New aspects regarding evolution and virulence of *Listeria monocytogenes* revealed by comparative genomics and DNA arrays, *Infection and Immunity* 72(2):1072-1083.
- Oevermann A., Zurbriggen A., and Vandeveld M. (2010). Rhombencephalitis caused by *Listeria monocytogenes* in humans and ruminants: A zoonosis on the rise?. *Interdisciplinary Perspectives on Infectious Diseases*, Volume 2010, Article ID 632513, 22 pages.
- Hagens S, and Loessner M. J. (2007). Application of bacteriophages for detection and control of foodborne pathogens, *Appl. Microbiol. Biotechnol.* 76(3):513-519.
- Loessner M. J., Kramer K., Ebel F. and Scherer S. (2002). C-terminal domains of *Listeria monocytogenes* bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. *Mol. Microbiol.* 44:335-349.
- Zink R. and Loessner M. J. (1992). Classification of Virulent and Temperate Bacteriophages of *Listeria* spp. on the



Basis of Morphology and Protein Analysis. Appl. Environ. Microbiol. 58(1):296-302.  
 Rocourt J., Schrettenbrunner A., Hof H., and Espace E. P. (1987). *Listeria seeligeri*, a new species of the genus *Listeria*. Pathol. Biol. 35:1075-1080.

Cummins A. J., Fielding A. K., McLauchhlin J. (1994). *Listeria ivanovii* infection in a patient with AIDS. J. Infect. 28: 89-91.  
 Adams M. (1959). Bacteriophages. New York: Interscience Publishers, 137-159.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 7

<210> SEQ ID NO 1  
 <211> LENGTH: 945  
 <212> TYPE: DNA  
 <213> ORGANISM: Bacteriophage ProCC P825

<400> SEQUENCE: 1

```

atggcattaa cagaagcatg gcttcttgaa aaagccaata gacgtttaa cgaaaaaggg      60
atgcttaaag aagtttcaga taaaaccctg gcagtaatta aagagatggc taaacaaggt      120
atttacatca atgttgaca aggcttccgt tctattgcag aacagaatga attatatgca      180
caaggcagaa caagcccgg caatgtggta acaaatgcaa agggaggtca atcaaatcat      240
aactacgggtg ttgctgtaga cttatgccaa tacacgcaag atggtaaaga tgtaatctgg      300
gcggtagatg ctaagttaa aaagattgta gctgccatga agaaacaagg attcaaatgg      360
ggtggagatt ggaaatcttt taaagacaac cctcattttg agttatatga ttgggtagga      420
ggagaacgtc ctaactccag cactcccgt aaaccatcca aaccatctac acctgccaag      480
ccttctgggtg aacttggctc cgtagattac atgaacagca agaaaatgga ttctctttt      540
gctaatacgt aagtacttgc tggaaaatat ggcatcaaga attatacagg aaccacttca      600
cagaatacac aactattagc taagattaaa gcaggtgcac caaacacgc tactccaaaa      660
cctccggcta aaccagctac ttctgggatg tacgtatact tcctgctgg taaagggtact      720
tggagtgtgt atccattaa taaagcacct gtaaaagcta atgcaatcgg agcaattaac      780
ccttccaagt ttggtggact gacttacaaa gtcgaaaaga attacggaga taatgttcta      840
ggaattaaga ctggttcctt tggacatgtc aaagtatatt gccacccatc aactggtgta      900
aaaattagca acaacggagc aggaaatctt ccgaatgttc agaat                          945

```

<210> SEQ ID NO 2  
 <211> LENGTH: 315  
 <212> TYPE: PRT  
 <213> ORGANISM: Bacteriophage ProCC P825

<400> SEQUENCE: 2

```

Met Ala Leu Thr Glu Ala Trp Leu Leu Glu Lys Ala Asn Arg Arg Leu
1           5           10          15
Asn Glu Lys Gly Met Leu Lys Glu Val Ser Asp Lys Thr Arg Ala Val
20          25          30
Ile Lys Glu Met Ala Lys Gln Gly Ile Tyr Ile Asn Val Ala Gln Gly
35          40          45
Phe Arg Ser Ile Ala Glu Gln Asn Glu Leu Tyr Ala Gln Gly Arg Thr
50          55          60
Lys Pro Gly Asn Val Val Thr Asn Ala Lys Gly Gly Gln Ser Asn His
65          70          75          80
Asn Tyr Gly Val Ala Val Asp Leu Cys Gln Tyr Thr Gln Asp Gly Lys
85          90          95
Asp Val Ile Trp Ala Val Asp Ala Lys Phe Lys Lys Ile Val Ala Ala
100         105         110
Met Lys Lys Gln Gly Phe Lys Trp Gly Gly Asp Trp Lys Ser Phe Lys

```



-continued

115	120	125
Asp Asn Pro His Phe Glu Leu Tyr Asp Trp Val Gly Gly Glu Arg Pro 130 135 140		
Asn Ser Ser Thr Pro Ala Lys Pro Ser Lys Pro Ser Thr Pro Ala Lys 145 150 155 160		
Pro Ser Gly Glu Leu Gly Leu Val Asp Tyr Met Asn Ser Lys Lys Met 165 170 175		
Asp Ser Ser Phe Ala Asn Arg Lys Val Leu Ala Gly Lys Tyr Gly Ile 180 185 190		
Lys Asn Tyr Thr Gly Thr Thr Ser Gln Asn Thr Gln Leu Leu Ala Lys 195 200 205		
Ile Lys Ala Gly Ala Pro Lys His Ala Thr Pro Lys Pro Pro Ala Lys 210 215 220		
Pro Ala Thr Ser Gly Met Tyr Val Tyr Phe Pro Ala Gly Lys Gly Thr 225 230 235 240		
Trp Ser Val Tyr Pro Leu Asn Lys Ala Pro Val Lys Ala Asn Ala Ile 245 250 255		
Gly Ala Ile Asn Pro Ser Lys Phe Gly Gly Leu Thr Tyr Lys Val Glu 260 265 270		
Lys Asn Tyr Gly Asp Asn Val Leu Gly Ile Lys Thr Gly Ser Phe Gly 275 280 285		
His Val Lys Val Tyr Cys His Pro Ser Thr Gly Val Lys Ile Ser Asn 290 295 300		
Asn Gly Ala Gly Asn Phe Pro Asn Val Gln Asn 305 310 315		

<210> SEQ ID NO 3  
 <211> LENGTH: 426  
 <212> TYPE: DNA  
 <213> ORGANISM: Bacteriophage ProCC P825

<400> SEQUENCE: 3

```

atggcattaa cagaagcatg gcttcttgaa aaagccaata gacgtttaa cgaaaaaggg    60
atgcttaag aagtttcaga taaaaccggt gcagtaatta aagagatggc taaacaaggt    120
attacatca atgttcaca aggcttccgt tctattgcag aacagaatga attatatgca    180
caaggcagaa caagcccgg caatgtggta acaaatgcaa agggagggtca atcaaatcat    240
aactacgggtg ttgctgtaga cttatgccaa tacacgcaag atggtaaaga tgtaatctgg    300
gcggtagatg ctaagtttaa aaagattgta gctgccatga agaaacaagg attcaaatgg    360
ggtggagatt ggaaatcttt taaagacaac cctcattttg agttatatga ttgggtagga    420
ggagaa                                           426
    
```

<210> SEQ ID NO 4  
 <211> LENGTH: 142  
 <212> TYPE: PRT  
 <213> ORGANISM: Bacteriophage ProCC P825

<400> SEQUENCE: 4

```

Met Ala Leu Thr Glu Ala Trp Leu Leu Glu Lys Ala Asn Arg Arg Leu
1           5           10           15
Asn Glu Lys Gly Met Leu Lys Glu Val Ser Asp Lys Thr Arg Ala Val
20           25           30
Ile Lys Glu Met Ala Lys Gln Gly Ile Tyr Ile Asn Val Ala Gln Gly
35           40           45
    
```



-continued

---

Phe Arg Ser Ile Ala Glu Gln Asn Glu Leu Tyr Ala Gln Gly Arg Thr  
 50 55 60

Lys Pro Gly Asn Val Val Thr Asn Ala Lys Gly Gly Gln Ser Asn His  
 65 70 75 80

Asn Tyr Gly Val Ala Val Asp Leu Cys Gln Tyr Thr Gln Asp Gly Lys  
 85 90 95

Asp Val Ile Trp Ala Val Asp Ala Lys Phe Lys Lys Ile Val Ala Ala  
 100 105 110

Met Lys Lys Gln Gly Phe Lys Trp Gly Gly Asp Trp Lys Ser Phe Lys  
 115 120 125

Asp Asn Pro His Phe Glu Leu Tyr Asp Trp Val Gly Gly Glu  
 130 135 140

<210> SEQ ID NO 5  
 <211> LENGTH: 459  
 <212> TYPE: DNA  
 <213> ORGANISM: Bacteriophage ProCC P825

<400> SEQUENCE: 5

ggatgaacttg gtctcgtaga ttacatgaac agcaagaaaa tggattcctc ttttgctaata 60  
 cgtaaagtac ttgctggaaa atatggcatc aagaattata caggaaccac ttcacagaat 120  
 acacaactat tagctaagat taaagcaggt gcacccaaaac acgctactcc aaaacctccg 180  
 gctaaaccag ctacttctgg gatgtacgta tacttccctg ctggtaaagg tacttggagt 240  
 gtgtatccat taaataaagc acctgtaaaa gctaatgcaa tggagcaat taaccttctg 300  
 aagtttggtg gactgactta caaagtcgaa aagaattacg gagataatgt tctaggaatt 360  
 aagactgggt cctttggaca tgtcaaagta tattgccacc catcaactgg tgtaaaaatt 420  
 agcaacaacg gagcaggaaa ttttccgaat gttcagaat 459

<210> SEQ ID NO 6  
 <211> LENGTH: 153  
 <212> TYPE: PRT  
 <213> ORGANISM: Bacteriophage ProCC P825

<400> SEQUENCE: 6

Gly Glu Leu Gly Leu Val Asp Tyr Met Asn Ser Lys Lys Met Asp Ser  
 1 5 10 15

Ser Phe Ala Asn Arg Lys Val Leu Ala Gly Lys Tyr Gly Ile Lys Asn  
 20 25 30

Tyr Thr Gly Thr Thr Ser Gln Asn Thr Gln Leu Leu Ala Lys Ile Lys  
 35 40 45

Ala Gly Ala Pro Lys His Ala Thr Pro Lys Pro Pro Ala Lys Pro Ala  
 50 55 60

Thr Ser Gly Met Tyr Val Tyr Phe Pro Ala Gly Lys Gly Thr Trp Ser  
 65 70 75 80

Val Tyr Pro Leu Asn Lys Ala Pro Val Lys Ala Asn Ala Ile Gly Ala  
 85 90 95

Ile Asn Pro Ser Lys Phe Gly Gly Leu Thr Tyr Lys Val Glu Lys Asn  
 100 105 110

Tyr Gly Asp Asn Val Leu Gly Ile Lys Thr Gly Ser Phe Gly His Val  
 115 120 125

Lys Val Tyr Cys His Pro Ser Thr Gly Val Lys Ile Ser Asn Asn Gly  
 130 135 140

Ala Gly Asn Phe Pro Asn Val Gln Asn  
 145 150



-continued

---

<210> SEQ ID NO 7  
 <211> LENGTH: 66849  
 <212> TYPE: DNA  
 <213> ORGANISM: Bacteriophage ProCC P825

<400> SEQUENCE: 7

tattaaattc tcatacagtg tagtcgtgtg tgttcgagtg aagcactggt aaagaggtag	60
gttctaaaca tatcttaact tgttatacat atactataac agtattaaat accttatata	120
attatatggc tataacacgt cacaacatgc cacacatggt atctcatata aaccgcttt	180
aacacgccaa taatggttcc taaccattcc ccaataagta cccacatag tccccaaat	240
agccccata ttcattcgct attatcctcc acaaatacc cggcttatct gccctagatc	300
gtggtggatt acctgtaata tatccccctc atattcccc tatattagta ctggtattat	360
actactatcc aacatatcac ctatataagt acccggatat taccgtaat tatacacggt	420
gtgacacgtc cccacacgca cccttatatt taaggggta aactgtgagg aaattctagt	480
gcgattatac aacacttaac ctacacttat ccacctttcc aaagttaaat gcgtagaat	540
cactccattt cactattcta tatttaagac atattctcta tctttagaat attcagactt	600
ctatatccat aaaaagagcc cccagttaag ggagcttatt tctggttatc taatttgttc	660
cattcccgtc cacattcagc caagaaggct tttatgcctt catttgtttg tggcagggta	720
tcaccttgca ttttaacatc ttccatttta tcccttacia acttgccttt acctccata	780
aactctgcca acccgttttc tatctcttca ttattcattg ttggaaccac accccattat	840
ccatgccatc atatccccac gcattacttc cagttgtgtc aattactaag acgtcttttt	900
catatacaat aacagctttg tctttgtaga tatttaagtc cacaggtttt tcatttggaa	960
agccgtactc ttttacaatc tgtttttctc tcatttctct cgttacttta ctttcagata	1020
ctgcactcgc attttcaact tgattaaaca ttaccaccaa tgttactaca ctcaatacta	1080
ccaacgctac aaataccatc atcaattttt tcatcttctc tattcctcct aatttttatt	1140
tcgtgttctt tactactctt atataataac ataggtagtg ttacaaaaca agcccatttg	1200
tgttacagaa ttattacatg tgtaaaggga gccgaaagct ccccgctggt attctttagg	1260
ctcaaagtggt gctaaacaaa tagctccaat tccaaagcag acgaatatca cgccaaaca	1320
tatcatgact ttgttattac tgtcaccagt cttagctaga attttatggc tatcactcgc	1380
ttttacttcc tgtataactt ttttaggttg tggggacggt tctacggctt ttacttttgg	1440
tttaacgggt tcttgtacag ttaaagcttt ctgaggagcc tcaacttttt cagatacaac	1500
ttctttttgt ggttcttctt tcacaacttc tttttctggt tccggttttt gctgtggctc	1560
ttctttaact ggtgcaacaa tttcgtccca cgttaaaacc attacgaacg tatcacaatc	1620
ttttagcact gaaatagtc cagtaaattc agtccccca aatggagctg tccaatcatc	1680
tttagaagtc ctttttgac catcctctgc cacgtaagtc catgtaccag atttttcatc	1740
taaggtcatt tttacattaa cttctttcat cgtttctgga ttccattcat aatctgtaag	1800
tacttcttct ccaccttta tttctgtttt agtgcctacc aatattttac atccagtaac	1860
ttctttatcc caaattactt ctacttgctg tccgtcgata tagtaaatat cgttatcatt	1920
cgataactgt tttccatctg tagtgattaa cgttctctct tttgcgtgca cttccggaat	1980
tttttcatct gcatttactt gtgccccctc aaaaatcaat actccaaaaa ctagactact	2040
cacgattaat ttacttactg aattcttctt catgtttttg ccctcttttc ctttattttc	2100



-continued

---

acttgacaac	tatatcacac	attgttaaac	ttgtcaacaa	cctgccagaa	cttctatacg	2160
gttttgata	agctcattac	tttctgtgtg	taattcgtat	gtacttatta	agtctacca	2220
aaatggatac	ttaagtttac	cttcttcttg	catttcgtcc	aaaattgtgt	tatactgttt	2280
tactgcatct	tgaatattgt	tagctgtaaa	gcttttgtat	tctgtcatgc	tggtatcctt	2340
ttgacaaatc	accgaccatg	tggacggcac	ttctttcaca	tctatatcga	aaatagcacc	2400
gtccacaaca	tctcgcaaca	tgaatttagt	cttaaccaca	atagcttacc	tcgaaaagtg	2460
cataccaact	tgaaggacgt	gcttggaaat	atntagtagc	attaattgca	tccattaaat	2520
agattgcgtc	gtcagaatcc	atatctacgt	gaaaagtgaa	accagagaac	aagtctgtgt	2580
caatctcacc	cgtattaaat	tcgtagtgct	cgaaaatata	cgtaactct	tctaagataa	2640
gttcttgtgc	aatttcttgc	atatcttccg	ctaattcttg	ttcatcttct	tcatatccat	2700
tccaccatt	tttaaacagt	tcgataaatg	tttctttgat	tgtgctatta	gtagatgcgt	2760
gaactggata	gtcttcgcta	tcaccaaata	ttatatacag	actaccttct	ccactttcta	2820
aacgtgtagc	ataatccttt	gcattaatac	tcatttctaa	gcttctaagt	tcattcattt	2880
ttaacgtcct	cctcttaatt	tatatacca	gtatatcagc	ctctttgtta	caattcaata	2940
cctacaatat	tacaaatgtg	ttacagtaag	tgtgaaata	tctgctcttg	tttgtgtgtc	3000
aagtataaac	tgttttgtca	atTTTTGGAA	ttacttaca	agtccatttt	gtcgataaa	3060
ttctttgatg	tggcgaactg	gcgtatttgt	caaatgttgt	acgtttgctg	taatataaaa	3120
ttctccatca	actaaagcgg	ctacaggcgt	ttatagctg	taaagaactt	tcgtgctgta	3180
ggctgttcca	tctctgtaga	tattcttctc	cgccacttct	gctttattgt	gataactcgt	3240
tacattctcg	aaaatagggt	ctaatacttt	aatagtagtt	tcttccgttt	taaacaattt	3300
gaccactcct	atatttttat	tctggttact	ttctgaattg	gtttgttaag	atagaatgct	3360
actgcttccg	cttgtttgtc	cgtgtaagtt	tgcatgaaac	ttgtaacgtc	catgctaaac	3420
aagttcttga	ccgctcttct	taattccaga	caatcaacca	ccacgaactt	acttttaccg	3480
attgaaagag	attgaataac	gttctgcatt	aaattgtagc	acctcctctt	tttccaagta	3540
ggctctaattc	agtgaaagca	atTTCCCTCA	atTTGTCCCG	cgtaatagtg	ttgtagtacg	3600
ttgtgaaatc	ttggtaagta	cattttgcca	atgcttcaat	tagtccgctt	cgttttgccc	3660
ctacatTTTG	cacgcaccaa	gcttggcggg	ctgaaactaa	catgctaaca	tattttacga	3720
gctctttctt	tgacaatctc	caaacttgtg	cagatacaaa	ttctttcacc	gctaattttt	3780
ctacttcgat	agttttactc	atTTTACTCC	tcctcttcta	atattggatt	actccggatt	3840
ttcttgtgtg	gcgttttatc	tctctttgta	gtacgctgtc	cgcaaacgg	aatcttgcta	3900
caattccatg	cgtgcttget	gtgttgcttt	taagttcgta	aattgttcca	tcttccattg	3960
tgatgaattg	ataaactaag	ctacctccat	agatactagg	tcttgactgt	aagtaatatg	4020
actcattttg	atTTACCATA	tctggattaa	tgaaccatt	ctttaagtgc	tttcttgtta	4080
ttttgtttgc	cattttctaac	acaactctca	tttaatttgt	gttgttcttt	actactcttt	4140
aactataaca	cgcccgtttc	agtttgtcta	ctattttaat	gttacaattg	tgttacaaac	4200
ttatttggtt	cttttactat	aaacttttgc	caatctattt	tggctttcga	aaactctct	4260
tactttaaat	acgcttgcgt	acctatTTTT	ttcacttoca	taaccaagca	ttgcaaaaa	4320
ttcctctggt	gataaaccta	ttccctcgta	agttgctttg	tcctttttga	attccgcaat	4380
cgtaagttct	atTTAATCCG	ctaaagctgt	taactccatt	tctgaaatat	cttaccaca	4440
tgaaccaatt	tcagttactg	caaaaagtgc	atcgggtgca	acaaatgcc	ttccttctct	4500



-continued

---

aatttcttgt	cttgctgctt	gtcttaattt	catttgaatc	aattcctttc	tacatttgat	4560
ataagattac	taacaacatc	ataacagata	atgtgataag	tgtcaagctt	ggaatagctt	4620
ttaatagaag	ttgtttcata	ttatcgtttc	ctttccgttt	tcaattactt	taattccgag	4680
cgttttgttt	tctatagtag	aaagtggttt	ttgtatatct	ccattttcct	ccatcatcgc	4740
ccggtgtatc	acgtgtaacg	cttgttttaa	ttccatttta	gtttgtgtgt	cgcatgtgct	4800
tttgtctact	acattatata	gagcgttcga	agctctgttt	aatagaatgt	aattacttgt	4860
tgctgtcatt	ttaaccagct	ccttttaatt	gataagctaa	tcttagcacg	cttttttctg	4920
tttgtctagc	ttttttgtgt	tacaagtttg	ttacagaagt	acgtaaattg	gatgacaaga	4980
gtttgattaa	agttgacttt	gacctttatt	gatgtacctg	aaatcgacgt	cttttttaggt	5040
gtctgcggta	gctttttgct	gctgatttcc	cgggcgcctg	cgttcagtcc	taaaaaattc	5100
cccggggata	tacaaaattt	cccccaaaa	atttccaccc	aatttatggg	tgagaataaa	5160
aaatccaccc	aattatttga	gtttgacgaa	cggaatttga	atcgaaacaa	ttaagtagtc	5220
gaagcagaaa	acgtaactca	aaataataat	gaatggatgg	atttaatatc	cagttcaaat	5280
ggaactgatt	tttgtaactg	ttttccaat	acatttgact	gttaatttac	agaacgctgg	5340
gaaagtgttc	atcattttta	gcagaaattt	gtattcaagt	tttggtctaat	gtttgcgaca	5400
acgtttcctt	aacttgtaaa	ttaattttac	cacagattgt	tgcatttgtc	aaatattgctg	5460
gaaaacgtgt	tgaacaagt	gataccaatg	gttttgagtt	tccccagaat	aaattttaaa	5520
aataatttca	aaaaaaatat	ttaaactctac	agaataaatt	ttaaaaatga	tttccaaaat	5580
gacccccact	tgtgttttga	attgaacttt	gtagaatata	ttttcaaat	aaataccaaa	5640
tataactaaa	atgtgatata	ataaaaagat	aaaggtggtg	ataaaatgtt	agatgatttt	5700
gtagaatttc	ttccaaacta	ttttgttaat	aaggaaggga	aagttctaag	taaaatttct	5760
ggaaaaatta	aggagttaaa	aggttctaaa	aatccacaaa	aatatcaaca	atttgggttt	5820
aaagttgatg	gaaaacatgt	tggaatacaa	ctacaccgta	tactagcaat	ggcattcatt	5880
ccaattccag	aagaattaaa	aaatgctaag	aattgcgtag	accatataga	cggtaatcca	5940
gaaaacaact	ctttagaaaa	tttaaggtgg	actaactacc	aagaaaactt	agcaaaagca	6000
ggtagagaag	gacaacgtcc	tatgttattc	acccatgaag	aggcacgtta	catgctgaaa	6060
gaatattggg	aagagggtat	gtccatagag	gatgtagcta	aagagtttgg	tggtggaact	6120
gataaacgtg	tttacaatgg	tgtacaaagt	attattaaat	acaaatcaat	gcaatatgta	6180
gcagacgaat	agccagagga	ttaatcccgc	tggtctttct	ttttatcttc	ttcttctatt	6240
tcaaaaattc	ttttaaagt	atctactaag	gcattaataa	attcatcagt	attcattgac	6300
tgattataaa	cattaaccat	aacagtattt	gtaaaaatatt	tttctaaaac	atcttcagaa	6360
actgctggc	ttatagctcc	gtctacagtg	tcatcccaat	caacctcgta	agcaatcatt	6420
cctgtcattc	cctgtgtaac	accaataata	gttcccttag	aattgttata	acgatgctgt	6480
acacgttcaa	acttttcaaa	cttactcatg	atacgttata	ctcctagaaa	tcatttgaaa	6540
aagttactcc	acaatattca	ttcttcccat	aatgtataaa	ggtacaggca	ctttcatctt	6600
ctctcacact	tattccaacc	ttcaccactt	ccccatctat	gggagattta	aatgttattt	6660
ttaaggcaac	tttatgatgt	gtattatggg	taatccaagc	ctttaccttg	aatattcctc	6720
ttcgcattct	tactacggct	gtattaggat	aattttggga	atgtttgtga	aaatttctctg	6780
tgaatggatt	aaacatttca	aatatatcag	ctctggatgt	aggtaataac	atatatctta	6840



-continued

---

cattttgttt	agataataac	tctctacctc	ttctgtcaat	tgctgaaaag	ctttcttctc	6900
cgtgtgtaag	taactccaat	actaattttt	ctgcaatttt	ctttccttct	ttacatcttt	6960
ctttcctcaa	ctgcttagtg	tgttttattct	tttctttaat	caatattttt	cttgctctgg	7020
aaaatttttc	cataattgct	ttcacctcac	ctctttatth	acctattaaa	ctaactataa	7080
tagctaaaat	aataagaaat	aatattacta	acataacaaa	tacaatgata	gcaaccaga	7140
taattattgg	aataaacact	gtccaccaga	caatattaat	aataccagtt	aattgaagta	7200
ttaataatac	taggaaagca	attacgcata	ctgcaactaa	tctcatactt	attcactctc	7260
ctattagttt	aatatcccac	gggctcatcc	aaacagttcc	aaaactattg	ttatcaaatt	7320
taactttata	aattagtatg	ccttccataa	gtgtccagtc	gataattggt	cctttttcat	7380
aattattggg	ttcctccact	cggttccat	ttgcataggg	atgttctgct	gacatattgc	7440
tgaatacctc	ctctttattg	ttaaccaat	ctaaaatctc	ttccaaagta	ttaataacta	7500
tcaaccccc	cccctctcta	tttaagtata	acacaagcca	ctgaaatatt	caatggctaa	7560
gtgcttttat	agttttattt	gttttactgg	ataaaaacca	agttcattct	ccgcattcaa	7620
ttgattaaac	cgctcctcag	aaatctgcac	atatgaagta	tctttttag	ttaagaatct	7680
attaagttta	ctaagtctaa	cctctttttc	ttctccaccg	tctacttcta	atgaagtata	7740
tactgctttt	ccctctgccc	cattagtagg	aataaaaatt	ataaataagc	gtagtagact	7800
tccttgttta	attccgtcaa	aatctttaga	agtagttggc	ttagcatcat	tatattcaca	7860
taatagatac	gcatatactc	ctgaactatt	actcatataa	atcatacct	tctgccattg	7920
cacgaataac	ttcctcagta	actacaccag	aaacacgtgc	cacttcttct	gactcttcat	7980
tatagagcac	aattgtagga	acagatttga	ttccctctgc	gattaagaca	gcttcgtctt	8040
cctccacagt	agcaatatta	taatggaatc	ctgtagcatc	tagttgtggt	tgtactaact	8100
tacatacacc	acagttttct	aattttttat	aaaatacaat	ataacctttt	gccattaatt	8160
tttccccatt	tctttttcta	ataattccat	taatatttta	atggttaaat	ctgttaattc	8220
tttatcatta	ttttgtaa	catctaagga	agcctttcct	ttgaagtagt	ttctgatatt	8280
catattaata	acctgttctt	gttcttccat	aaatacttct	ttgaattcta	tattaatcct	8340
actcaatgta	tccatttcat	ttcattttc	cacaaaaacg	gaataccaat	aaataccgtc	8400
attatctaag	tggtattttt	ctaattcttt	tggagaaaaa	gctataccta	tttcattatt	8460
aaattctttt	ccatagtcac	gtagtttggt	gaaatcttta	aatctccaaa	ttaaactggtc	8520
tccctttttg	tttaagtaa	gaatttctct	ttcttcatca	tatctaagta	gtacaaaaata	8580
gtgcttactt	tcatccaaat	ctgcaaactt	agtcactctaa	tcccctcggg	ttctttgtgt	8640
atttactagc	aggctcatat	gggttattct	cttttgtaat	agtcattcct	aagtatttac	8700
ctctagttgg	tttgtagttt	cctcctttat	ctattacca	tgttcttaga	gaagttttag	8760
gaactcccca	caaatctgca	actgcatcat	gtgttttctt	tgcttttaaa	tctctataat	8820
aatttgaaag	agtgttaatta	gcaagagaag	tacatgataa	ttttctatca	taacctttac	8880
ctatttcttc	cagctctgct	agctctttac	caagctccat	aacctcttta	caccattcaa	8940
actcttctg	ccacacgtca	ttataatcat	taatctctgg	atgttggtct	aaaatgtcat	9000
ggagggcaat	tcttaattct	ttagctcttt	cctatttttt	cattatctaa	caatcccttt	9060
ccaaaaacaa	taccaactct	attcttctct	aacatagtat	atacgtctga	tggcacaaca	9120
taatcatatt	ttatgatatt	cataactaat	tctttatctt	ccagtttggt	tgtaatatct	9180
tcctccaaca	tacttgata	cttagaaagt	cctctacgtg	ccttaccttt	cttttcctg	9240



-continued

---

tcttctctt	gcttaacacg	acaagacacg	tactcatgta	ttaactcaga	ttcttcattt	9300
gtcaacatgt	aagcaatctc	ttcatccata	ttaaacttca	ctcccgttc	tttactcgta	9360
gtctttgtgg	gaatttctac	cccattcagc	acagcttcta	taaatagtct	agctgttttc	9420
tgttctgtct	tgtaacgaat	gcggggaatg	tttgctttta	ttggtgcaat	gttatttaaa	9480
atctttttca	aaatatctga	atcactactc	atatcttacc	tccttaactt	tatattaaaa	9540
ttataccaca	ctatttttaa	tatgtcaaca	aaaaagagag	cataagctct	ccttaatctg	9600
ctgttacatt	tctagtgggt	tcagcgttgt	ttacattggt	gttaatagtt	gcaattacag	9660
atcttctcat	gtcaatagcc	cactgaatag	cttctaatac	ttctgacttt	tctttcttct	9720
tagataaacg	tttgtaagaa	gcttccaata	ctttaatgtc	ctttactaac	ccctcgataa	9780
agtcaatctg	gttttgtgtt	tcctcattaa	tttctttcac	ggttctttct	cccatctata	9840
attaattttt	taaccattt	aatttggttt	tctgctaatt	cttgttttgt	tttggctaac	9900
tgttctcag	cttcaaagaa	tttttcttc	attttatcct	ctagtcgtgt	aatttctct	9960
aaagcttctt	cacaatcctt	tgccagtttt	tctgggtaat	ctaaatcgta	gcaaacttta	10020
acaatgacta	cctgctcact	tactcttttt	aaaaactcca	cataatctgg	taataaatga	10080
ccatatttat	ctttgttgca	atatattacc	tttgcaaaac	tatcatattt	ataaggagcc	10140
tttcttaatt	cttcgtctac	tcogtatcta	atcttcttct	cttcttctat	catttttagtt	10200
atcttctgta	cttctcgttt	tgtttttctc	caaataatct	tagtcttaaa	ggtatctcca	10260
aaaaccattc	catctaaata	tctttcttta	actagcaata	accatattaa	taaataactc	10320
acagccattg	aaaacaaaat	aacacagatt	tttaatcctt	cataggtggt	gtattttccg	10380
tcattgtctg	ttgttaccag	tgtccataat	gttgtaaaaa	tgaaaaatcc	tgctaattgt	10440
attaatgtca	aaaattctat	tttaatgata	cgattaatat	atcttttaag	gtctttacca	10500
aaacgcttga	aaggaagaca	ggcaccagta	tagccctcca	atatagtttg	tatagcgtaa	10560
tcatataaca	tcctatctat	cttcttattc	atcataaaac	ctccctcgta	atatatttat	10620
tataaccaga	gaaaggcgta	ctgtcaaacg	attaattaat	aatttttgta	tcaaattccc	10680
agtcatagac	gttctcacgt	aatgttagta	atctacctct	tacagtatta	attgccatat	10740
tagaagccac	gtgagaatca	tttccggact	gtgttacagg	aataataaca	acatcttctc	10800
ggaatgtact	catgttcggt	gtcttaaatc	ttaccaaacc	atggaattct	gtcctaacca	10860
atcttctcaa	cttccatttc	ttgaatattg	attaacagtt	taccactcgc	aaaaggctgt	10920
aaacgtctgc	gtaagctctc	ttggaatatt	aagaattccc	ctaaattcat	ttcttctaca	10980
ggactaagag	aactaaattc	aaaatccatt	gaaaacctac	ctccatcaat	cccattctta	11040
caaatacgaa	gataatctac	tactacatta	gcgttgatg	ttccatagt	ttatttgtcc	11100
ccttccaata	aattttttaa	tagttgcata	atatctcggg	ataaatcttc	ctcctcatcc	11160
tcttcttcaa	tcgttactcc	atctatttct	tctgaccact	ggctatggat	ttcttttgca	11220
atattatccc	catatttata	cccatattct	gctttaaaat	ctttatcagc	caccaaattg	11280
ttcataattc	cctgtacaag	tccttcaca	gtagctcctg	caaccattaa	aatgtcttg	11340
tcggtatctt	tcatattttc	tggttctggg	aatgttgca	tggctaaatc	cactaatcgt	11400
tcgccgaaag	agtttctata	agctagtaca	aattccatta	atcgtttga	tttaatattt	11460
ctactatttg	ctacggaagc	catgtctttt	aatctttcag	ttatttcatc	aatgctgtg	11520
gaagtatctt	cttctcttg	actttttgac	aatgacctt	ctttcacttg	aaactcctca	11580



-continued

---

tgtacgtttc	ctttgtagat	aatattagta	tcactatcct	ttaataatcc	ttgtgaatta	11640
tcaattaaat	cgtctaggtc	tgtctcgtaa	ttttccgcgt	cttcttgaat	atattcattt	11700
aacttatccc	aatctttatc	tactgatttc	ttattaaat	tatctaacgg	attaaattta	11760
gtcatttatt	tctcctccaa	aattaagttt	aaattgctct	gttgctagtg	cggaatttac	11820
tctagctaat	acggcacttc	tggctaagct	ggttgcttcc	tcgtctgcgt	cttttgtgat	11880
agcagataag	gcgtgctcca	aaaggataat	cgctgcataa	atctctgctg	cggtatctcc	11940
acttgctgag	aagctagaaa	tccccagcat	tcctctaaa	tcgatttcca	catcaatact	12000
tccactaaaa	ctactttctt	ccatttaatt	ctcctccttc	tgtaagaaaa	atztatcata	12060
aatttcttca	tctgtcaagt	cttttattga	ataataatta	aggacgtgtt	ggaagttttc	12120
ctctggcata	gcaatttcta	cagcttctct	tgtttcagaa	ttactttcaa	gagtacgtcc	12180
atatccccat	ccaaaactac	tagctgcccg	tattctacta	atctgtaatt	ctagtaaagt	12240
aaataacagt	cttcgatacg	tacctacgtt	agtaaagga	aaataaagcc	gagaggtgtt	12300
aaaactatct	tcaaaatctt	taatagtga	agctactaca	gaagcaatat	catctgactc	12360
ggatgctttt	cctactacaa	tgcgtaatct	gtatttata	gacaatgcca	caattatfff	12420
aaacactttc	aacatataat	catttaaaga	ctgtgcccga	atgtccgcta	atgctgtaat	12480
ccctacataa	atactaattg	caggaacctc	tttcatccct	ctacggcgga	attgtcgtgg	12540
atgtccaata	agagaacgtg	gaactgatag	agaagagcct	gtaacgctcc	actccataga	12600
acctttctca	agaatttget	ggaacctagt	tagctctctt	tggatggaag	cttgttcact	12660
ctcttcgatg	tagttagagt	ggaaccgttc	ctttaggta	ctggcaccta	ttcctccatc	12720
tctccaatcg	tcactctctt	ccatattctt	gctgtaatta	aaatcacttt	gtttcttttg	12780
taaatcttta	aaaatatttt	cgtagtcatt	tcctacatat	ttagttaata	aaatactatc	12840
ccaattgccc	tcttttgta	ttggattaac	tatctctcta	tggctgaaat	tattttcaac	12900
aacatctagc	acaaactttc	ctttctcttc	tgccatcctt	acacctctta	aactttatff	12960
tttattgtct	tgagaagtca	cccaatctct	aaaattgttc	cacacttcat	ttcctgctaa	13020
agaactagcg	tgtttacttt	ccaatccttt	tcgaatagaa	gacacatcag	cccacgctag	13080
tgctttaaac	agaacatttt	caaatacgaa	gccttctcca	aagccttcta	gttttttgta	13140
ctggctcata	gcacggtaag	agataacgtg	gttaatcatg	ttggcttcga	ttacttcacg	13200
gcaacgggta	ataaactgga	ttaaatacatt	atcacgggta	gagataatca	attctaattt	13260
cttgtcataa	tcaacatgaa	taggaacaaa	acggtcaagt	gtcgcagcat	caatcttggt	13320
acgacctgtg	tagttcatgt	ctcccccttt	accaagcgtg	ttacctgcca	caattacttt	13380
aaagtcttca	tgtgcatata	ctgtttcgtc	tccgccgtct	gcactagaag	ggaaggctcat	13440
aaaattgttt	gcaagaacag	tattaattac	gataagggct	tctgggtaac	tggcatcgat	13500
ttcatcaata	aataataacc	caccattctt	catcgcttta	tacaagtttg	ttgcttggtta	13560
tttaccggtt	ccatcacgga	atccaataag	ctgtgtgaa	tcgtctgtaa	ccttctgcat	13620
tggatagaag	tctaaaccaa	gtttagtaga	tacgttttgt	gcaatagttg	ttttacctgt	13680
gcctgcttga	ccatgtaacc	agcagtgcaa	acctgcctgt	gtcatagcag	agatacgtcc	13740
tgtttcacaa	tgttcatcta	ctcctgcact	atatgcttct	gtgctgacat	agtaggtgtc	13800
atagttttgc	tcacgtaaga	agtttaagc	aggtgattcg	aattctactt	tttctaaagc	13860
atcctccaaa	atctcgaaag	ccttttcttt	aacagtgctt	tctaattctc	caaacatggt	13920
gctttttagt	tcctcgaatt	gctcctcaaa	tgtttttact	ttagaatttt	cagtcattat	13980



-continued

---

ttaaatctcc	tcttcctctt	aattagatc	agtattttta	tcttcatatt	taggacttag	14040
aatccttact	gttgtggagc	gtaaacgtct	gttattta	tccaaacgta	gtagcgaatc	14100
tgaaagttct	tctaaggctt	gtgcccgttt	ttcttgtggc	aatgttccat	cttcaatttc	14160
ttttaaagtg	actaaagctc	gttttgcttg	atttaggtgt	gtgaaatttt	tattgggtta	14220
ttcatttact	gttgtgtaca	cgtgaactaa	atcagaatca	cttggctctt	ctggcatatt	14280
ctcacctcct	gtattactac	tataccacaa	aataaaaacc	ctgtcaacaa	taaagtgaca	14340
aggtttaaaa	attatattga	ttccgcacta	tcccaatcaa	tttcttctgg	gttaattgga	14400
gcgttagggg	ctgggtgcatc	tgggtataata	aagaatacat	aagcaccatc	tgggtttcta	14460
aattccactg	acaatacctg	tgaaccttca	tcctctaact	ggttggtagc	atatgttaaa	14520
cgttttgcta	attcgtcccc	atcgccatcc	aaataaataa	ctccacgtgt	atatccttta	14580
ttactcatag	aatatgtgcg	tgcgcagttg	ctttccatcc	acatacaagt	ggttaggcga	14640
ttggctatct	ttctttttca	ttacaaaaat	ctgtcgtttg	tactctgcaa	tttctgcatt	14700
taattttctct	tcattatttg	cagaggcttc	tagttcatcc	aatagacttt	tgttctcttt	14760
ctctaaatct	tccacaagca	tctttagta	ctgttttgag	ggcattagcc	caccttcttt	14820
ctagtaccaa	cgtgaatga	tatggaactc	tttagcttcc	tcccaagttc	catagcgttg	14880
tgccacatag	gcatctgctg	cacgttcttg	gttagcaggc	gaatagtcac	ctttcaagtt	14940
ccattcttct	agttggtatc	ttccaatata	ttaccagtt	gcggaacggc	aattataatc	15000
tcctcgtgac	tccacatagg	cgatatattc	cttagcagat	agtccattct	gcgttccttc	15060
tggaataatt	ccttttctg	tacttgattg	tgatgtctcc	tgcttggctg	gctcttgaga	15120
tttctcttgg	ttaggagaag	cttgttcttg	ctgttcttgt	tgagcttttt	cctcagcttg	15180
ttttgcttcc	aaagcctgct	gtgcttcttc	tgcttcacgt	tgctttttaa	gagctaattt	15240
acgagctgct	tccgcttttg	ctttaagttc	ttttgatgt	tttctgtaa	tttgttttgc	15300
ctgttccaac	gatttttctt	gcttagttgg	tacagatgcg	aacaatttgt	caatattgtc	15360
tgatgcttca	ttctgcttct	taagctcatt	caagtgttca	ggcagatttt	ccacagcagt	15420
taacgcactc	ttctcttga	ctgggtcttg	cactggcttc	actggggcag	ttgttaaact	15480
aactgccata	gctaattgta	gtagcattta	tttctccat	ttgattcgtg	tatttagtca	15540
caatttgtgc	ctatgactat	gatacagatt	atagcacggt	ttgttgcac	tgtcaactat	15600
taattttaat	taagtcgttc	gtctattctt	aatcgcagta	cttgaccacg	tgttttgtat	15660
ggtctatcca	ttgaaattgt	tttgggaata	cgccgttctc	cattattatc	tacttctaaa	15720
ataaagttag	aaagtaacat	atacagacgg	tttggcaaac	tgacggattc	aaattcctca	15780
tagaaatctt	cgcagattcc	ttcaactatt	ttagaacgaa	gcagtgcttg	ttgtaaaaca	15840
atttcttctt	cttcaggaac	aggcataatc	aagcgaggat	tattttcttc	gtgtgcttct	15900
agttcttcga	gaacatccca	ataaaagttt	tctaaacgac	ttgcatagtg	tctctgtcgt	15960
gtctttttac	taagttgtcc	atagcgtttt	ttctcgtct	ctgagttcat	ttttaaactt	16020
ctcacttctc	cgtagtattt	ctttaattcg	tataacttgc	ctgtagatag	ttaccgggtg	16080
ggctccta	atatccgcaa	tttctgatat	tgtataatca	taaacaaaat	aaagaatagc	16140
taccttttgt	aattttctg	gcatattaac	tgtcttaaac	gcatcttcca	aaatgtttta	16200
caactgattt	tgaacacttc	cgtggataga	ggtgctatcc	ttttcatggt	ctgaaagtaa	16260
tttcaaaaca	ttattattca	ttattactaa	cttttttaggg	aagtaatctg	attcatttgt	16320



-continued

---

ctctaggaaa	ctcatctttt	ttccaactct	caagtaaadc	cagtatttgg	tcgtataactt	16380
ccgtgtaaga	acgtccgtta	tttgtaataa	cagcatctat	tggaatgtct	tttccatcaa	16440
atactacatc	taattcatta	tttatttcta	ggtcttcacc	taaagtgtct	gcacgtttta	16500
aggctacatc	atcatcacia	acaacttgaa	taattaacat	gccacctcgt	atacagaaat	16560
ctaattcgtt	ctcttgcctt	acgtcatcta	tgacaacacc	tacagagccg	acgggcattt	16620
gggctgataa	cttcttaacc	caaacgtcct	cgtaaatctc	tctcatggct	tgtccgtact	16680
ttatgtatcc	atctcgtggc	ttcggtgacc	gtggaatata	tggaatgtt	ctatggaatt	16740
catctttcat	tgctttgcca	aatcccatgt	ggtgattacc	agtatagctt	gcaataaact	16800
ctgcaatagt	tgacttacct	gttcgtgatt	ttcctataat	tgcaataact	ggatatttca	16860
tattattcag	tccttgtaga	caatgaacgt	agttcttcaa	tatcctttaa	gaacgttaac	16920
gctacggcaa	tagcatctgt	ttcatcgtct	gagtattcta	gcggattgtc	catatgtatc	16980
cagcgaggta	aggcatccgc	tacttggtgc	ttagaggaat	ttccgttccc	tgtcactgct	17040
ttcttaactg	cttttgcat	gtagacattc	atcttctttt	ctccgttgcg	gaactcatag	17100
tacaaatggt	ctagcaccac	ataaaattta	tagagaatct	tagttgctct	gtttccgtgt	17160
acaaaccac	cctcacgaac	aataatatcc	ggttggaaat	cttcccaaat	agctaactg	17220
gctttctcaa	atacatctaa	tcttctgcca	atatcccaag	ttgagtgggt	aatgatgata	17280
cgtgtttcaa	ttagattaca	gttacgtaa	gcatcacgct	ctacaatagc	tactccagtt	17340
ttaacacttg	ataaatcaat	tcctacaata	atcatttagc	tctctccctt	atctctttaa	17400
tccatctata	agcttcctta	caaccactct	gcatccattt	aggcatagta	gatacttggc	17460
tgttatataa	atcaatggaa	gcttttaact	gttcatttgt	taataacaaa	gctgtatgaa	17520
gtttaaattg	agagaacgtc	catgctgtta	catcaaatac	tggtagtctt	tttgcattag	17580
ccaatctaac	ggcttctgct	aaatgtgctt	ccacatcgtc	tttcatttct	tgagttacat	17640
gaattccaaa	acatctcata	ggtgggtgtt	taataagctc	ttgttcatcc	atgttccaag	17700
attgtttact	tgcttctggt	tacataatta	tgtagtaatc	taaactcgtc	ataagtgagt	17760
atgatgtaac	ctgcttaacg	tgtttagggt	ctggctctct	catggagtat	aaggacgttt	17820
tagctgctgt	tccttgttta	gactttactt	ccagtccaac	acgaatcttt	cgccctgtgg	17880
acgttggtga	caccatgaca	ccatctactg	agccactaat	agagaaatct	tgtccattat	17940
gactaaaata	tgctacatct	gtggagaaat	cttcaaagaa	cggaaactgt	tttccatcaa	18000
tttctttgcg	gtcaaaacca	aatttaggtt	tctctccaac	aatactttca	taatgttttt	18060
ctttagtaga	taaattcttt	tgaaccatat	ccccaatcac	ggttccaata	tcttgccact	18120
gaccgtgatg	ccacatcttc	actgctttat	cataaggtgc	ttttgtcaat	ctcataacgt	18180
gattccataa	gctatctcct	gttgagcttg	ctctaaatgt	tggaatgcct	tgtgctgggt	18240
gaggctactt	aaacgtaggt	gaagttgcat	aggcataaga	actatatatg	taatggctca	18300
ctgctttatc	ttcacgtccg	ccagctcccc	agaaattctt	gaactgttgc	tcaagttctt	18360
gtgccatctt	ttcagcacgc	tgttgttcat	tagacactta	ttttttccct	cccaaatccc	18420
atctttcgtc	aacgacaata	cctgcatagt	aaacaattgc	tgtaaatgag	ctggtaggtg	18480
acataggttc	cgcaacttca	aaggtaaagc	cgtgcacgga	agggcgtttt	ttgttaatta	18540
cttttgaaat	acttctgcca	gggatgccag	ttacttcatg	tgctttcgta	acactttcaa	18600
accaagcaat	tgcttctcca	tccttaaaca	tttctatagg	acgttttcct	cgaattgctg	18660
tggcatcttt	ggtatgtctg	taatattctt	tcatgttctg	tgagctatca	caccactgta	18720



-continued

---

gattaagtaa attattatth gttttgtcgt ggtctatatg attaagtata gcatagttta 18780  
ccggattatg caatagtgtt tcaccaataa ttctgtgaac aaatactctt tttcctttaa 18840  
tagatacttg catgtatcct tcaatattag cagtctgttc caaggaact aatttagtgt 18900  
tgttttgaaa gtectgttcc tctttaaaga ttgttccatt actgctggct acgtatccag 18960  
ttaggacttc gccattaagt actgcccgtt taataatata tgettaccatt ttattactcc 19020  
tcatatgtac gtcaaaagga gagaaagctc tctccatatt gactttatth gtogaacat 19080  
tcttcgactg aaactaaacc atcttctttg acaatgttat catatthtcc atacttctca 19140  
caccaacgtt taccaattgc catatcagtt ttagctggaa cagagaactt aactgtttca 19200  
atcataacgg aacgaatcat ttctacttct tctctagtaa tctctctgg aacgtagaac 19260  
aataatcat catgtacctg tgaagatatt tcaaactttc gaccgggtgt tgataattht 19320  
ttcattagtt tagattgtgc tatcataact tcttttgtct gagtagctgc tccacctgt 19380  
actttggcat tagtaatthg gcgaatctgt ccacggaatt cccagtcaa agcacgtgt 19440  
gttttcttac tcatthctct gtogaatct ttaccaatgg ctttagggaa tctgtctact 19500  
cttctcgc aatcttcaat gtagccccgc tgtgttactt cactgagctt attatctatc 19560  
caattcttaa cggaaaggaa cttagcatag aagttatcca tgattgattc tgcttcttth 19620  
aaatctactc caagactatt ggctaaagct ttaggagaca tgccataaag gatagcaagt 19680  
acaacccgtt taatacgtt acgatacact gtgccatctc cacatthtct aagtggtact 19740  
tcaaatgtt ctgatgcaac ctactatat aagtcactc cttctctgta gaaggctaat 19800  
agtttagggc cttgcgaata atgtgctagt agtctgggt cttgtttag tctcttagac 19860  
ctactagacc tttcagctc gttacactct tcccagttt cactaggact ggactaactc 19920  
ttgccgccat gtggttagcg accgtgggtt tccaccccc acttgggggc gtacttctc 19980  
tcggaatagt ctctactc gggtttatta ctttaattt tccaaatgaa tctgcataa 20040  
ctggtagtta aacctctgc cgcctactt atttggttat tatctaaacc agtcatatta 20100  
gaggcatcag taggtgactt aaattcacca atcagttctc cttcttagt atactgaaac 20160  
acttttctaa ctttaactct tctttatgt gttcccctat tgacagcatt tatttggttg 20220  
ttttgttgt ctaccattc caaatttct acacggttat cacttctatc tccattaatg 20280  
tgatttactt gaggcaagt atttggatta ggaatgtaag tttctgcaat tatacgggtg 20340  
actctgtaca atthtctag aatatctctt tgtaatctaa ctctaacata accgtcgaac 20400  
aatggtgaca acgtgctctt aaccattca ttagtcttac ttaggtagta gacatthccg 20460  
tctgtatctg cttgtaaaa cttgcttgg aatccgtctg caactatatt tttcacatgt 20520  
tttctctc tcttattatt tttttgttac cacatatta ccttagcacg ggattggcat 20580  
aggctacgcc cttagcttcc cccgttttag ccacgtttt attcagcaa cattaactga 20640  
aatcggcaga tagtattaac tgccctttg gtgcaataaa catcttacga gcttctggcg 20700  
ggatattctg gaagtttgg tcttagagc tatatcgacc agtctttgtt ccattctgtt 20760  
taaactgtgc atgaatcgt ccatctgggt atactttgtc actagcttcc ttaacaaatc 20820  
cgtctagcag tttggatact ttgcgatatt ctatgagaat cttgatagct gggtgacgg 20880  
tttctagttt ttctaact tctttgccag tgcttctgtt atthtctct tttgaagctaa 20940  
cgtaatcacc taatttaaac ttatcatata ttacttctcc aagttgttgt ggagaattgt 21000  
agttgatact tccaaaccag ccatctagtt catctttaa acgtgctgat tcttgttcaa 21060



-continued

---

ggaaggcttt	ctggctttct	acttccatca	agtcaagttg	gaaaccaaca	cgttccatgt	21120
catttgtaac	actgataaca	ggctggtcca	cttcctcata	taacgtttta	actccagcga	21180
aggttggctt	actcatgtaa	ttcattaaga	atttaaatag	tctaagtgtt	aatgagtat	21240
cctttgctgc	atatacggaa	gcatattgga	taggaacata	tctaaagtct	ttcgcatctt	21300
tgaatagtgt	gtcaaacgta	tctgattcag	ctccaagata	tttaggtgcc	aaatctttca	21360
gacgatagct	tactaagttt	tcatccatca	agtgcataat	aacagcagtg	tcatggatgc	21420
gacctttaat	ttctatggtg	tttgaataca	ggatgtctcg	gtcaaaaacta	gcattatgga	21480
aaactaggtc	tgtatcttct	cttccaacta	attcagctaa	ggcactcatt	gcgagatgt	21540
ttccatcacc	atgatagtta	gtgccatcca	tgtgcagaag	tggtacataa	tagtgtttgt	21600
ctgccttgtc	caaagatact	gagtatccaa	ctgttctgtc	tctataaaca	tctaaccag	21660
ttgtttccgt	atctatcgcc	attagagttt	ctttaccocg	cagctttaac	atctctaaca	21720
tttcagcgga	ggttgtaata	gtatagtaat	tatctggctt	agtccttaga	agttcttcta	21780
gtttttcttg	tcgttggtct	gcttccacct	tcgtatataa	tcgtaaggct	tctgctttgg	21840
taaaacttct	aggtttcttt	cctacttgag	gctctcgga	taattttcct	tcatccatcc	21900
gttgtttaac	aatacgtaac	ttctctttag	ctgattcaga	attcttcatt	tctgcaatag	21960
ctttccaagc	atcttccaaa	ggttctatct	cgtaggtttc	tttgatgcgt	tcttttacct	22020
cagctacttc	ctttggaatt	cgtgctgtag	gtgccttaat	cttatctaaa	ttcaaggctt	22080
ttaaaacagt	gttttcaaac	ttacctggg	atttaccac	atcgcatatc	ccccttctta	22140
tatttgctca	tgaatttttg	aagtcctttc	gtagttgtgt	ttaaactttt	ggcgacttct	22200
tccacagaac	atcccgact	gatacttaat	aaggcattcc	aaatatcatt	aggaaattct	22260
tcgtcatctt	caatatcgta	cgggtatgta	tccagcatat	ctcgtaatgt	ttcttcaagt	22320
agatgttctg	gcgttctttc	tttatatgta	ctaagtattc	tataattggt	tgtgtgcttt	22380
atcaaatcac	gtatatcttc	tgtttttaaa	tctggaaact	tcttaatcgt	ctcttccatt	22440
tccgtgtata	aattagctct	caaagtagtt	acttcggctt	ccgttatgtg	gaagccttgt	22500
ctagcctggt	cagtaactac	gagtatgagg	gcataaatct	gttccatttt	taccatgtac	22560
tctcacctat	ttcattaagt	attcttttcc	attttgcacc	tgtttcaaga	cttcggaagc	22620
tagggaatcc	atcataggca	tttaataaat	cattaaaatc	ttttatttca	tctggaaaca	22680
ctaccataaa	tctatcaatc	atgtaccctt	cgaaactttt	gtacatcgct	ttattaatt	22740
ctcttccctt	tttatcattg	tctcctgcaa	agaataggcg	tttaattcct	agtgataaaa	22800
tagaatcacg	ctgtacctta	gttaatcggg	aagttcccac	ggctactgca	cagtatccga	22860
tagcacgaac	ggacatagca	tcaatttcac	tttccacaat	tattaatgta	gaaggcttct	22920
gctgtagtgc	ttgtggcaat	ccaaataaat	tattctttgt	aattcctact	tctttgtgta	22980
acgtttcaaa	tcccttttta	tccgtataac	gtatcttaca	agcaatcaaa	tcattctttc	23040
ggtcatacca	tggaatatag	actttgcggt	cttctctcgt	agttccatac	atctcttgga	23100
tttctttagt	aatcccacgt	gattccaaat	aggggctaaa	tacttgtgat	gggattgtta	23160
gaggcgtgac	ttccttgctc	caaagttttc	cctgtagttt	aggaacgcca	cttttgagtc	23220
cgtaagtttc	aactagataa	tctgctactt	catcataact	tatatctcgc	agtcgtgaaa	23280
gtaatgaaat	tatgtttcct	gtttcaccac	taccactgtc	tccccagtt	cctcctccat	23340
ctgacctgtg	gaagtttaca	aggtaacaa	agaatgacgg	gtgagaatct	gctctaaaag	23400
gtgagttgca	tattaacttg	tcttctgacc	atctagcgtt	tgtccattcg	tgctcttgta	23460



-continued

---

gttctgacac gatgtcaaca ttgattctat ttccacgtat ctttattaac gtcactgtaa	23520
acactccttt tctctatata ttataacata acaaaagtgt gaagtcaagt taaccgcaca	23580
ctttatTTTT attagatgaa taaatctttg tttgcggatg gttctatttc gtgaatcaat	23640
ccataactag gtagccatac tccggttagt tcaacgttct ctccgccagt acgcccttta	23700
acaatctcta caatgaagt cttatccatg gaatcgaatg caataactac agcacagtct	23760
tccaaaagag aagatgtttt cttcacttgg tcacgagttg gggcaagaag ttcccgcctg	23820
tctttggata ttttaagttc ttctgcttgg gtgattaagt gcataacgat gttgtgcttc	23880
gcagcaatct tacgaacacg tttagaagtt tctgctgctg ctccctccagc tgttcttgat	23940
gagttatTTT catattccaa aagatagaaa gcatcaatta gaactacatc tgcattagtg	24000
ttacaatgt cgtcttctag ttggtcacaa ttccaactat caaacctgg ctogttggct	24060
gaacgtacaa taatacgtcc cataactttg ctcataatat ctgccatagc ttctgcgaaa	24120
tcttcttcat ctggaataga tagtttacca ttcattaaag ccttaacact atatcctgct	24180
aagtattctt caataccaag cttaacacta ttcttcttat acatcgctgt gataatagaa	24240
taagcacgtg tgaagtattc atacttagac atttccagat tatagataag aactgtggca	24300
ccttcgatag ctgatttaat agcttcttga agtgttatta aagatttacc acgtcccga	24360
cgcccaaacc atagaataca gttaccagaa ttatatccgc caacctcttt attaatcgta	24420
gggaaagatg aatcccaagt tttacgtcca acacctgttt ggatattgct gtactcttct	24480
tggaaccaat caaagtcatt aataatatct gctcccacgt ttgcaggcat ggcattatta	24540
ttttgcattt gtttagcacg gtcattaaca aattcccaga agtcatctac tgagttatag	24600
ctatcgaaac tegttagaac ctcatcatta ataaagttta ctgtttctac ggctaaatta	24660
tagttctttg tttcacgtgc catatattcg aacgttgcat caatagcagg catatagcca	24720
aactctggat acttagtcac aacggtttct gcatcagggc atttaccata tctatcatga	24780
tattgtttaa tgaatagata agtttctttt tctgtttgag ttagaaaatc ttttctttg	24840
attccaaatt cagctaaggg acggatgttg tcatcctcaa tgatacggct taggaattgt	24900
gttcataat aatagccat ctagtctact cccttacgtt tggatttacc cttgaactcc	24960
actacgaatg tgttatgacg aattctatcc cacaaacgtg tgtctaagga cattgccatc	25020
ttttgcattt ctaagttgga tgtataaata gtgatacgtc tgctggttac tctgagttt	25080
attaaatcgt gaatgtccc acgcaatcct tctgttacag aacgtactcc aatatcatct	25140
atcacaagaa tctttgcttc ttttgctttg tttaatcggc gataaaatc tgtggaagct	25200
tccgaagcca tctctgtact gcttgaagcc atccggttaa actgattgta aagtgcctgt	25260
aattcgttca tgtctacata atatgcgaag tttctagtta gtttctttcc gtgtttatta	25320
gcgtaatacc aaccatcaaa tacaagctga ttaagtaagg cacatgcaga agttgtttta	25380
cctgttccgg ttgcatcact atagaagtac atgtttttaa tggagtttgc ggggtcgttc	25440
atgtctgttc catcaaaca tctctcaata gatgggacat agttagggaa aatagttccg	25500
tataattctt tttgtcccgc tttcgtggt gaattatcca acataatatt ggaaaactca	25560
ataggaatat tagcattacc atatgaacct cctactccac taccatataa atcaatgtaa	25620
aggagtttgg ctctattaat aacatcctct aaatccatc cgttcttttc agacaatcgt	25680
ctgcaaaatt cttegtatc caaaccttct cccctcgggt attaaaagaa atcactgtaa	25740
tcaattttgt ctttatctac gtcaatagta gactccacat cttctcccat gaactgagca	25800



-continued

---

attgtagcac	gttcaatctc	ttctcgtaaa	ctacaataaa	taaacaatgaa	attaataggg	25860
gttgttcttc	ctttaaactg	ccaagcttca	aaactattat	caataacctg	tttaacgaat	25920
tcttttgtat	gctgttctcc	gtatcttttt	attagagaat	tctgttgagg	gtatgaactt	25980
acatgatggt	cttttccaaa	taatgccata	ttcttacttg	ctatataaga	attgaagctg	26040
ctaccattcc	actcacttac	tggaaactct	tcccaatctt	tataatcaat	tttcttttta	26100
gccattaata	tctcctccta	aatatcttct	ttcgttacta	agcatatctt	atcactactt	26160
ttaattattg	tcaaacataa	atctccaaca	ataattgtgg	tggcttttta	atctaccatg	26220
taaacaatctg	cttacgccac	tgggggtgaa	tcctcccaat	ctttttgctt	caccaatact	26280
tttaaatatt	aatatacttc	cgtcacttaa	agaagtgcct	attattgctt	tacttctttt	26340
atctatactt	ctttgcagtc	ctgttccatg	gttcatgttt	tctttatttg	ttaccatttc	26400
aagattacta	acattattat	catccttaat	ttcgtttata	tggtttactt	gtggtttatc	26460
ctcttcattt	ggtataaatg	ctaaagaaac	tattcgggtga	acctttactc	tcttagtttc	26520
tccacacgaa	gaaagttgaa	ctgttaaata	tccatattta	tccttcgtag	gaactagaaa	26580
tctattttcta	ttatggctaa	atctccttcc	atctgaataa	accgtgtaat	taggaaaacc	26640
ttctacttgt	tttttgtaa	tcacccaaaa	cttcctctct	attatataat	tttaatagat	26700
aaaaagaaaa	gagataaaga	actttccggc	aaagccggtc	gccaaaggcg	aaactctttt	26760
aatctcttga	ccttaatctc	ttaaagaact	tatgttagta	attaaaagat	taaatcactt	26820
tactcggcaa	cgcaagcaca	aatactaaag	ttcataccta	agacctattt	ttagtattag	26880
tgtttcgtta	cggatatatt	catgctataa	tatgtatata	agttagccac	aaggttagct	26940
tagtgaaaag	acatcatcac	ctttcgttta	tgtttatttc	acacacctcc	ttcttaatta	27000
ttttgtggtg	gttgctaata	tatcaactgc	cacattatgg	acagactagg	ttcatagcct	27060
atgaagtccg	ccaaatagta	tgttgtgata	ctagctttcg	atactttata	tatgtggagt	27120
ggagtttgtt	gtagagggt	tgtccgctcg	ctactatgac	aaacacataa	ccgtaatata	27180
gaggacgtgg	cagatgagat	tgtcatgttg	ccagacaagg	gcttagtact	tgctcgtcgg	27240
tctcgggtggg	agacgtattc	ccatcctaata	ctcacatcct	gtccgcataa	tggaaagtaa	27300
actggtctgt	ggcatttggc	tgtatgttaa	cagcttatac	ttgtgacgga	aaaggtaagt	27360
tcacctcatg	aagtagttaa	tgggttgggt	aagaaacgta	ggctcttattc	cttaaaagtc	27420
ctgtaaaaca	aattaattag	ttcataaaaag	taaaatcctt	tccgagtatg	taatatccag	27480
tccattctaa	ttctgtacgc	agtctatgga	tacctcagcc	cacgggtagt	agcaagttaa	27540
atgagggaac	aaaagacaag	acgaagacgt	tcgtcacctg	agaagtccca	ctggttttat	27600
aaactacgggc	tattatcttt	gatacaagcc	ttggacatcg	cttactggcg	taattaacca	27660
tgtaaattat	attcatgatt	tttccttctg	gtaccgttgg	aaagacaggt	aataaacaga	27720
tgccaaggc	gtatatgaga	aataatagga	ggtaggaaaa	tgacatcaaa	ctatagtatc	27780
ttaacaaact	tgggtgtca	ttggacatgc	ccttactata	ttgttaacga	taagattagc	27840
catcgttacg	aggatttcaa	gggggaaaat	aatgaatga	taatttaaaa	aacataatct	27900
gttttttgtc	tgaaaagatt	atgaaattag	aagaagaaaa	taatgcttta	aaaaaagaaa	27960
accaagcaat	ttctgtttat	agcgaataca	caattgaaga	gttacaggaa	aagcttgata	28020
atgcttccca	aggaaatgat	tatgagctgg	aagaagttaa	gagagtacag	cgtgaagtag	28080
aatcgagcta	ctcagtaaaa	cttgccggagc	tagaaacact	tgttgaaaac	aatcagaac	28140
gtattaaaga	attgtcaaag	gcttgttcag	atgttcatga	ggagtattta	gaatctgcaa	28200



-continued

---

aagaaaatgc	ggagaaagat	acccaaaattg	cagaattaga	gaaaaagatt	tcagaggggt	28260
tcgtagatag	tgattacaac	aaaacactag	tagaagatta	tgaagctgct	gaaaaaatgt	28320
taacagaagt	tactcttgaa	aacttagaac	tacagaaaaa	gtagatgcc	aagtttggt	28380
aagtagaata	gcatatttcc	ctgtctgggt	gcagactgca	agcccgacct	aagcttcac	28440
aacctgctct	tttgaagag	taagtgtcga	ctaaaacagt	tgcatgataa	gtgaagcgat	28500
attaggctcg	tttgataaaa	acattaaaga	ggtggaatgt	aacgggttct	cagccctcta	28560
aaaataaatc	ttatatattg	tgtctgcaaa	ccggtatata	aaataaaaag	tctgtatag	28620
gcaaaggaga	actacatatg	gtaaaattag	gtagcgaagc	aaaagaagca	ttatttgagg	28680
aaaagaaagt	aacaaaacga	gtaactaagt	tcttgaagca	ggatgagggt	attgtattac	28740
aatttgcagg	ctttgaagaa	ggctatgcac	aagcaatgca	acatcagtat	tacggagtgt	28800
ggaaaaggttc	tagtgaatgt	actggaaatg	acttatacga	taaagcagtt	gaaatgattt	28860
atcaagaagc	aaaagaagca	ccaactgggt	ccgatgaaga	aaaacgtcta	aaagacttag	28920
catatgcaat	caaagctaaa	ccagtgttct	tgtttggttt	ctgggaagta	gctacaggtg	28980
aagaacttat	tttaccagtg	tcttctaaga	aacaagctct	agctctttac	aaagcgtag	29040
aaaaacatga	gaagaaattt	ggtaagaaag	cttttgaaat	cgaacgtatt	caaggtggat	29100
atthagtatc	tccacttgac	cttgacgaat	tagacttaaa	caacaaacaa	gtagaagact	29160
ttgaggcaca	tgtaaaagat	ggtttcaatg	ttgaattata	cgatgaggct	ctttggaaag	29220
ataacgaaga	agcacaacta	gaaaaacttg	cacaagctgg	aattgacatt	gataaattaa	29280
tcggaagtgg	acatggtaaa	actgctacac	cagcaccagc	tggaacagaa	ccattaccat	29340
tctaaggggg	aactatcatg	caagaaaaca	atztatcttt	agtagtactt	aaattacatg	29400
atgatattga	agacttagaa	acttgtattc	taggattgac	tggtcttata	gacgatgata	29460
agcttcaaga	acttcttgaa	ttgcttgctc	cagtctatga	agcagaaatc	tttattagag	29520
gatacgcagc	caaggattta	gataaccatg	caaataaag	atgaaatggt	ttataaagaa	29580
gatggaacta	ttgatgttcc	gagagagttt	ctaaacaaca	tgtagtact	aagtacgtta	29640
gttaaattat	ctacgctatt	agatggaaca	atgaagatgg	ttgatgatgc	catcaaagaa	29700
gaaactctat	ctgaaacagt	ttatgattat	actactaaca	ctatagaatc	ctctttaaaa	29760
gctattaaag	ctctactact	catgacggaa	ggtcttgata	atatggacat	tccagtcgga	29820
ggagagagta	gtgatataga	tgttttgtct	attgttctag	cactcgtatc	ggtgatagaa	29880
gaagcagaca	gagtgattga	aggaataaaa	cttgtctaac	actccacaag	gcgtagatat	29940
tggggatatg	gtagatata	tgggatgtgg	cggttgttct	ggtcattata	ctcatctaca	30000
aacatatgaa	gtggttaaat	taagcccca	tctgccacgc	tacttcttta	tagtagatga	30060
tagaggtaat	gaacatcttg	taaagctagg	cgtatacttt	aaaattgcat	aataaaatcc	30120
ctcaccatac	ttgacgggtg	gggatttttt	tgttatacta	ttttaagaaa	cctttagca	30180
tagcagaagt	tgttgtctca	gcttggaaaa	tcgctggata	agttccagac	acaagttgaa	30240
caccagaaat	aagacctaca	gctgtattgt	ctgtagtagt	tcccgaatgt	gaaaacataa	30300
cacgcatatc	cgtatcattc	acatcgaact	catcatcaac	ggaactatcc	cacgtgaaag	30360
catatctagt	ccactcgctt	gtaatgggaa	caacttgtgc	aagaatatca	gcacccgggt	30420
ctgggttggc	actttgttta	cctctttgag	ttctaaagat	aacacggatg	tccatttctg	30480
cggatgttga	tacgttactt	gttttagccc	agaaggaaac	tgtcaaagca	gaagcattct	30540



-continued

---

ttaagcttgt	gtcatacaat	gttgggcttg	ctccagcagg	taagaagttt	acttttagcac	30600
gtaaatgtaa	agattgatac	caagcgttat	tccacttagg	acaaacagct	aaactatacc	30660
cagatggaaa	tgggtgttca	attgaaagtc	ttgcattaga	ctgtgtccct	gtcgagctgt	30720
accagttgaa	tgggtttgta	cgttgtggat	ttggaagccc	tgcttcattc	gatgctgcaa	30780
agtctgtgca	gattggaata	gagtctaate	catcgttggt	ttggatgact	tgaatttctt	30840
tactggaaat	aatagggtca	gctaggaagt	tagaagctgt	ctgtgctaate	tgtactaaac	30900
cttcatcaac	gatacgggaag	gaaccgccgt	taatctctat	tccagagtta	tctagtgtta	30960
agttgctggt	acgtactgta	acgtgttccg	actgaataag	aatatcatta	gcagattgtg	31020
acataataga	acctaagtta	gtaccagtca	aagctgggtc	gccgtatttc	catgaaccct	31080
ctggcggtag	ataggattgg	ttgacatcgg	ctgcatatgt	gcttacaaga	actcctgtag	31140
tacttccgtc	atccacacta	tcttttaata	atgaaggtgc	aggactaacg	ctttttaaag	31200
atgacttaag	aagggcagga	ggagcagaag	acggtgctat	gattgcttcg	tcagctggaa	31260
ttaaccccg	atcgagggtta	acatttgtat	cttgaaacat	tgttccagtg	aaatcatatc	31320
caccatcat	tctgtaggg	aaataataag	taatagttac	agaaagaatc	tctgtggctt	31380
ttaacttact	aaaatctaca	agaaatcctc	ttctaacca	cgctgtaacg	gggtctttga	31440
atgtcaaaacc	atcactgtat	gtaactgttt	tagatacacc	tgtagactgc	atataagtta	31500
cagttactgt	agttgtaacc	tctccacctg	tgacagaacc	tctttcatac	cagctataaa	31560
gcattttatg	tccaaataat	ctgttaggag	agcggacttc	ttgagtcatt	gtatctaate	31620
caattaaagg	agatgtccat	ccaagtgaac	agtagttttg	aatttcccct	aatccttccg	31680
cttgtggaaa	taccacagtt	gaagctgttt	gaggaaatc	ccactctaga	tattcagaac	31740
gaaaatctgc	atttaacata	atatttgcag	aactagcatt	atttaaactg	tcattaagag	31800
aaaataatc	tcttttaatt	gcttcgatag	caggaacatc	ttgtacattt	attggaataa	31860
atttaccgaa	cgtaatttga	ttattttctg	gatttgtact	agactttcta	agttctatta	31920
cagtagcttc	taaaccaagt	ggaggattaa	atgtattatc	tttcaccac	actgtgtccc	31980
cgttgtgaac	gtcttctcct	tggaatccaa	gtgcttctaa	atcaagcacg	ttaactgtgt	32040
aggaaacatc	aggttggcta	cgtttcttta	attcttcaat	accttcaacc	acaagacctg	32100
cttgtgtcac	gccagaagta	gaagaaacat	aaagacaaa	agtattctta	ccttccacac	32160
cccactctct	tagagcagat	ttagatacaa	tataattatc	tgtttttagct	ttggtgaagt	32220
tcttgtcacc	tatgttagca	gtgtatccaa	ttagattagt	tcttactcca	ttaccatttt	32280
tctgtgatac	tggaattatg	gctgtacata	ggttagtata	atctaccact	ctctctacac	32340
taactaaate	tctatcatat	ataaagtatt	taccttcatg	tattggttta	actgaataaa	32400
tattaacaac	acgcttagta	atthttggtac	cgctctgaaac	acatgtaaaa	ctatatacca	32460
catcgatttg	ttcttgtaat	tgaagcaaag	cagctaaggc	agtttgtgtt	tctgtagact	32520
caaaaccacc	tgctcccgt	ttaataacctg	aataatcttt	gtatgtccac	aacgtgttag	32580
atagtacagc	tttaatacaa	tcttggaaag	tgttgccacg	gtatggatta	gaaaaagagg	32640
agttaagctc	cgtcacttga	attccttcac	agtaaacac	tgccactgga	ttagctctat	32700
cagagttttc	atctacttta	ataatagtaa	ataaaagttc	ttcttcgtcc	tcgtcaacaa	32760
atgacaggcg	gttttagacct	gtcaaatatt	gattaacaga	agttcccagt	ggagttgtaa	32820
atacgaatga	tacctacca	gtttcagaat	tgttcacata	ttcgtcatcc	cagtaaggaa	32880
caccgtctgg	ggattgattt	gtaagatggg	cgacaatgtg	cccgttctg	tcgtaaatgg	32940



-continued

---

ttaacatggg	ttcactcctt	aaaatactct	attatgatat	tgaacagtca	tatctacatt	33000
tgctgggtgtt	actactagat	tattatatcc	gggtattagt	gggaagaagt	cactagttgg	33060
gtcaagcaag	gcaggtttca	attgtccggt	aagatatatt	tgaccacttt	gcatatctat	33120
atctactacg	tcatccttaa	ctagatgaag	tggtggcggtg	gatgtgtctg	gtgggtcaag	33180
aacttcccat	acacgtatat	tagcaatctt	ggcagagtta	cattggtttt	tcttccattt	33240
tgagcgtgca	ataacaatac	caatttctgt	tgcttttgta	ttcatggagc	tgtctgggtgg	33300
aaggttaatc	caaggagacc	accaagtaga	acgaagggca	gatgttccgt	agaagtagcc	33360
atctttaact	tcatattggt	tagcattacg	gaactcacca	gctccccaac	ggaatttacc	33420
attacgtctc	tgtatcatta	tcttaccata	aaaatccgtc	cagtcattac	ttactcgtct	33480
taatagtcca	tcaggtacag	aaccatcatc	aatacgacaa	acaccttgac	cttttagtag	33540
agaggagtac	tctaagttaa	cactgatgaa	accttgcca	tccgcaccaa	tcatagagat	33600
acaaatgtag	ttagaagcat	tcttatcacc	tattttatga	tgtaaataaa	gcacagcttc	33660
catatcaaag	tttagtaagg	catgtggcat	agctgcttta	ttcgtctctc	cgtaataggc	33720
agcaatgtcg	tcattagcag	gtttaggcgg	atagttagaa	ggtttcatat	aaaacgtgtc	33780
actagctcgt	gagaaagttc	ctccatattt	aaatccttgc	gaacctaaac	cattaaaacc	33840
ggaagaccag	tttgtccaac	gtgtctcgtt	tgactcatg	tagctttgga	aaacctaggg	33900
gtgtaaattc	acaggtggct	ttggcttagc	atccccggga	ggagttccta	cagttacatc	33960
cccattagcc	cctactaaat	ttaaatagag	tgaatcttct	ttcatcgtga	tagataccaa	34020
aggatgtgtg	ggagcatttc	cgctaacaag	aatactagaa	ggtttagtgt	ctgcatttgt	34080
gaatctcctc	tctattaatt	ctccttctgc	ggagtttga	acacaaataa	atgttaaatgt	34140
ccctgcccct	acgtgtaggg	cttcttctat	tgaagtggag	ccatctaatac	taaccttcca	34200
cacataatct	gggtcatcag	aaaaccttaa	taacatatct	tcgtctggat	gatttaaata	34260
ggtagctaata	tgtcttacac	gtccccgaag	taattcaggt	ttatcagcta	taataaatat	34320
atccatagaa	atgtatctta	cgtctgctga	ttgtttatag	aaataatttg	ttgcccctct	34380
tccggtttgt	tgataatttg	aaacaatagg	tggtagagca	tcgtagtaa	ctttttgtac	34440
ccctacatac	caaggttgc	taacccatt	taatgaaaat	gttcttgggt	ttgcatcttc	34500
tttaggagaa	tagtcaagt	aaaggaacac	gttacttttg	cctgttactg	ttgttgatc	34560
ataagccaga	acacttacac	gaatacttcc	atcaggatat	acatattgtc	ccgcatcaga	34620
gctagtttgt	acacttgtgt	taagaggagg	tcttgatagt	acaaggttgt	tattttggct	34680
taccgaacta	tttaaaciaa	tatcacagtt	agaagtatct	gtaaccaacc	cgcttggtaa	34740
cacagagata	cgagttaatc	ttgtttgtag	tttagcacgt	tttcatctt	ctgtaaaaac	34800
atctccaaag	aatcagggga	aattctgttc	caccgtgtgt	actgcatcaa	aacttattag	34860
aacttgatgt	acttcaactat	ctgctgaatc	tggagtaagc	gttacaggaa	gagcactaac	34920
tgttgtccat	gatgtgtttt	ctaaatcaag	agtaacgctt	ccaaaatctg	tagtattttt	34980
atataaagta	gtattagagg	cttccacaaa	atactctgcg	aaagccggat	tacctgtata	35040
tctgcccctg	tttaaacc	ctttgtatcg	gttatttgta	ttagttttat	ttgtttgagc	35100
tcggctcata	acatcagaag	tggctcttgc	aaattctcta	ccattgatgt	ataatggaac	35160
agtaatcaca	ggagtagctg	gattatttcc	gtcatcgagt	tcacgagcga	tacttctagc	35220
aaatggctgc	atgtatgtag	cattagctaa	aggaagaacc	atctcacgac	cagcttctgc	35280

-continued

---

ataggttact	ccgccacgtg	caaatttctg	attagtgggtg	ttagctaccg	atTTTTgacc	35340
agtggaaaca	ccaagaggca	atccactagg	agtcatacca	ccatgagctc	gggaaatcca	35400
attatctcca	aagtacttat	tctgattctt	tttctgtaca	gctgctttac	caataccgcc	35460
accgggagtg	ttaactactc	cttgactat	attaacagaa	gctgtgaatt	gagctttgtc	35520
ccatttactt	ttaaacgcat	tcatcttatt	ctctgcatct	gatgtttccg	cagaaacaat	35580
gatagtaggt	ttagaatctt	tagctccttg	ttctagcttt	tggattttat	ccattacttc	35640
attatacata	atatctgctt	gacgaatagt	ttcatctgct	tgttgagttg	catctgcaat	35700
aagttgtgcc	ttggttctcc	ctgtggcagc	tatctgttca	tcactcatac	cattaattgc	35760
agctattggt	tgagctgctt	gttccatagc	tgcatTTacc	gttttattac	gttggctctc	35820
agcgtttgca	attatcttat	ctttggactc	tttagaaata	gtttggcgag	aatTTTcaaa	35880
gtactcaatt	tgtgctaaca	gctggtcatt	ggtaccttgt	tctgcttgta	aaagtaaggt	35940
atTTTTtctt	gttcaataga	ctgatactta	gctaatgcag	catttcttat	tccaatatct	36000
ttagattgta	aatcatttac	taaagcta	tgttgttctg	tatatttcat	cattaaagct	36060
tgtTTTTtctt	gattggaatc	tttgactggt	tttatagcaa	agtacttata	ctcatccgtc	36120
atattcttgt	tcttctcaaa	gaaggtagct	aagatgTTTT	gttgtgaaga	aagaccttct	36180
tgttTgTgTg	ttagtgcaact	ggtgttcgca	tcttttattg	tctgtacttt	tgatgcagag	36240
aattctTTta	acttatttcc	ttccatagtg	agggtagcta	cagcaatctg	cgatacagct	36300
tcatatgcag	atttagaagt	ttgtttatat	gcttccatat	ttccagaagt	tataaattta	36360
actttattag	aataagctaa	aacagaacct	aaaccagctt	tagttgtatt	ggataaggag	36420
ttccaagctt	ttccttctac	tccatactga	gcagctaaat	cttttgaacc	ttgtatcatt	36480
ttagcatatg	ttgttcggtg	ctgttcggca	cgagttaggt	catcattcat	agggtatttc	36540
atctTTTTtag	tgcctcttcc	ttaccatat	agctctatag	ccttttctac	aaaaactttt	36600
ttatctttat	agatactttc	agcagatact	aggtctccct	tttctccttt	atctttgggtg	36660
ctttttttca	ggtcttcggt	ctgtctttta	gcttcttttg	cacctttggt	aaactcactg	36720
aaagcatctg	ttactttggt	aagtcctttt	gtaaggacat	caagaccccc	tttaaccatc	36780
ccgtctattg	attcacctac	ggcaatTTTT	aaagattccc	agctagcttt	cattctgtta	36840
atagagccct	cagtagtggc	acgcatcttc	ttagcaactg	agtctgattt	accagcggag	36900
ttctcaattt	tcttcgcat	gtcctcgaaa	gcatccccac	cagcgttcag	tagttgtagt	36960
acagaaggca	tggcagtaac	gccaaacatt	tgtgtaacca	tcttagagcg	ttcaaacctg	37020
gacattccag	ccatctcttt	atttaaactg	ttgatgatag	taccaatact	tttaaattta	37080
ccagaagcat	ctgtggcaga	gaaaccaata	gatttcatag	cttctgcacc	attcttagta	37140
gggtttacca	aagagataaa	catcttacgt	agacctgttc	ctgctgttga	agcggaaata	37200
cctcggtcac	gtagtaaacc	agcagcggca	gctacttcac	taattgaaat	acctagttgt	37260
tgagcgggtg	cccctgcata	tttaaataca	taactcatat	ctttcatacc	tgctgcggta	37320
gcatcggaag	ccatagcaag	cttatctgcc	acaccgccag	cttcactagc	ttccatagtc	37380
cacgttttaa	gtgctgcgga	aacggtatcg	gttgaatag	ataaatcttc	ttgagaagca	37440
tctgctgcat	ttagtagagc	aggtagaatt	ttaatagagt	ctgctactgt	ataaccacgt	37500
ttagctaagt	cagtaaata	ttcaccgata	gactcagcac	tgtgaccagt	cttcttggac	37560
atgtcaaggg	ttactgcgga	aagttgttcg	aatgtttctt	tattaccatt	agagataacg	37620
ttagcatctg	ttattacttg	gttgaacttt	gcgatgctt	ttacagagct	gtttacaaat	37680



-continued

---

ttacctacac	catacacagc	agcaccagca	ctggctgccg	cgatgggtac	gcctagtagt	37740
gatttagaaa	gagagttaac	atthtgacca	aaactttgca	tcttggtttt	acctcttcca	37800
ccgaagtgtg	taactcgtct	attaacttca	tccattcctt	tattcattcc	gccaaaggat	37860
gtttttggtg	aagcccctgc	tgcgacggct	gccatattaa	acttctctaa	agaccttgca	37920
gctgcattca	tcttacgagt	aatccagca	gtatcagccg	ttactactac	acgaatatct	37980
gccattaact	ttcacctcc	atthcctttt	ctttattacc	aaacttagcc	atagcttctt	38040
cccacatagc	cttgcatcc	tcattgcttt	caggaataat	aactccatta	gctgtttcgc	38100
ctttttcttg	ctctccattt	gtaatcttaa	caccacaaa	ctttctgcg	gttggcatct	38160
tgtagtggtt	ttcttgagg	atgtgtgggtg	acatttcata	tagcattaat	tcgcttccc	38220
ataaatcctt	tttaactttt	gctttttgta	tagcagaata	ttcagcaaaa	gtaaggatcat	38280
ccaagcatct	tgggtctatt	cccatctctg	ctaatgttac	taccatgtta	cgaacatcaa	38340
ggaagtctct	ataaagcttt	tcagttaggt	cttcttcatt	atctgtatct	acttttaaag	38400
gtttaaacgg	aacaacatct	actacttggtg	cgaatgagtc	tgaatatgct	tttgcaagtg	38460
ttcctgccc	ttctctatg	taatctcggt	cttttgattc	taagaattct	aaagcccttt	38520
tttgaaaatc	agcaaaagg	atatttctaa	actctctctg	gtttataaac	atagaccaac	38580
aaagtaatcc	ttcatcgtct	aattctaat	ctttccaatg	tgctaactct	tctgcgtagg	38640
gtttctctgt	tactgcttca	atatatttag	cagaacgtat	agtaaaagat	agttcatata	38700
gtttatcttc	aaataaaatt	agtctcatag	ggcacctcat	aaaataaagg	gaagaaagac	38760
tgctcgtcaa	tctccctaa	tctttagtag	ttagctagat	ggaatatcaa	actgttcaac	38820
cgtagaccac	actaaagtag	aaccttcggc	tgtcatcatt	tgattagcag	catctatagc	38880
tttttcaaca	tcactctcac	ctgtaccac	ataagtgtta	cgagaagcag	ctacagaaac	38940
atcaagtttc	ttgccageta	aatctcctgt	tccacctgta	tcattggaaga	taacatcttt	39000
taacaagtca	aacgaattaa	cttctgtgta	ataaatacga	tttcccggtg	tttctccgtc	39060
aataccataa	cgtaccatat	aagagtccgc	gtctgtcaca	gcatcccaag	ctaacttaac	39120
tccatctggt	gtaggtggag	cagaggaagt	taggttagca	ggtgctgcta	gcggtacatt	39180
aggggtgtagg	tactacaatt	gtaactgttt	gagaacagct	atttaatgca	gtagctgtaa	39240
atttaactcc	aatgagcca	gtcttaagt	gtgtcacttt	gtaagcttct	gttccagaaa	39300
tcttctctac	tttcaagtct	gtagcagtag	taccacttac	atactcaaat	tgagttcctt	39360
gtggagcatt	agttggttga	atcgaagtta	cgatttgga	aggtgtgtta	actgcaatat	39420
ttgaaggaag	agcacttgta	gtcaaagtag	ttgggttgac	aattggtggc	tctgtgtagt	39480
ataattctcc	acgaccagta	agtgttctct	cgaaagtgtc	aatgtcatca	taaggggaagt	39540
ctgagttgaa	ggtagttaga	atggctgtac	catattccac	accaccatca	gggtaactta	39600
cttctacgct	tacacattct	ttgtttgtga	aggtgcacg	taaacgtttt	tgaccttcat	39660
ctgtacctac	taacagtcca	tctaaatcaa	tagaccaagt	acgtacgccg	tactctgaac	39720
taccccatcc	gaaatcctct	ttggagcttg	catcaattgt	atcagcttca	cggttaatag	39780
taccaccacg	ttgatagcct	actgcaatca	ttgccccagc	gttggttaggg	tcacttactt	39840
tgatgatgat	ttctacgcca	cggttaaagt	tacttgcaaca	ttgtaccatg	tattatttcc	39900
tccgtttaca	ttttatttta	gaactgtaaa	agttacggtc	acatacgtct	tttgaaaatc	39960
ttgaacgctt	acttgtgcc	gcttaaaatc	tatattagta	gcaacaaatt	tagctacaca	40020

-continued

---

ataccatca	gctagttgta	aagtagttcc	tagacgattt	atgacatcat	ctgtaatctg	40080
ttaattctt	aaggagccat	ttttcgagtc	ccaaatatcg	atatggagtt	ggtgtctagt	40140
tatttgcca	ctcttagaag	agtcataaat	taatgtctca	tctccaataa	caatataagg	40200
ataggtggaa	tcgtgtcgcc	aaccgtcaaa	tacttcataa	tctttattta	gttcattata	40260
tatagcttcc	tgtagtgcac	tagaagctga	tatatcttca	gaatatggag	gaactgcatt	40320
tatatcagcc	attaaaatcc	tcctagaata	ttactaattt	tatcatcaat	catggttagct	40380
atgtgtggct	ctataatagc	ttgagcatcc	tgtacgttaa	agaatgcttg	agaatgagat	40440
gtaccttctt	caacatagga	agcataagca	actccatctt	tagggttttt	agaatcaatt	40500
ataatagata	tttgagaaga	accagttggg	tcataacctca	cactatcata	catagcacct	40560
gtaagtatat	taccattcgc	agctatattt	gacctaatct	gttctacaaa	caattcccca	40620
acgtcatcca	ttgcctgagt	tatctcattt	gttactttaa	taatatcccc	taaaaatgtg	40680
tgacttccca	ttacattaat	accaaccatc	tgtgcaaaaa	gtatcaactc	ctttttcgag	40740
tttattttct	ttcttgacat	ctgggtggatt	tgtgttaaac	ttgggacgcg	gatagcgata	40800
ctcgccaaca	taactacaag	tcatactttg	tgataaatca	tttaccactc	cgtagtatct	40860
atccttccac	actccatcaa	taggaacaag	accatcaata	ggcacaccgt	agtaacgtga	40920
ctctttatgt	tgaaacctta	catgggtgtg	ttgagacatg	gtggcttgca	taggaagttt	40980
tgtaataatt	tgtgaaccac	taatcgtacc	acgaactggt	ccaacaactt	ctaagatgta	41040
agcaccttct	ccaccggtct	catcaggaat	ggaagttttg	cgaactagtt	gaaaccgata	41100
ttgtcgcttc	atagcatccg	caaccttcc	tttccctcag	tagggttatt	gattccatac	41160
tgtcaagat	atggaagcca	gttcttatag	atgtcagcaa	tatagtcaaa	ccttggtata	41220
tccgttgact	ctaatttaag	accttctgag	tttagctggg	tgtatcgttg	agctagaatc	41280
tcatacagca	taaaatctaa	atccgcttct	gggtattcag	tataaggcac	accaagcaca	41340
atacagataa	ctttttgaat	atggcttttt	agaattgcta	aaaccaagtc	ttggtcatgc	41400
tcatacagcg	gtaaacctat	aataactttt	atagcttcaa	tgtttatatt	tgataactct	41460
ggtggcatat	actaacctcc	catctgccac	aaaaaggggg	agaaagacga	aatgtcaatc	41520
tcctctctt	agtctcttat	tatgattaag	atactgtgac	agtgtgagtg	gcagtaatag	41580
aaccatcagt	attggatact	gttaatatat	atctacctgc	tggcacgtct	gttccagtat	41640
agttaacttt	taagccatcg	ataatagctt	ttatagcaat	agaatcagca	ccatctttat	41700
ctgtaacctt	aacttcaaaa	gcttctgtag	catctgtagg	gtctactgca	actgtaaagc	41760
taccagttaa	tgcaccgaa	gaagatttag	aagacgtttt	aggagaaaca	gttaagctaa	41820
caatttcttt	attactagaa	gaacgtaaca	ttgaaggact	tgcagatggg	acatctacag	41880
taactagggt	agaccatgca	gttacttcat	tgtattctgc	actttctaaa	gcagaagtgg	41940
catcccgta	aactccagca	aattgtgcta	catatacgtc	aattttctta	ccagcgaatg	42000
gagctaatgc	tactactaca	tcctcagtag	ctgtaaagct	attagttgta	gttacaaaaa	42060
cattattatc	tggcaatcca	tctccattaa	tgctaaacg	aacaacatac	gttttagcat	42120
taaatcctcc	attaccctaa	tcaatagtga	aagaatcaga	ttctaatct	gttacattaa	42180
cattaatagg	agcaggtgga	tgaatactag	tatcagatac	cagtgtttta	acgttaattg	42240
ggtttgcca	atcacttggt	ttaatactga	cgctactacc	agtagttgta	acttcatgac	42300
atctaactaa	atactggtag	ttagtattag	gaagaagatt	atcatctctc	caatttccag	42360
cggaacata	tgtagctacc	acattgccgt	tacgtttaat	atcatatttc	ttaacgggtg	42420



-continued

---

gcatttacta attcccctta cttagttttg acgttaattg gagcagtcca ctcagaggta 42480  
gattttacta caccagagtc tacctcacgc acacgtactt ggtattggta gtttgttttt 42540  
ggtaatacat cattatccac aaagtcacct gaagcatgga acgtttcgat aatggtacca 42600  
tttttcttaa tatcatattt cttttctaca gccattgatt tattectccg attcgattat 42660  
aatagactta taaccagcc gaagctgggc ttagtcttta ttaggcaggt aaagtaattg 42720  
taacagaaga agcagttgta gcaggagtcg caatagttgg agccgctgga acagcagtgc 42780  
ctgcacctac ataaacaatt ttatcttcat cagccataaa tgtagcatag tggcggtcac 42840  
cacttattaa tgtagtgtga gaaagtaaat catattcagt aagaatacgt gtatcttggt 42900  
taagagcaat accaagagca ccagctttaa tgaagaagaa ctcaccgtct tgtactttat 42960  
cagaaagaac tacagtacat ccataaagag taccgatagt accattgatg atgatagaac 43020  
cttgattaat gataggaaca aacttatcat cagaaaagaa caaagcataa ctgtagtgct 43080  
ttactaaaag atatgtagca tcttcgtaaa gagtttcacc aaagttagct aaagctaaag 43140  
gaattttggt gattgcatct acagtaagag ccgctccagt tgaagggtct acagcttttt 43200  
tagcagaacg agcaatagca attaaatcat catctacttt ttgagctaaa gccattgcca 43260  
tttggtcaac aatttcatta acagggttac ctgcggaagc tagttctagt tegtctgaga 43320  
tagctacagc tttaacagct tttttaactg ttacagagat ttgagattgg ttaatagtgt 43380  
caatattaga agtttgacct tctgcaacaa cttctgcttt accaattttg ttccagttag 43440  
gaagagtgat tgtatcccct acagaacctt gtaattgatt gaatggtgta gctagtgggtg 43500  
caaagcgaat atactcgtac attttctttg caaggtatgg accgacaact tgtggtacaa 43560  
acatatattg taacattgtc agtggttggg aagggtgaatt agccattaat aattgactcc 43620  
tttgtcattg tatttttatc cttgaagagc agtataaagt tctggattac gttcatataa 43680  
agatagttgt tcttctaagg acattttttc taacgcttct tttgtgagag agtcatcaga 43740  
cacaccacta tcgtagaac caccaccagc aggagatgaa taagcacctt ttaatttagt 43800  
gtcaactcgt tgttgaacca atgcgataac ctcgttctgt aaatcagata cccggtgatt 43860  
aacggcttcg gtcgaatcgg caataacaaa gtcggctaac gtaggagaaa gctcacgttt 43920  
agataattca cgcactcgt gagttcgc atacttctgt tgagcacgtt gctccgcacg 43980  
ttcatatttc aattccagtt ctogaatgcg tttttgttca gcagtttcag acggattggc 44040  
tttggtact tctcgtctaa taatagtttc gaggttattt gttttccaag tctcaatacc 44100  
tttagtaact tttgaatcta taataggtgc gattaaattt ttaccgctct ctgtttgaag 44160  
gtattcattt acagtgtcct tattaagaa cgcacctcgt aaatccgctt caagctctgt 44220  
attttgttt aggtgttctt gcaattctgc aaaagataat tggctcttca taggcatttc 44280  
ttttccct ctcacctta gagtccaatg tctccaaag tttagatata tttcctgtg 44340  
ttggttttac atactataaa caggactat agtacaacga caaaaaggat gtacggggat 44400  
aactggaaca ctatctttat catagattcc gtctccgta atccctccgt tttcaagttg 44460  
tctacaatgc ttacaagtg cattcttaga taactccggg gctgtcgtat attgataata 44520  
cataaactg tttgcagtac cttcgtcata gatagattgg tttactgctt ttgctgtgct 44580  
agttcttatt gctctcttag cttggctact agcttgggaa aaagctttta atgcttcttc 44640  
tcttgcttct tcttcggaat atccctgaga taagctacgg tgtagtaaac gtggtatagt 44700  
aataataaga gctgctataa taacatttag tttgtagaa tggctaccg ccttgcctc 44760

-continued

---

aaatgagtcc	aaagtgttag	ataacttttc	ttccccata	ggtacagtag	aagaccctat	44820
ttgttgcaatt	tttctgaata	tttttcta	cgcttcatct	tgggcaattt	ttacatcggt	44880
ttggtactta	ataactatgt	tctgcaacaa	cctatttatc	aaataaaaag	cttgcatacc	44940
ttcaaaagaa	ttgatataat	tattattaac	ttctccggtt	tcatcatatg	ccttggagag	45000
gtaagttaat	acctcatcca	aaacacggtg	aaggtctact	gatagctctc	catccacttc	45060
ctcaatccga	gacatcgcat	caaacatcat	gtagcatat	tgagcttctt	tttgtggagt	45120
aacttttgcc	atctagcatt	acctcgcttg	tctttgtttt	tcttgtgtcg	ctgaatcttg	45180
aacgtttgta	ccttgtgcat	tagtagtaat	tccttgtttg	gcacgtccat	tagaattatc	45240
atttgcttta	acattcgaag	ccgtcatagt	agttgttgcg	ttttccgcta	tagaagtttc	45300
tgctacaaga	gcaatctctt	cttgtttctc	aattgcaacc	tgtttcattt	ctttcttaac	45360
atctgtaacg	aaaggaattt	gatgtaacag	agtttcatta	gaaacaagtc	cacggaactt	45420
aacagaagta	tcagcaagtt	ctgcaagaga	agcaggtaag	caacgagtaa	atactgggtga	45480
catgtcttta	gcatctttaa	gagcagatga	ttaactgca	attaaggtag	ctattaagtt	45540
aatagttca	tgaagtccaa	tctcaaactt	acgttgttta	gctgatgttt	taatctcaag	45600
attattcaag	gcatatttga	tggcaacacc	agaaaggtta	ttagcagttt	gcattccatt	45660
agtatcaggt	gtgaaagatt	gttccatgat	ttcttttggt	aaacgattct	tgatgttctc	45720
taagtgtttg	tcagggggtt	gcttagtaat	aaacttagca	tccccgcctt	ccactagaac	45780
cattacacgg	ttttgtttca	tggagcggac	gtcttcacta	ttagtaccgt	ccatacctgt	45840
taacataagg	taagcatcat	tccagtaaga	gacatcattt	acactatcac	acacaactaa	45900
gttaagtgca	tcaacaagtc	caataactgt	ttcgaaatcg	ccaagacgtt	catcgttage	45960
taagtactca	atcataggaa	cttctccaaa	atagtgagga	gttactttct	cattgtatat	46020
tagattatta	gatgactctt	cttctcccgt	tgcatctctc	tctgctacag	aagcatcccc	46080
gccaccaagt	gaaactttga	attgtagaat	gcggtctgga	tagtatacag	taacacttct	46140
tcgcttctcg	gaagagatag	catccgtata	atcgttatat	acaacgccac	acagtttggt	46200
ctcatcta	gtagaatcat	atagataaaa	agcgtttgag	ggagcttcat	atttgaatct	46260
atggttggcg	ttcttatctg	tccaatgaat	ctcaaaagcg	tgtccataga	tagatactaa	46320
tttaccta	tcagaatcaa	catcagtaga	attattagcg	ttcataacat	ctgtaacttg	46380
ttgatgggtg	ttgtcactcg	ctttggcata	tgtaattgca	ttaccagtaa	agtacgagtt	46440
agcagttctc	acaatcagtt	taggatagtt	atgtacaagt	ttattatttg	gtttcaactt	46500
atcattgaaa	gttctcttta	aaatatcgtg	gttaccaata	tagtaatcgt	gcagatattt	46560
gtagatgaac	ttacgctgag	aatgccggtg	aattagaaga	agtacgcctg	caatattagg	46620
ctcttcatct	gcaataaact	ttctattaaa	tactactgtg	ttaactcgtg	aaccccgcg	46680
aacatagtc	gtaggctgag	aatctggttg	aatgtttaca	ccattattag	ccatacga	46740
ctccatttct	gcaagtattt	gttctgtctc	ttctctgct	tttaccattt	aaattcctcc	46800
attaacatg	aacttactga	ttagaatcca	agtgccgact	taggtatagt	ccgtgctcta	46860
ttacgtggga	ttacttcttc	caacgcataa	cgcaaggcat	ctaagccgtg	attgtattcg	46920
tcaatagggt	tgtttatata	ttcgtttggg	ttttgtttgt	ctttctgcca	agcatagttt	46980
tcaagttctt	ctctaagtgtg	agtacatcga	gggtggacaa	taatttcgaa	tccttgcaca	47040
aattgaatac	catgtacaat	tgaatcttta	cctttacgag	ctgctttgat	tctccatata	47100
cctttacggc	gaatctcttc	aatagattta	ggctcagaac	tatctgctac	tattttctct	47160



-continued

---

ttagcccaac	ctttctcagc	tatcttgcca	acaatatcat	cattgagcat	tcgttctttt	47220
tgtttaatat	tattttggta	ttcatcgtaa	atataaatct	tcttggtgcg	ttcgtctaca	47280
atacaagcaa	ccatcgctgt	agcatcattg	gcgtaaccaa	agtcaagacc	aaagtaagac	47340
tttaatccag	cacgtttgag	ttggctctacg	gttgggtcaa	tgttttgcat	accataaggg	47400
tcatggatat	taggaatctt	ccactctctc	caattgggtg	agacaagctc	accgagagaa	47460
gcaaagtctc	ccatggcata	gatacgggtg	taagtcggat	ttgttttcat	aagctcttct	47520
aaagtattaa	gatacttttc	tggaagaac	ttattatctt	tgtaggtagt	atgtagtatc	47580
cttaaatctt	cgggacgttc	atctgctgta	gttgggtcat	gaaataatct	atataccag	47640
ttaacttttg	agataggggt	ataacagaga	atcatctgtc	cctcttttct	ccgtttacct	47700
gcaagattac	gcatacgtag	ttgaagctgt	gtataatcat	ctaaggtaag	ttcogttgct	47760
tcctccaaaa	atatatcatc	aataccagat	atagatttga	ttttctccgg	gttatcaatt	47820
cctttaaata	gaatttgaga	accatttgga	agaacgatac	gaagttggga	agtgtaaatt	47880
ctacatctat	cagcaagctt	gaatgttgat	aaagctttag	taaattctga	aaatacagaa	47940
tcccgtaaag	agtttgatt	ctttctaact	actaacatct	ttcttttttc	tcgcatcaag	48000
cgaataacag	aacgttgtag	cgcccaaca	gatttaccag	aaccgctcc	accataaaaa	48060
atgatagtag	ggtcattcca	ttctaaacta	ggtaggtaca	ctttgttaa	cattcgttca	48120
tgaatattta	atgaaatatg	ttctacttgt	ttctcctggt	tcatatgtat	tctcctttat	48180
aaaagtaacc	tccaccttat	attatatcat	aaggcagagg	taatgtcaag	cattaattct	48240
gaacattcgg	aaaatttct	gctccggtgt	tgctaatttt	tacaccagt	gatgggtggc	48300
aatatacttt	gacatgtcca	aaggaaccag	tcttaattcc	tagaacatta	tctccgtaat	48360
tcttttogac	tttgtaagtc	agtccaccaa	acttcgaagg	gtaattgct	ccgattgcat	48420
tagcttttac	aggtgcttta	tttaatggat	acacactcca	agtaccttta	ccagcagggga	48480
agtatacgta	catcccagaa	gtagctgggt	tagccggagg	ttttggagta	gcgtgttttg	48540
gtgcacctgc	tttaacttta	gctaatagtt	gtgtattctg	tgaagtgggt	cctgtataat	48600
tcttgatgcc	atattttcca	gcaagtactt	tacgattagc	aaaagaggaa	tccattttct	48660
tgctgttcat	gtaatctacg	agaccaagtt	caccagaagg	cttcgcaggt	gtagatgggt	48720
tggatggttt	agcgggagtg	ctggagttag	gacgttctcc	tcctacccaa	tcatataact	48780
caaaatgagg	gttgtcttta	aaagatttcc	aatctccacc	ccatttgaat	ccttgtttct	48840
tcatggcagc	tacaatcttt	ttaaacttag	catctaccgc	ccagattaca	tctttaccat	48900
cttgcggtga	ttggcataag	tctacagcaa	caccgtagtt	atgatttgat	tgacctccct	48960
ttgcatttgt	taccacattg	ccgggctttg	ttctgccttg	tgcatataat	tcattctggt	49020
ctgcaataga	acggaagcct	tgtgcaacat	tgatgtaaat	accttgttta	gccatctctt	49080
taattactgc	acgggtttta	tctgaaactt	ctttaagcat	ccctttttcg	tttaaacgtc	49140
tattggcttt	ttcaagaagc	catgcttctg	ttaatgccat	tatttatctc	cgctctttcg	49200
aggttcagta	taatttaaag	ctctttcgct	gtcgctaaat	ccagaagttg	tagggctctac	49260
gtagttagca	ataagagctg	tgataaccgc	aatgatagct	actggcttgc	ttatgaattc	49320
gcaaaaggca	ttccacaata	aactccaact	atctaaatct	gatacttgaa	atccgccagc	49380
agaccacaca	attgtaagaa	cagctactgc	ggataatagc	catgttcgcc	agttcttgaa	49440
tcttagtttc	cagttaatat	tcatcgtttg	tatccctccg	tgtgttttac	ttctttaata	49500

-continued

---

tcttcttcga	tatagtcaag	acgtgtttca	atcttatctg	cacgtccttc	tatcttatct	49560
actctagtat	tggttttggt	aatgcggagg	tgtatttgca	ttcggctctg	tttgctttcc	49620
tccaattgac	tagctaagtt	atccatgcta	ctagttagat	tatcaaactc	atccataaat	49680
ggcgatgcta	caattctctt	gaatagccaa	gctagcccac	taaacaatcc	cgtaactagt	49740
ccaattaatg	ctaccattc	tgtaatctgt	agtccccaaa	taactgctcc	tatctgcata	49800
cttgctocca	cttccatctg	tattaatact	ctaatacttc	ctctagccgt	actctatctg	49860
accagtttgt	agtattggca	ttgttatcgt	gacctactaa	tcggctcattg	tatagtctta	49920
ccatcttcac	tattgtacgg	ttaccagcat	aatcctttac	agtatcgttt	gaatatgcta	49980
taactgaacc	tacagtaact	ccttcacgag	cttctacatg	tcgtttaggt	acgtaagtgt	50040
aggtgtagtt	tatgtagaa	gaatcccacc	tccaaacaag	gataattcca	ttacgcatat	50100
ttgtgatatt	cttaccaaa	gtaactgttt	gacttgcggt	tggatatacg	ttagtgttgg	50160
ctttaagaac	acgtgaagac	catacaacat	tatctgtgta	tgttttcgca	tttgctgtag	50220
ctgttggtat	ggcattttgt	tgagcagtg	tagccttcgt	tgtagcgtcc	gtagaggcaa	50280
ctgattgaac	gtttgcatct	gctgtgtcca	tttgctcctt	agaagcataa	gtgaaccaag	50340
gaagggttac	gccggacgtg	tcaacgtgca	tctcatacgt	cacactatct	ggtacagtcc	50400
ttaataactaa	aatctttggt	ccagatcttc	ctgttgtaac	atctaattga	aagcttacag	50460
cggttggtgt	tggtatctgt	ggggggaaac	ctatagttgc	tttgtcagcc	aatgaagcgg	50520
gagaaacacc	ttcgtatagc	ttcgcactca	atgtaggtag	tccgggcat	agtgctgtca	50580
atgttcctaa	atcaattcta	gttccgtag	catttgtaa	agcgtacggt	tgatagtttg	50640
taatatctgt	tttaagaact	acttgattgg	catcaataga	agcttgtagt	gcctttactt	50700
ctgtatcaag	tggtgctaca	tttccagtca	atgctgttac	atcatcagaa	gtattatcta	50760
gttctggttg	tacatctgca	agctctgctc	tgatagcatc	tttgaaagct	tcaatatctg	50820
atgtaaattg	tggtggttgc	atggaattat	ttgttgcat	atgttgaata	gttagagaga	50880
agttctgggt	agtaacacgt	ttgttaactg	ttccaacaag	ttgctcta	gcaaagtatg	50940
cctctggcat	gtatccaact	tttgaccaca	cttctttaat	aaatgtgtag	cggaatattc	51000
cctgtgaagc	atctactatt	tctaagttct	gataaacaga	accgtcatca	cgtacatagt	51060
taatttggtc	gccgtcttga	taaggaagac	gacattcaaa	atagattgaa	tagccagtta	51120
aattgatagg	cagtcacgtc	ttggtagct	taactagaat	agacgttaaa	tctctgtcgg	51180
caaggcgacc	tataactctt	tggttttcat	aaggcttctg	tacgtctagt	ataatgtcat	51240
attcttttac	tgcatcagcc	atgtgtcatc	ctccttagtc	aatataaaat	tctattggcg	51300
ttaaccaaat	accttggtt	cggttaccat	ttatccatac	aacctctaag	ttacctgcac	51360
tgcttacata	aacctctgcc	ataaagttaa	caccagtgg	ttgacgtgca	catatccaac	51420
cattttgatt	acctaccatt	ggacgataac	cagcaggaag	tggtgcgata	acacctttct	51480
tagcagcgg	atccatgtga	acaactccac	gtaatgaaac	cttattacct	actttacgat	51540
atgccggagg	gtttgtagca	tcagttgacc	atccagaatt	aaatcctgtg	atatttatcc	51600
agccagtatc	tcgtgcatct	tgcactctcc	atcctcgcca	cactccgcta	tttagttggt	51660
tcattaccat	agtctggttg	gagcctactc	catataaatt	cccccaagta	ccttgtagct	51720
caatataggt	atateccccg	atgggtgtag	gaggaacatt	agtattagga	ttgtgtgttc	51780
cagcagtacc	agaaattcgt	gtcatataca	taccagccgg	aactttatct	agctctgtgt	51840
aaatatctaa	tccactgtcc	gtatctagat	ttactatagg	aacaccgcta	ttatcaata	51900



-continued

---

gctggatggt ctgcatggaa tccattctag tgtttaaggt agaaactgcg gttgctaatt 51960  
ggtagcaac atcagacatt gtggcgttct ctttccaagg aagtacccaa ccagctgttc 52020  
catttaagaa agttgaataa gagtttccaa aggaatccca tccaattacc catccggttg 52080  
tagctgttgtag tagatgagaa attcctctta aaggagtatt agccgttggg ttatttacag 52140  
cacctgatac tgcatagaat gttcgtaaac ctattcctgc tgtttttata atatcaagaa 52200  
tatcttttga agtgtctgag ccagttgtaa gtaagttggc acctgtgtca tcagtaatct 52260  
tctgtttctg ccagttaact gcatcagctg ttttgattac ttggtagct gtaatcagtg 52320  
cttctatctc atccatctgt gcactagcat ctgccacatc tgctttcagt tgaaccattt 52380  
cagcaattac aggagcaagc ctaatttcaa tctcagcttt aagcgactca atgtcagaga 52440  
tgtaatcgtc agcatttatc tttccttcaa tagcactatc tgttacaatg attttaaagt 52500  
tacgagttgt gacacgtttt acaatatcac caactgggtg ttctaaagca aaataggcaa 52560  
tgtaatagc ccctactttg gagaaagtct ctttaacaaa gttgtattga atgattcctt 52620  
gttcggcacc tacaataatc atattgccat ttgctatccc atcatcacgg acgaagttag 52680  
catactcacc tgtttggtgc ggtaattgac actcaaatag cggggtacgt cccactaagt 52740  
ttattgcttc tccgttgttg gttagcttaa ctaatacggg tgttaaatct ttgtcagcaa 52800  
tgccgggatat tagtaccacg ttttcagtat ctttaactaa gtccaatgct agagtgtatt 52860  
tcttgtcagc tgattttgga actgggtggat tagcttggct atagatagga acaggacatc 52920  
tcgcaagctc tttagttcca ttatacataa tcattgtaac cactgtggtt aatgtgattt 52980  
gagatttgat agtggaaacg tcagccataa aggttgtccc attagtgaat cctgcaattg 53040  
catttaagtt agtatcagtt ccgttaagta atatcttaac agtagttaat gtttcgtcta 53100  
cctcgtaaac gccatgaata aaatcatccg tgccgtcaaa ggcgtaggag tttgccatga 53160  
tatagttagt cattcttaat cctcgccttc ctcaatagag taatcaaagt tatcttgcca 53220  
gtcgtcctca tcgtcctcgt cttcgtcatc tccaacaata tccacggtaa taactgtttc 53280  
gactttgatt tcttgtttct ctttccacat gccataggat ttacctaca tctcagcagc 53340  
tttattctta tcgacaatag aaggtttctt attaaccttt tccccttttg cagttacgaa 53400  
ttcttctect tcttctcctt taacaactcg tgtataatat tccagaatat ctttttggtc 53460  
tgcaattgta ctgtagcat ttgattctgt aacatagcgt aggtaagctt gattttcttc 53520  
tttagccaaa agtgtatgtg cataaggtct tgtatatcca gactctctcg cagcacgaga 53580  
aacattatgg tcaactagat attctctaag taaacgtttt gtcttaggtt taatcacact 53640  
aaatttttct gggtcattat aaatgtttaa cgccacaaac tttcactccc tttctctctt 53700  
gttctttttt ttggaggtat ttctttttta ataaaagaca cgccagtgtc ttataaataa 53760  
gtgtagcccc gtgcaaaatc tttcgataaa tctttaaact ttactctctt ttagttctat 53820  
cgagtaagaa gaacctttac tctttaaacc atgtaaagat acagttttaga cccccctttt 53880  
gttgcgtttt ctgggaaaat aactgggtata agtgcataat taattttttt tgaagaaaat 53940  
agttgacaat tagaaaggta cgtgctaaga ttagtttata aattattagg aggagatata 54000  
aaatggctga tgtagtatat gcggaatgga actggtcaga agaccaaca aaagaagaga 54060  
tggaatatgc tttagacttg attaaagaaa tggttggaaa gattaataag aaggaacaag 54120  
tagaacctat tgatattccc gctttgggtg aagaaagatt ccacggaaga agtgtagaga 54180  
aagctaaaga tgaacaact attacaattg attccacaag tgaatctaaa tggaatcctg 54240

-continued

---

ttttggtaga	attggagaaa	ttcgctaagc	gggtggagga	aaaggattat	attgtgttgt	54300
ctgatttaac	aagttggtta	gaaccaatta	acgaagtatt	aggaacagat	ttaaaatacc	54360
gcagagaggg	aatgcgtatt	aatcgctagg	tgataaatatg	aaacgaattt	ataaaatgtg	54420
gattgaacct	tttgtcggta	ttgcaatfff	tatgttgccct	ttatttgctt	ccggaggaga	54480
agaagctact	acaggatggg	aagtagcttt	agcgtttatt	ctttcactgg	gctatgggta	54540
ctttgttggg	agacccatgt	tgtattactt	tttatttgat	ggagtaaccg	cagaagcaca	54600
caaaagagaa	attaatagct	tacgaaccta	tattaatcaa	tgccaagaag	caatgaatgc	54660
tagtggtaaa	acatgtagag	acctaaccga	tagagttgtg	ggtttatata	gctccaacaa	54720
agaacttttg	gatagattgg	aatatctcca	aaaagaagca	gaaaacttac	aagaagaatt	54780
gctcatgtta	cgagaagaga	atgcacaatt	aattatacag	gtaaagaaac	atgaagagta	54840
ataaaccttc	tttacttggg	gcatgtttga	cagatacagc	aagtggaaaa	gaatatacctt	54900
atgaatttag	ggcaacacat	catttaataa	gagttttagt	ttcctacaga	actaatatag	54960
caggtaagcg	ggagttttac	gtagattggg	aatctattaa	ttattcggat	ggctgggaaa	55020
taactcctta	tgatgaggta	tatctaggag	aaactacttg	gggttgagag	gtgttaacga	55080
tggaacaaa	tttgccttcc	ctatcttctg	ctcttttgca	tgacttagca	tgtagtaggc	55140
aatatgattt	aagatatgta	gatgtagtta	acgttacaat	aacaatgtgc	gaggacactc	55200
ctactagtaa	agaatftttc	agtatagaat	tagaaacaaa	atataaccgt	aatatttggg	55260
aatttgagga	aggtagatat	acagtagttc	ttggagaaac	aacgtggaag	tgaggtaatt	55320
ataaatgagc	aagatftttc	catccctgcc	aacggcacat	ttacagtatg	atagctatat	55380
tggtgctcat	ccttatgaga	aagatgtaac	acataaaaata	ataagaattg	ctattactaa	55440
agataataga	ttagcaggtg	ttactgaatt	tgatgtcatg	atagagtctg	aattaaactc	55500
tcaggcgtgg	ggcaagagtt	atgaactagc	taatgccata	catctaggag	caacttattg	55560
ggaaacggag	gaatgagtgt	gactaaaatg	tatccgatat	tagataatat	cgtaggaaga	55620
gattgggaag	gtgactggct	tcgtattgca	aatatgtcaa	actacgggat	aaccaatata	55680
aacatatttt	tggatgagga	gggagattgg	aatataaatt	taattagtac	ttctttggag	55740
gagtttgaag	catgtttcca	atatattgaa	tctattagta	ttatagattg	ggaagaggtg	55800
gagtgaaccgt	ggttaaaatg	tatccagtat	tagcggatat	tgtaggattt	tgtagggaac	55860
taagaatgtg	tggaatgcgt	cttaatgacg	gtcatggggg	ttctaaggta	agcatagagc	55920
tcagcaacgg	taattggagt	ttgatcgtag	ttaaaaatc	aggagacggg	aacggaataa	55980
gttttatgag	tattaatggg	gtagaaatag	tagcttggga	aatgaaggag	gaaagaggat	56040
gagtattaaa	tattcccttc	caaaactaag	agtaggggaa	agacttcaa	gtggacgtaa	56100
agcaatfttt	gatttccttc	aacgcaataa	aaagaatggt	acaagaataa	gagtatggcg	56160
aaatagtaaa	tcaggtaaat	tgcgagcggg	agttactgga	gacagtggaa	gagaagagtg	56220
gtgtgctttt	ttagaagaag	acgagactat	ggtatatatt	ggagagttgg	tgtggaatga	56280
gtaatgttaa	atfttcactt	ccagacctgc	gagtaagatg	ggttgataaa	atatatgtgg	56340
aaaggaata	cttatttgac	aaagcagata	caaaggacgt	tatacgaatc	aaactaggaa	56400
taacctcatt	gggtacattc	ttcttacaga	tagagccagc	agatggaata	ggtgattata	56460
ccagcatttc	acgtgcagaa	gaagaggftt	tatttgagga	ggtgatttgg	aatgagtgtt	56520
aagttttatt	taccgacctg	tctagctgaa	tggttagatg	gacatggaat	aataaggaca	56580
accgftttta	atccaattaa	tactaccaat	gtagttaata	ttactgtaac	taaaagagga	56640



-continued

---

aacgggaaat	tgtacttgca	tgtaaatgga	gataaaacaa	cttcatatga	agaggataac	56700
atggctctag	gtgagcaagg	ggatggttatt	tattggtgaa	gaactgtgtg	ggaggattag	56760
atgtaatggg	taaaattgaa	atgtcttttc	cagagcttag	tgtgtctttt	attgagttta	56820
caggagatag	aggggttgc	ggatggaatt	caccaagtac	tcacatgta	aggcgtataa	56880
cagttatgtg	cctagatgag	cagagaggca	ctgttttgat	aatgactgga	caagatgaag	56940
aagaagattg	gcaagcaata	gatgaggacg	gcgacttagt	tacttgggga	gaaaccgttt	57000
gggaggaaga	tagttgacag	tctttctcct	ttttggtata	cttaaatagt	aggaggagat	57060
tatatgaaag	ggataggtta	tttaatagat	tgtattagta	acaatttgtt	gttagaactt	57120
aaagtaattg	aggataataa	atttgattgt	tcatgtttaa	ttacgtactg	gaatgaagag	57180
tacggaacga	ttaatacttt	tagatttagt	aattcagata	caattttgag	agcgttgttc	57240
tatgtaatt	acagaaagga	taaggcacag	attggtcacg	agtttactgc	tagtaggaga	57300
ggagcgtttg	taattgaaac	aacctaaaca	aaagtatagt	tacgtgtata	caagagatgg	57360
agaaaaagtt	acacatatta	gattatacaa	aaaaccaagt	agtgaggaga	tattgactat	57420
gtttaaaaca	gtatctggat	gtagagaaag	atattacgtg	gatgagccta	taagatatgc	57480
tttaacaatt	tttatatatg	attgtatagt	gaaataaagg	agagtgcgat	atgccggata	57540
tatttgatag	cgtagacaga	tttgaagaag	aggataagag	agttttacga	attgagatac	57600
gttacttggg	aaataccgga	gcatttaaaa	gaaaattcct	gtatgacaat	ggaagacatt	57660
catatgcagc	taatttgtgg	gaagaagtgg	cacaagagtt	attctatgca	ggaataactg	57720
atgtgtacat	taaagagtga	ggagtaatta	ttatggatag	caaactttac	aaccacgtta	57780
ttgcagagga	tattagcaca	gtatatgaag	tagttattaa	aagagatggt	aatggtgctt	57840
ttgttatatc	ctatctttat	gttattaact	caatattaaa	tacaatgagt	ggaagagtta	57900
ctagaggtaa	gttaaatcgt	attaataaaa	gtttgcaggt	tatctctact	aaaatgtgtg	57960
ctttacaaaa	ggaagagaaa	tatataaggg	aatgataaaa	acaaatggca	aaggtttttg	58020
atactaacia	aaggtaccgt	ataacttatg	agaggggaaga	agtagtaact	attaagattt	58080
tagagaaagg	aatatctcgt	ttagaaaaga	tttatcaagg	taactggggt	ggcggatttg	58140
ctgtagcatc	ttgtgaggaa	tttttaaatg	atttaaccgt	aactgataaa	gaggaggatt	58200
taaagataga	atgaaaaact	atagagtata	aagaatagaa	tccaaagatg	cgaagccatt	58260
tatattaggt	ctacattatg	cacaacgtat	gccaaagtatt	tcctacgctt	acgggatatt	58320
ccttggagaa	gagttgctgg	gaatttgtac	cattggaaaa	cccgccagta	atcctttatg	58380
tgttgagta	tgtggcaaag	agtattcgca	caaggttttt	gaattgaata	gattgtgtat	58440
gaaggataaa	ctaggttaaga	atgttttgag	cttctttgtg	agtaaagtgc	ttaaagactt	58500
gaagaaagaa	aacctcatct	taatttctta	tgcagatact	ggtatgaacc	attctggata	58560
tatctaccaa	gctaccaact	ggatgtacac	gggattaact	gctggaagga	cagataaata	58620
tacgccagag	aataaacact	ctcgacacta	cacgaacgag	tttaaccact	tgcgaaaagt	58680
aaggacggct	aagcatcgtt	atatctatgt	ggcgggagat	aaacgttttg	taaaagaggt	58740
taaaggaaag	attaggatat	taagaacaac	catatcctaa	agataactaat	agtgattatg	58800
agttaggaac	tcgccagaaa	acaaagatac	ttaacacaga	ggataatacg	gtgttttatc	58860
agtaatttat	ctgtcctagt	tgacattggt	ttaactttgt	ggtaagctct	tattataaag	58920
aaggaggaga	taaatatgaa	taagtatgaa	agatatgttg	taggttggtg	tgatgaagat	58980

-continued

---

ggtgactggc actactgttc gagccgtaca ggtgttttaa aggaaaccgt aactgaagct 59040  
 aacaattgcc gaaaagtga acagagacat cttttataca aatataaaag tttggagatt 59100  
 ggtacaatgt actttgaggg tgctttaaat gaagaacttg ttaaaccaat tattgcagaa 59160  
 gagaaagagt atgcgattcg ccgtcacgag ttaagagatg aattcgaaac aattgctaag 59220  
 gaaagaggat taaataattt tgggactgag ttaataaaag cttttgacga atggatagca 59280  
 actaaggagg attaaaatgg actgctataa taaatacaga gtttgcgtat tttatggaga 59340  
 aagagattac gaatttttct acattgaagc atacgacgaa ttttatgcta agttagatgc 59400  
 tatggatatg tatgctaatt tttcacgaga gttatactac gatgaagtgc ttccagtttt 59460  
 ctctgttgaa atcgaacaag tagaggagtt ttaaaaatga gaatagtatc agcaattatc 59520  
 agcacgcaa aatgtatat ctatgattta catcagatag ataatcacac aggattagaa 59580  
 gttattatga ttgaagaacg gggcaatgga gttattatta cgtttaatga cggctctgct 59640  
 cgcaagttca gaagtgattg ttatagtttg ttttatgagg gagctgtagg cttttgagtt 59700  
 ggcttacaag aaggaaaaaa gatgctagag taggagagaa ttatgttcct aaaacagtgc 59760  
 caatgaataa tataaagaat ggagaagcta aaatgccaga acctattaaa gaggtaaaaa 59820  
 tagaattacg gtataaaatt ggggaagaga ttactatctt aaaccagaa actaaggaaac 59880  
 gagagttagc caaagttttg ggatttggag tagaagaaga tagtaaaatt cagtattacc 59940  
 atatctctac tttggatgaa cctcagaagg agcttaaggt atatttaaaa gacattggaa 60000  
 aagtatattt aaaagttgaa cacatcacta ctttgggtgt tgtatacttt gctggaaaag 60060  
 aaattaagta cattcccga gagaactgtg aggatgttgt agtaggaact gataaagaga 60120  
 atgtttatgt ttcttttaag gatggaaaga ctagatgta tcataaggta ccatttatgc 60180  
 aagaacacgc agagaaaaga tacaagcact ttacaaaaaa tactcccga ttttatttat 60240  
 acccacattc tgggtaccgt gaagcagaca tatactataa ctactatgac gaggaaaaag 60300  
 tgggattata tgaaggaagt ggatattaaa tggaaaccacc agatttagaa agcctaacct 60360  
 tgtgggtgat ttacgaccgt gttagtgaca cgttccacaa aggcgggaat caatacttct 60420  
 gctctagtcg ccagaagaaa gccattaaga cgtatggaac acttcaatct gctacagctt 60480  
 tgttaaaaca gatagaaggt ggagggattc acccagtaga tttagtgtta gtggaattag 60540  
 agtgtgagat tatggatttt atcgaagtag aataaactaa aaggagaatg attagatgaa 60600  
 aaaatcaatg atagctttag caattggggc agtattatta cttggaggat gtacttcttt 60660  
 tgatgattgg agtaagatt gggaaagtga caccaaagga ttagaaagaa caatcactat 60720  
 ctacagcaag actggcgaag ttcttaaca gtatgaagga gaaaacgttc gtactaaata 60780  
 ctacagatggc gggactcaag ttgttcttaa cattgatgga aagcgtgtcc aagtagttaa 60840  
 tgcagatggt gttattacag aaaaaggtgc agagaaatac gaaaccaa atggtttgac 60900  
 aactaaataa atgctgtgta taattagttta taccaattaa gaggagttag cgattatggc 60960  
 aaaggctaga gatattctgg atgctacgaa gtggacagag attagagatt tccgaagata 61020  
 ttccataaac agggatggtg aggttgctaa taatattaca ggtcatttgc ttaaagtatc 61080  
 gtttgctcct cgtttgggtt atacgggtta actagtggat gacgtggcta acttgcagag 61140  
 agtggttaag ctggcgatt tactggctag aacgtttggt cctagtgtat taggtgctac 61200  
 acaagtagta tttatagacg gcgataaaaa gaatttggat taaataatt tggaaacag 61260  
 attgtgaggt ttaatcatga agtattgtgt ttgcgtatgg gaagccactt ttaacttctc 61320  
 cataagttta ggactatttg ccacgaaaga acttgcagaa gaagctgtta aaagagattt 61380



-continued

---

agaagattat acagaaagag aattagataa ctaccaagtt tttgtagag gagtgtctgg 61440  
 attttatgtg taacttaaaa ccagctatac cagatatgta tgtttctgct gtaaaggatt 61500  
 tatatatgga taattatfff aatgagagtt ccacagccat cactaaaata attataggat 61560  
 attctgaata ctgtaaaagc acatgtatag gagtaacaag tggggactat aaacatgtaa 61620  
 agctgtttgg ggaagatggt attactctac acataggaga ggtggtttgg aactagttat 61680  
 gcactatcct tccaaacaga aaggggaata atcactacta tgtatatttt aatacagcta 61740  
 gtagattggc aaaaggatga tgaagttggt gctggaaaag tattaanaagt aggaggttgc 61800  
 tcctttcaag gagttaagat attgttaagt aaacacatga aagatatggc tagtttgcac 61860  
 gacagagcct cctacaggta tgctactgca cttatggata gatgtatgaa tttagatagc 61920  
 atatcccgca cattaagaac acacacagag tggcgagtaa aatttaaagt agtttttaga 61980  
 gaggaatggt atgaataatg gaaaaattag atactatgga acaaattact aagttacaga 62040  
 agaaagcaat tgaggtggcg aaagagttat atggtgatat taaagaaaca gactttacgg 62100  
 taattcagcc atatgcagat ggacacggaa tttgttttag tgtagtgat gacgaccaag 62160  
 gagaacgcac tatgagtgtt aacgtttag acacgttgac agtgcttcct gctattgatg 62220  
 ggacttttaga tgcttacgag gaagaaacag aatgatgata gtgtggataa tcttaattat 62280  
 tagtatcaca ttctttttaa cagcacgcaa actagaagac gatgtggcaa ttgtttggat 62340  
 acttggtata tatttagcaa tatcttttct tttagtaaat ttgacaaaaca cgtaagtaag 62400  
 tggatattt gtaatataga aggagggaaa cacatgtatg aatattgttg caaagaagta 62460  
 aatgaacgta agcgtgatac caacttaatg tatccagaca agggattatc ctatttagat 62520  
 gaggaggatt gtttggcaat tttcttagga gattttggag atgacatacc ccatacatta 62580  
 tatgtgctag ttaagcactg tccatggtgt ggaagaaatt tggaagagga tgtagtggt 62640  
 gagtactgta atagagacca caatttaaga caaacaanaag aactacatgg atataacgag 62700  
 gtaanaatag atggagacaa cgatttacag gtaacttatg aattaggtgg tgcagaggaa 62760  
 gaccttttgc tagaanaatg ttattgcctt tgggtgtgga gtaagttgga aggtagtgaa 62820  
 ttaanaatggc taaattcaa gtaggtgatg aagtatatgc ttcctatgta gatgaaatag 62880  
 gaacagttat tagaatcgta tgggaattat cagaaggcaa ctcaggtttt aatgcttatg 62940  
 aagtacaatt taacgaccag tcaagagttg tagccgaact agctttaca ccatcaacca 63000  
 agcaatagta cgtattaaat taaatggagg aatattgatg gaattttata atggtcaaaa 63060  
 gatagagttc atttcttgta ataaaaaaca agtaggggaa atagtagaag ttcacctga 63120  
 aagcgggata ttgagcatta gagatagtga tggaaatagag ctagggtgaa gaatcaacaa 63180  
 tgtagttgaa tataaagaac cagaattacc tgtagttccg aagtgtgtgg cgggttggtt 63240  
 tgaanaaat aagaataatt tagataatga aatttggcga tatattcgca actttgatga 63300  
 gcagaacaca gatagtaatt tttacatggt catgaatgat gcgacaagta atcctattga 63360  
 gatattggtg gaaatgaaga atggatataa gattgaagct acacctgcta cgtatgtgtc 63420  
 tacgtgtgga gaagatacag aagtaaagta tgtaatttta agagataaag aaacaactaa 63480  
 ggtagatggt acgtattacg ttaggatggg cacaccgta gctaaatcat ttgaatatgc 63540  
 tcttacacca gataaggaat gtgctattat tggagataag gtaaacatga ccgcaattgc 63600  
 atgtttotta gcttccaaa atactagcca cacgtttgac gttgtgcat atgaggaaga 63660  
 gatttaatga agcacaaggt aggagataaa gtagaactaa tttggtacga ggtaanaaga 63720

-continued

---

gaagtaatta	ttgtagagga	acttccaaaa	ggggaatatg	tagtagaatt	tgtgcacgat	63780
gggaaaagag	agacaatcca	tgaagcaggt	atgatggaaa	cgggaacgat	tacaaagtta	63840
gcaagtgaag	agctagttaa	acttcccact	tatatggaag	attgggttaga	gtttggagat	63900
aggcagggat	atgatttagt	cgatttgttt	aattactata	atagtaacat	gtccaaagag	63960
gtagaagagt	ggatagtaaa	tagtgaaacg	aaccagtata	aatttgctat	ggcttggtta	64020
tgtggatatg	ttgtggagga	ggaattagca	aatggataaa	tcacgtataa	ccgtattgct	64080
aaaatcgggt	aatagatgtc	agattactca	tccagatgtg	gtggaggaag	tttgggaaga	64140
gttttcttta	gaaaaggtaa	aacaaggagt	tactttacaa	gatagacact	ccaaaacaat	64200
tatcccgtat	gagtctatcg	attgtatcta	tattgaagaa	ttggaggcgg	aagaatgaac	64260
gataaaaaga	cagattataa	agtatataaa	ataacataca	agcaacgttt	tatgggggaa	64320
gttattgttg	actcatatga	aagaacggta	aaagatgata	acgaattacg	gtctgcaatt	64380
aacgctttat	atgacgacc	acatgtgttt	tcagttagta	gtgaagaggt	ggcggaataa	64440
atgggagtga	gtattgattt	atacagttat	gattatgaag	cacttgtgga	aggcattcaa	64500
agctatacaa	aagcggaaaa	tacggaagtt	ataagaaaa	tacttcta	aggcggaaat	64560
gtcgtagggtg	ataaatatat	cattttaaac	aatgaactct	gggaagataa	cagttcatat	64620
tacaacgttc	cgaacgcttt	agagcgtttg	tataaagttg	atgatgtcct	tggaaaaatc	64680
ttctgtactt	ttgatgatag	gttcggtaga	gagacgctaa	ttaatggttg	tgatacccca	64740
gaagaaat	tagaagaggt	gatggaatga	cgacatttaa	accgagaaac	atcctaagtt	64800
ggcgcagtgg	attgccttac	gataatacga	gattttcaat	aggtagacct	ccagcaggcg	64860
gacaacatag	tgatgaatgg	tataacggag	aatgaatgt	aatgtaatc	agcattgaat	64920
atatactgcc	taatccaatc	acggaaagca	caggaaacta	tattatcaag	ttggaagatg	64980
ataggagaat	tgttatctcc	gaagaaattc	cgtcttttat	tgaggaggtg	gcggaataaa	65040
cgtagtggat	attaacgtat	cagagttgat	gaaggagtta	cagaaaatcc	cgccagatag	65100
ttcaattttt	atagaggaat	attgttacgt	ttctgatagc	gctagggtta	agtatagtga	65160
aaaatattgg	gaggtacgtt	tgtgtactaa	tgaataggag	gaaataacat	ggctaaagaa	65220
ccaagagacg	tgtggatagt	ttattatgaa	gtacttggcg	gggtggaata	ttacttagct	65280
agctccaaca	tagacaagct	tatttttaga	ccaagtacac	tagaaggaaa	tgcttttagaa	65340
ttccctacac	aagattccgc	agagggaatg	gctaagggtg	ctaatacgct	ggatactaac	65400
caagaccatt	gggtggaagat	taagaaagtg	gataaacctc	aagtgtatgt	gatgtttgca	65460
ccagttatta	ctcacttgat	acaggtggca	gtaaataccg	acacgccaa	agatttagca	65520
gatttacagg	tgtgtgaggc	tttctttagt	gagtttcacg	aattagaacc	tgttacccta	65580
gccaagagat	ttacaagaga	agaatttgaa	gaacttaaaa	caagatacac	aggattatg	65640
gctattccag	tagatgacgt	tatgaatact	ttagaaagat	tctataacac	ttcctcttat	65700
aataaaactta	agaagggtaa	agcagttatg	gaagtgttcc	gggagtataa	agcaagtggg	65760
aactaatatg	ttcgtagtgt	ggttcgcaat	tattagctac	ttttttggaa	gtattactac	65820
catatttact	gggtgtgtgca	aagtaagaag	tggtgaagaa	gtggttggtg	gcgttataga	65880
catattggct	ggctcctat	ttgctggaat	gagttggtta	tttatagtta	tatttctata	65940
gataaggaag	gagttgttta	atgtgttgg	agtgctagga	attgtgttct	ttctttctat	66000
actgtcaatt	gctggtttcg	gactggttat	ttatagttgg	agaagtgaaa	tagtcgtagc	66060
tctttttgga	ttatttttag	ggatgattac	tttatttagt	gtttttgtat	tgttgtttaa	66120



-continued

---

```

tacttaagga ggtgaaaaac acaatgacag atatagtagt gcagatttta acttatatat 66180
tgatagtggg ctttagcttc ttcgggataa ctaaccttat tgagggtatt aaaaataaag 66240
ggaaaagacc cgcttattct aggttcctag atattactac tgggtgtggga ttgtagcac 66300
tagtttggct ttggtttacc caaggtggag tatcttaatg aaaattcccg catagttaa 66360
ccagagagtg ccagttaggt actctttttg gcgtggttg gaatagttgt ggctagtgtg 66420
gacgtggtgt ggcgtggtgt gacaaggtgg cggtttactt ggtaccccca gtcgtaaccc 66480
atacagtga aataggaaac gtgaaattgt aatagtctgc ggagaattat cagaattttt 66540
tgaacacccc tacgtctccg aattttccga ctcttctaac tactcagtct actcgctcgc 66600
tttcgctcgc tctcgttag ctcgacacgt attgcacact tgctttattt atattacatg 66660
tattagcatg tgagtgcgtg tgtgcacgtg tactacagta actacacata gatatacatg 66720
ctacaggtac tattaatat aagggctaata aaaacgctta cattcgatta gctaattata 66780
cttctataa catacattat gttaacttgt tagatgagta taaaataata gataattata 66840
ttagataa 66849

```

---

25

The invention claimed is:

1. A food product comprising a bacteriophage having a genome

- i) comprising the DNA sequence of SEQ ID NO: 7;
  - ii) having at least 90% or 95% sequence identity with the DNA sequence of SEQ ID NO: 7; or
  - iii) having at least 90% or 95% sequence identity with the DNA sequence of the genome of bacteriophage ProCC P825 deposited under Accession No. DSM 23783;
- wherein the food product is selected from the group consisting of a dairy product, a fruit product, a vegetable product, a meat product, and a fish product.

2. The food product of claim 1, which is a dairy product.

3. The food product of claim 1, which is a fruit product.

4. The food product of claim 1, which is a vegetable product.

5. The food product of claim 1, which is a meat product.

6. The food product of claim 1, which is a fish product.

7. The dairy product of claim 2, which is a pasteurized dairy product.

8. The dairy product of claim 2, selected from the group consisting of yoghurt, ice cream, cheese and butter.

9. The meat product of claim 5, selected from the group consisting of pate, hot dog, bologna, salami and cold cuts.

10. The food product of claim 1, wherein the food product has undergone thermal treatment prior to introducing the bacteriophage.

11. The food product of claim 10, wherein the thermal treatment is at a temperature of at least 70° C.

12. The food product of claim 2, wherein the bacteriophage has a genome comprising the DNA sequence of SEQ ID NO: 7.

13. The food product of claim 1, wherein the bacteriophage has a genome having at least 90% or 95% sequence identity with the DNA sequence of SEQ ID NO: 7.

14. The food product of claim 1, wherein the bacteriophage has a genome having at least 90% or 95% sequence identity with the DNA sequence of the genome of bacteriophage ProCC P825 deposited under Accession No. DSM 23783.

\* \* \* \* \*